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General introduction 
Introduction 
During the last decade, impressive advances have been made in the techniques 
available for the treatment of ARF in critically ill patients [I]. This has led to the 
increased use of continuous hemofiltration and its derived modifications on the 
intensive care unit (lCU) as opposed to the use of intermittent hemodialysis and 
peritoneal dialysis [l]. In spite of this, it has not been possible to demonstrate an 
improved outcome in these patients, which is ascribed to a change in patient 
characteristics [2]. One major reason for our failure to demonstrate enhanced survival 
may be the lack of validated and objective illness severity scores that would allow an 
adequate comparison of outcome data from different reports [3]. Today, ARF is most 
often encountered in the setting of the systemic inilanuuatory response syndrome 
(SIRS), usually as a result of sepsis, which is characterized by the release of a myriad 
of inflammatory mediators with vasoactive and cardiodepressant properties into the 
circulation. 
It has been suggested that these middle- and large molecular weight mediators may 
pass the membranes that are used in continuous renal replacement techniques (CRRT) 
and that this may have a beneficial effect on the clinical course in critically ill 
patients with ARF [4]. There is, however, still much controversy as to which dialytic 
treatment modality should be preferred in the setting of ARF on the ICU [5]. 
1. Acute renal failure 
ARF, defined as an abrupt decrease in previously stable renal function sufficient to 
result in retention of nitrogenous wastes in the body, is commonly encountered in the 
hospital setting. A prospective study of hospitalized general and surgical patients 
showed an incidence of almost 5% [6]. A higher incidence of ARF is seen in selected 
clinical settings, particularly in the critically ill, where ARF is reported to occur in 15 
and 25% of patients admitted to the ICU [7,8,9]. After excluding prerenal azotemia, 
postrenal obstruction and inflanullatory renal diseases ('nephritis'), the term can be 
used in a more restricted sense, referring to acute intrinsic renal failure ('acute 
tubular necrosis' [ATN]). This is more appropriate as ATN is by far the most 
common cause of ARF in the intensive care setting (60-80%)[9,10]. ARF is 
traditionally viewed as the result of either an ischemic or nephrotoxic renal injury. 
Clinically more conunon, however, is a combination of various acute insults 
(Table I), often on a background of preexisting chronic risk factors, all acting in 
concert to induce renal failure [II]. Several authors have studied the causes of ARF 
(acute insults and risk factors) in critically ill patients [12,13,14]. Sepsis is repeatedly 
shown as the major aetiologic factor for the development of ARF in the ICU. 
Another, often coexistent, major risk factor for the development of ARF is prolonged 
prerenal azotemia due to unrecognized intravascular volume depletion. It may be 
quite difficult to acertain whether a patient who is grossly edematous as a result of 
the 'capillary leakage syndrome' and hypoalbuminemia (e.g., due to sepsis or trauma) 
is really overhydrated or that in fact this patient is suffering from severe intravascular 
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volume depletion, thereby being at risk for renal hypoperfusion. Several predisposing 
factors for nephrotoxic or contrast-media induced ARF have been identified and are 
depicted in Table 2 [15-22]. 
Table 1. Insults Causing Acute Tubular Necrosis 
Hypotension 
Trauma and bums 
Surgical 
Sepsis 
Cardiac event 
Drugs 
Profound and prolonged volume depletion 
Rhabdomyolysis with myoglobinuria 
Haemolysis with haemoglobinuria 
Nephrotoxins 
Sudden decrease in renal blood flow 
Cross-clamp of aorta or renal artery 
Renal artery embolus 
Table 2. Predisposing Factors for Nephrotoxic Acute Renal Failure 
Risk factor Cause 
Volume depletion Pigment, contrast agents, aminoglycosides, 
NSAlD's 
Advanced age Contrast agents, aminoglycosides, NSAID's 
Diabetes, multiple myeloma Contrast agents 
Prostaglandin-dependency of GFR NSAID's 
Old age, cirrhosis, nephrosis, 
congestive heart failure 
Angiotensin-dependency of GFR Converting enzyme inhibitors 
Renal artery stenosis 
Pre-existing renal disease Contrast agents, aminoglycosides 
Sepsis, endotoxemia Aminoglycosides 
Fever Aminoglycosides 
Reference 
[11,15,18] 
[15,16,17] 
[11,15] 
[11,19] 
[11,20] 
[11,15,16] 
[21,22] 
[22] 
Abbreviations: NSAlD's: nonsteroidal anti-inflammatory agents; GFR: glomerular filtration rate. 
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Despite impressive advances in medical care, survival from ARF in recent series 
(50-70%) appears to be no better than that reported two or more decades ago [7,8-
13,23]. It has been suggested that this continuing high mortality is due to changes in 
patient characteristics, which may have masked an improvement in outcome [12]. 
These changes include: (I) a reduction of cases of uncomplicated ARF; (2) an 
increase in ARF as part of multiple organ systems failure (MOSF) resulting from 
extremely severe illnesses, accidents and operations, also affecting older patients. 
Indeed, it may be that patients are now treated for ARF who would formerly have 
died before the condition could occur [10,23,24]. Outcome in ARF patients is mainly 
dependent on the factors that determine failure of other organs as part of MOSF 
[25,26,27J. As well as being the major causative factor, sepsis is established as the 
principal cause of death in critically ill patients with ARF/MOSF [23,24,28]. This 
particularly relates to surgical ARF, as it is intra~abdominal sepsis that carries the 
highest mortality [25,26J. Giving the grave prognosis of these patients, efforts should 
thus be directed at preventing ARF, such as the recognition of predisposing factors 
and the identification of patients at risk of ischemic or nephrotoxic renal injury 
(Table 1,2). As there is no specific treatment for established ARF, management is 
directed at measures to prevent or treat complications associated with this condition. 
These complications are: (I) bleeding diathesis due to uremic platelet dysfunction; (2) 
acid-base and electrolyte (e.g., hyperkalemia, hypocalciemia) disturbances; (3) fluid 
overload; and (4) uremic immunosuppression [29,30]. All this may lead to 
cardiovascular (tachy-arrythmias, pericarditis, myocardial infarction), pulmonary 
(pulmonary edema, ARDS), neurologic (encephalopathy, seizures) and infectious 
complications as well as life-threathening bleeding complications [29,30]. 
If conservative measures fail to correct uremic symptoms or fluid and electrolyte 
imbalances, kidney function should be replaced by intracorporeal or extracorporeal 
dialytic treatment modalities. Conditions that mandate initiation of dialytic support 
are shown in Table 3. It has been suggested that the initiation of early, intensive 
dialysis (,prophylactic dialysis') in ARF might avoid some of the abovementioned 
complications (e.g., the occurence of gastrointestinal hemorrhage or septicemia) [31~ 
34]. A recent controlled study failed, however, to show any significant benefit from 
intensive dialysis [35]. It may be that the possible beneficial effects of this approach 
are offset by the side-effects associated with IHD, such as hypotension and the 
prolongation of ARF (see below). 
Table 3, Condilions That Mandate Iniliation of Dialytic Support 
Refractory acidosis 
Serum urea> 35 nmlOlIl 
Serum potassium> 6.5 Illlllolll@ 
Diuretic-resistent fluid overload 
Pericarditis 
Encephalopathy 
Haemorrhage 
@: despite conservative measures directed towards acute'y lowering serum potassium level (cation-ex-
change resin, correction of acidosis, glucose and insulin infusion). 
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2. Dialytic modalities 
Four main goals are to be achieved with blood purification teclmiques in ARF: to 
remove toxic substances presumably responsible for the uremic syndrome; to remove 
potassium for treatment or prevention of hyperkalemia; to administer buffer~anions to 
control metabolic acidosis; and to remove excess body water and sodium [36,37]. 
Various methods for blood purification in ARF are now available, including 
hemodialysis. peritoneal dialysis, hemofiltration and hemodiafiltration. All these 
methods can be performed either intermittently or continuously. Solute movement 
across a membrane occurs by two processes: (1) diffusion, where movement is 
passive, rapid and down a concentration gradient; and by (2) convection, where 
solutes are dragged with water as it moves across the membrane (ultrafiltration) down 
a hydrostatic pressure gradient. Small molecules, such as urea (60 Daltons [Da]) and 
creatinine (113 Da) move mainly by diffusion, whereas for molecules of size greater 
than 500 Da (so-called middle molecules) diffusion is less efficient and movement 
occurs predominantly by convective transfer. In dialysis solutes diffuse from blood 
through the peritoneal or dialysis membrane into a dialysis solution. Dialysis fluid 
represents an ideal plasmawater composition and provides the osmotic gradient for 
diffusion. Hemofiltration relies on solutes being carried along with the bulk flow of 
fluid in a hydraulic~induced ultrafiltrate of blood (i.e, convective transfer). As small 
molecules diffuse more rapidly than large molecules, higher molecular weight solutes 
are cleared much less efficiently with dialysis than small solutes. With hemofiltration, 
clearances are similar for all solutes that have molecular weights in the range to 
which the membrane is readily permeable. 
Intermittent hemodialysis 
Before the advent of continuous hemofiltration and derived modifications, 
treatment of the acutely uremic patient usually consisted of every-ather-day IHD or 
intermittent/continuous PD. IHD requires specialised equipment and personnel. Only 
shori-term anticoagulation is needed. IHD is highly efficient in small solute removal, 
the urea clearance amounting to 160-200 mllmin with a blood flow of 150-250 
mllmin and dialysate flow of 500 mllmin. Because treatment times can be kept short 
with IHD (usually 3-5 h), the patient is free to be mobilized and undergo other 
therapeutic or diagnostic procedures. However, its efficiency brings with it potential 
complications, especially when used in the setting of ARF. The so-called dialysis 
disequilibrium syndrome is a much feared complication and characterized by 
headache, nausea, muscle cramps, disorientation and eventually coma and seizures 
[38], Its occurrence may lead to dangerous increases in intracranial pressure in 
patients with preMexisting cerebral edema (e.g., traumatic, post-hypoxic, hepatic 
failure). Rapid volume and solute shifts may induce or aggrevate hemodynamic 
instability and prohibit the necessary ultrafiltration to control fluid balance. Indeed, 
fluid infused to maintain a mean arterial pressure sufficient to be able to perform 
IHD may result in the patient ending dialysis more fluid-overloaded than before 
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treatment. This often results in a tendency to restrict fluids and nutritional intake, 
thereby aggrevating catabolism. Several other factors, such as the buffer-anion used 
and the type of membrane, contribute to the side effects of IHD. Use of acetate as 
buffering-anion may aggrevate hemodynamic instability by inducing vasodilation 
[38,39,40]. The vasodilating effect of acetate might decrease pulmonary hypoxic 
vasoconstriction resulting in increased pulmonary shunting [38]. Furthermore, acetate 
metabolism leads to alveolar hypoventilation and an increase in oxygen consumption 
[38-41]. Lactate as buffering anion produces less vasodilation compared to acetate. 
However, unphysiological concentrations of lactate (usually D,L lactate) are needed 
to correct acidosis and may cause metabolic disturbances [42]. Bicarbonate seems to 
be the obvious buffer choice as it alleviates much of the symptoms associated with 
IHD [38,42,43]. Bioincompatibility of dialyser membranes may also induce 
deleterious side effects. Cellulosic membranes induce complement activation with 
generation of C3a and C5a which may result in pulmonary leueo-sequestration, 
(local) release of inflammatory mediators, micro-embolisation and increased 
pulmonary shunting [44,45]. In addition, IHD using cellulosic membranes aggrevates 
sepsis-induced neutrophil dysfunction, thereby contributing to susceptibility to 
infection in such patients [46]. Indeed, a higher incidence of sepsis was observed in 
ARF patients treated with IHD using cellulosic membranes when compared to similar 
patients treated with IHD using biocompatible (i.e., synthetic) membranes [47]. In 
addition, use of cellulosic membranes prolonged the duration of ARF when compared 
to the use of synthetic membranes in experimental ARF [48]. 
It should thus be recognized that side-effects of IHD may be diminished by using 
bicarbonate as buffering anion and by using biocompatible membranes (as used in 
CRRT!). In addition, other simple and inexpensive maneuvers have been shown to 
stabilize blood pressure during IHD, i.e., the use of high sodium dialysate [49,50] 
and the use of cooler-temperature dialysate [51]. Therefore, further studies are needed 
to assess the 'real' side effects of more contemporary IHD in ARF patients. 
Peritoneal dialysis 
Acute PD may be an alternative to IHD in certain patients with ARF. The main 
advantages of PD are that no anticoagulation is needed, there is minimal effect on 
hemodynamics and the ease of implementation. No specialised equipment or 
persolUlel is required. Therefore, in patients at risk of bleeding or patients who are at 
a greater risk from hemodialysis-induced hypotension, PD may be the preferred 
treatment modality. Other relative indications are difficult blood access and 
hypothermia, for which central core warming with intraperitoneal fluid may be 
desirable [52,53]. However, PD is less efficient at the removal of waste products, the 
urea clearance usually alllounting to 7-14 Llday (5-10 mllmin)[52,53,54]. PD efficacy 
lllay be further compromised in the critically ill by reduced splanchnic flow during 
shock or use of vasoconstrictors, and low oncotic pressure due to hypoalbuminemia. 
Acute PD may not offer urea clearances sufficient to ensure azotemic control in 
catabolic patients and it may be inadequate for the ultrafiltration requirements needed 
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to maintain fluid balance. This disadvantage often precludes the provision of full 
nutritional support. Efforts to increase either solute or fluid removal include 
increasing volume/exchange, cycles/hour, or ultrafiltration/exchange [53,54], but all 
of this will substantially increase the work load. PD may be contra-indicated or 
impossible to perform because of intra-abdominal pathology such as infection or 
recent surgery. Large volumes of intra-abdominal fluid may lead to splinting of the 
diafragma, atelactasis, decreased functional residual capacity and respiratOlY 
insufficiency [52,54,55]. In addition, consecutive hypertonic exchanges to achieve 
high ultrafiltration rates may lead to 'overfeeding' hyperglycemia with detrimental 
effects on metabolism and respiratory function [56]. Other complications are protein 
losses with the dialysate (10-20 g/day), hypernatremia following aggressive 
ultrafiltration. blockage of the catheter with drainage failure, access infection and 
peritonitis [53-55]. Both intermittent and peritoneal dialysis, therefore, have 
significant disadvantages and potentially deleterious side-effects when performed in 
the setting of ARF on the lCU. 
Continuous renal replacement therapy 
As early as 1977, Kramer and co-workers described a method to treat diuretic-
resistent fluid overload in critically ill patients with ARF: continuous arteriovenous 
hemofiltration (CA VH)[57]. This process of arteriovenous hemofiltration imitates 
glomerular function, a function of the natural kidney (Fig I). The pumping force of 
the heart is utilized: blood is conducted through a bundle of capillaries, i.e., the 
hemofilter, via a tubing system, from a large artery (usually the femoral artery) and 
returned to the patient through a large vein (usually the femoral vein). The driving 
force for blood flow and filtration is the difference between arterial and venous 
pressure: that is why this filtration method is called arteriovenous. To inhibit 
coagulation, heparin must be added continuously to the blood as soon as it enters the 
artificial circulation. The hydrostatic force aeros the hemofilter membrane results in 
the formation of an ultrafiltrate, consisting of plasmawater and non-protein bound 
low- and middle molecular weight solutes [58,59]. Blood cells and proteins are too 
large to cross the filter membranes and thus remain within the hemofilter tubules and 
are returned to the systemic circulation. The composition of the ultrafiltrate is similar 
to that of the plasmawater. Non-protein bound electrolytes are present in the 
ultrafiltrate in concentrations similar to that observed in plasma. For non-electrolyte 
solutes the concentration in the ultrafiltrate progressively decreases with increasing 
molecular weight [58}59]. The concentrations of various electrolytes and solutes in 
plasma and ultrafiltrate and their sieving coefficient are shown in Table 4. The 
sieving coefficient represents the ratio of the solute concentration in the ultrafiltrate 
to the solute concentration in the retained plasma. The sieving coefficient depends on 
the particular membrane, molecular size and protein-binding properties of the solute. 
It is not affected by changes in either the blood flow rate through the hemofilter or 
the ultrafiltration rate [58,59]. It may be noted from Table 4 that cations have sieving 
coefficients slightly less than 1 and anions have values greater than 1. 
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Figure i: Schematic representation of conlimwlls arteriovenous hemofi/tralioll (CAVH). Abbrm'iafions: 
A, artery; ~~ vein; HF, hemofilter; S, substitution fluid; H, heparin pump; UF, ultra filtrate. [From 
GfJlltiler Slabon. Arlerio~vendse hamofiltration. In: Kramer P, ed Arterio-wl/rue hamojiitralion 
Nieren-(ersatz)-Iherapie 1m intensivverpflegebereich Vandenhoeck & Ruprecht Gdffillgen, Ziirlch 
1982:2} 
This phenomenon is caused by a small Gibbs-Donnan effect, in which the negatively 
charged proteins attract cations, thereby decreasing the transmembrane movement, 
and repels anions, increasing their transmembrane movement. Clinically, this effect is 
unimportant. During CA VH, fluids must be administered because of the large amount 
of plasmawater removed as ultrafiltrate (usually 10-15 L/day). Fluid replacement 
serves two purposes: (1) it prevents the patient from becoming too volume depleted 
as a result of ultrafiltration; and (2) it serves to decrease the concentration of 
nitrogenous wastes and creatinine by a dilutional effect [57-59]. Several commercially 
available (sterile) filtration replacement fluids are now on the market. 
The technique of slow but continuous ultrafiltration (i.e., isotonic dehydration !) 
avoids the rapid changes in osmolality and intravascular volume as seen with IHD. 
Indeed, in 1984 Pag(\oini and co-workers rep0l1ed its successfull use in 23 oliguric 
ARF patients who were unable to tolerate bicarbonate lHD [60]. 
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Table 4. Electrolyte and Solute Concentration in Plasma and Ultramtrate and Their Respective 
Sieving Coefficient 
Solute 
Sodium (mmoVI) 
Potassium (mllloUI) 
Chloride (mmol/I) 
Bicarbonate (mmol/I) 
Glucose (mmolll) 
Urea (nlllOlJl) 
Creatinine (pmoUI) 
A Ihumin (gil) 
Concentration 
Plasma 
(II ~ 10) 
136.2 ± 10.4 
4.1 ± 0.7 
99.3 ± 10.8 
19.8 ± 4.7 
9.2 ± 4.3 
39.6 ± IS.I 
570 ± 348 
26.5 ± 5.1 
Sieving 
Ultrafiltrate coefficient@ 
(II ~ 10) 
135.3 ± 11.2 0.993 
4.1 ± 0.7 0.985 
103.7 ± 9.6 1.046 
22.1 ± 5.1 1.124 
9.6 ± 4.S 1.043 
41.5 ± 19.2 1.048 
586 ± 353 1.020 
0.21 ± 0.43 0.008 
@: represents the ratio of the solute concentration in the uitrafiltrale 10 the solute concentration in the 
retained plasma. 
Due to its simplicity and its capability for physiologically continuous fluid removal, 
this new method was soon widely accepted in many ICU's [2,4,58]. Intravascular 
space for the unrestricted infusion of parenteral nutrition, blood products and drugs 
(e.g., inotropics, antibiotics) was easily provided. Any existent overhydration could 
be easily corrected at any time of day or night. Disadvantages of the technique 
include the need for continuous anticoagulation, the requirement of arterial access, 
and the confinement to bed of the patient, which may interfere with other forms of 
patient care (e.g., diagnostic or surgical procedures). Other disadvantages are the 
possible impact of CA VH on serum drug and nulrient levels [57-60]. In addition, the 
syslem ofCAVH proved unable to produce a filtration rale (usually 10-14 Llday, i.e., 
urea clearance 7-10 mllmin) capable of compensating azotemia in highly catabolic 
patienls and additional isovolemic IHD was often required [59-62]. This has led to 
Ihe development of pumped continuous venovenous hemofiltration (CVVH)[61] and 
continuous arteriovenous hemodiafiltration (CA VHD)[62,63]. In CVVH, enhanced 
solute clearance of both small- and middle molecular weight solutes is achieved by 
using a blood pump in the circuit, thereby increasing the blood flow and 
ultrafiltration rate (Fig 2a). In CA VHD, enhanced small solute clearance is achieved 
by adding a diffusional component to the continuous filtration of CA VH. Sterile 
dialysis fluid is pumped slowly through the ultrafiltrale compartment of the 
hemofiltcr, usually at a flow rate of 1-2 Lih (Fig 2b). These intensified continuous 
therapies regularly achieve a significant reduction in serum urea and creatinine 
production, even in highly calabolic patients [61-63]. For the purposes of clarity, all 
these forms of continuous therapy are shared under the acronyme 'continuous renal 
replacement therapy' (CRRT). 
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s 
HF 
~R 
CVVH CAVHD 
Figure 2a,b: Schematic representation of (a) continuolls (pump-driven) venovenolls hemofiltratioll 
(CVVH) and (b) continuolls arteriovenous hemodiafiitratioll (CAVHD). Abbreviations: A, artery; V, 
vein; H(D)F, hemo(dia)filter; B, blood pump; N, needle (double-lumen catheter in CVVH [bJ); H, 
heparin pump; S, slIbsfiflllion jluid (S" prefilter; S" postfilter),' F, filtrate: R, reservoir; Df, dialysis 
jluid; Di, dialysate; Bi, balancing system (regulating subslitutionjluidjlow rate); Ai, air delector, 
2. Severity-DC-illness scoring systems 
The many choices available today of blood purification are in striking contrast to 
the limits on management of ARF three decades ago [37,38]. However, despite an 
impressive decrease in mortality following the introduction oC dialytic treatment, 
recent mortality rates seem to be on the rise and comparable to that seen in the 
predialysis era [10,59,64]. Kjelistrand and Solez [65] suggested that maximal survival 
benefit was probably achieved with every-other-day IHD treatment and that no 
impact of a specific dialysis procedure on mortality is to be expected. Other authors 
have propounded the view that no survival advantage is to be expected from CRRT 
when compared to contemporary IHD and that improvements in outcome will depend 
on advances in the treatment of today's principal cause of ARFIMOSF, i.e., 
septicemia [66,67]. 
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Some authors, however, suggest that progress has been made but is masked by a 
change in patient characteristics (see chapter Ll)[64]. One reason for our failure to 
demonstrate progress unequivocally may be our failure to provide data in a form that 
allows a meaningfull comparison of outcome data. Indeed, many reports contain 
patients of varying qualifications (usually a case-mix of medical, surgical and/or 
obstetric ARF), not all of whom required dialysis or stay on the leu [64,68]. ARF in 
the critically ill should be considered as a syndrome and not as a specific disease 
entity. Closer attention to other factors surrounding the course of the patient with 
ARF may aid in delineating any changes in mortality associated with changes in the 
severity of these other factors [64,69). However, the incidence of ARF and the trend 
in terms of the population base has yet to be defined. 
Specific risk models for acute renal failure 
Considerable variability exists in the design of outcome studies in ARF: 
differences in inclusion criteria; large versus small patient groups; retrospective 
versus prospective; univariate versus multivariate analysis of risk factors [66,70-79]. 
Indeed, even when statistical methodology and patient numbers are similar, inclusion 
criteria can range from mild increases in creatinine to only dialysis-treated patients 
[70-79]. In addition, some authors studied a more general ARF population (i.e., 
including nephritis), while others studied predominantly ATN cases [70-79). Except 
for identifying risk factors influencing the development or recovery of renal failure 
and ultimate patient outcome, the need of measuring the severity of ARF is becoming 
increasingly important. This would provide us an objective method to risk-stratify 
patients in therapeutic trials (e.g., different forms of dialytic support), for audit of 
clinical performance, and in the prediction of outcome. Its accuracy should be 
verifiable against clearly defined outcomes which do not form part of the criteria 
employed to construct the system. It should be reasonably easy to use, and applicable 
to as wide a population as possible [69,80]. Based on uni- and multivariate analysis, 
a multitude of risk factors for the development of ARF and mortality has been 
identified [70-79]. Results are, however, confusing. One particular example is the 
importance of age: some related age to mortality, while others did not [66,69). The 
same inconsistency exists for several other variables [66,69]. Some studies [72,73,77-
79,81) provided a severity-of-illness score and an equation by which the chance of 
survival in ARF patients could be predicted (Table 5). Most of these models, 
however, are not formally validated and do not reach a discriminative cut-off point 
allowing identification of the patients without hope of survival. In addition, none of 
these models is widely accepted. Furthermore, Paganini and co-workers recently 
showed that these risk models may be institution-specific [82). 
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Table 5. Variables Found Significant in Outcome Prediction in Acute Renal Failure Patients 
Author (Ref] No of Type of ARF Variables used in outcome prediction 
Patients 
Cioffi e/ al. [77J 83 Postoperative Age, # of transfusions, cardiac 
surgery, cardiac failure, sex, vascular 
surgery other than AAA, interval 
from ARF to dialysis, preoperative 
hypotension 
Liem et al. (78) 59 Only needing rHD CNS depression, inotropic support, 
age 
Corwin et al. [73] 232 AlN Sepsis, recovery of renal function 
Barton el at. [79] 250 Only needing Age, ventilation, inotropic score, 
CVVH urine volume, bilirubin 
Liano et al. (72) 353 AlN Age, sex, nephrotoxic, oliguria, 
hypotension, jaundice, coma 
unconsciousness, assisted ventilation 
Halstenberg et af. [81] 512 Only needing OS Sex, intubation, platelet count < 
50« 109/1, bilirubin, 110 surgery, low 
serum creatinine, organ system 
failure, change in urea 
Abbreviations: ARF, acute renal failure; IHD, intemlittent hemodialysis; AAA, abdominal aortic 
aneurysm; eNS, central nervous system; A TN, acute tubular necrosis; CVVH, continuous venovenous 
hemofiltration; OS, dialytic support 
The APACHE 11 scoring system 
The need for measuring severity of illness and predicting outcome in leU patients 
has long been recognised by intensivists. Using multivariate analysis, several risk 
models have been developed for use in the general ICU popUlation [66,69]. Of these 
models, the acute physiology and chronic health evaluation (APACHE) II scoring 
system is the most widely used and validated form [83-87]. To quantify severity of 
illness, APACHE II generates a score for each individual patieut (scoring range 0-
71); the score is the sum of three parts of the evaluation, i.e., the acute physiology 
score (0-60), an age-related score (0-6), and points for chronic illness (0,2, or 5). The 
acute physiology score is based on the: worst values for 12 commonly measured 
physiologic variables obtained during the the first 24 h of ICU stay. The patients raw 
score is entered into a logistic regression equation together with a disease-specific 
coefficient that reflects the relative mortality of the underlyiug condition or pathology 
(Table 6). 
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Table 6. APACHE II Equation to Predict Hospital Mortality (%) for an Individual Patient'8.l 
Ln (RlI-R) ~ -3.517 + (APACHE II x 0.146) + D + S 
Where 
R Risk of hospital mortality 
D Disease weight according to relative risk imposed by a specific disease 
(range: -3.35 to +0.89) 
S = Additional weight (0.603) for emergency surgery 
Ln = Loge 
From [83). @: The predicted death rate for groups is calculated by sunillling the individual risks and 
dividing them by the total number of patients 
The equation than yields an estimated mortality risk for the individual patient. The 
expected deaths for a group of patients is the sum of the individual mortality risks. 
APACHE II has been used extensively in risk-stratification of patients in order to 
control for case-mix so that appropriate comparisons of therapy can be made [84,87]. 
It has also been used for comparing outcome of different leU's, resource allocation 
and individual decision making [84,87,88). The routinely use of APACHE II in many 
leu's and the familiarity of the system to most physicians involved in the care of 
critically ill patients would also favor its use in patients with ARF. 
To date, however, only few authors have used the APACHE II system in ARF 
patients [89,90]. In addition, while validated for use in the general and surgical ICU 
population, it is not clear whether its use is valid in specific disease groups such as 
those with ARF. One particular question arises as to whether the APACHE II system, 
originally intended for use during the first 24 h of leU admission, is automatically 
transferrable for use in patients who develop ARF during their course of stay on the 
ICU. 
4. Inflammatory mediators and acutc rcnal failure 
Mediatol's of the systemic inflammatory response syndrome 
Today, ARF on the ICU most conmlOnly occurs in the setting of MOSF, usuaUy 
as a result of septicemia [4,23,24,29]. Sepsis results in an extensive triggering of the 
bodies host defense mechanisms, resulting in the release of a myriad of mediators 
with vasoactive and cardiodepressant properties (Table 7) into the circulation [91,92). 
However, non-infectious insults (e.g., burns, trauma, pancreatitis, severe hemorrhage) 
may produce a similar response [93-95]. The acronyme 'systemic inflanmlatory 
response syndrome' (SIRS) was therefore proposed to describe this inflammatory 
state, irrespective of its cause [96]. 
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Table 7. Inflammatory Mediators of SIRS and Their Molecular Weight 
Mediator 
Cytokines 
IL-IB 
IL-6 
IL-8 
lNFa 
Platelet activating factor 
Arachidonic acid metabolites 
TXA, 
Leukotrienes 
Prostaglandins 
Humoral defense systems 
Complement (C3a, C5a) 
Kinins (Bradykinin) 
Others 
Myocardial depressant substance(s) 
Endorphins 
Histamine 
Serotonin 
Molecular weight (Dalton) 
16,800 
22,000 
10,000 
16,800 (52,000)@ 
500 
350 
-500 
--{i00 
10,000; 11,200 
1,206 
10,000 - 30,000' 
---4,000 
127 
210 
Abbreviations: SIRS, Systemic intlanllltatory response syndrome; @: bioactive TNFa may exist in the 
circulation as a trimer [100]; H: ultrafiltrate experiments for detennining the molecular weight(s) 
yielded differing results. From (4,92,93,97,100}. 
Although endotoxin directly triggers the activation of a number of mediators, 
cytokines appear early in the sequence of reactions initiated by endotoxin and playa 
major role in amplifying the subsequent release of soluble mediators and the 
activation of different plasma cascades [91,94,97]. Cytokines exert their influences on 
diverse cell types, such as neutrophils, endothelial cells, and lymphocytes. A 
comprehensive discussion of these factors as well as a detailed account of specific 
cytokine functions is beyond the scope of this chapter and one is referred to several 
excellent reviews [97-100]. It appears that tumor necrosis factor-alpha (TNFa) is a 
central mediator in septic and non-septic shock. Infusions of TNFa into experimental 
animal models mimic many of the hemodynamic and vascular changes of septic 
shock, including hypotension, coagulopathy, Jeucocyte aggregation, vascular leakage 
and myocardial depression [97-99]. Numerous reports have documented elevated 
circulating levels of TNFct in a number of inflammatory and infectious conditions 
[98,101-103,105]. III addition, (persistently) elevated TNFa plasma levels has been 
found to correlate with poor outcome [99,101] and blocking TNFa might ameliorate 
some of the deleterious effects of SIRS [97,106]. Its short half-life, however, suggests 
that TNFa exerts regional and local effects rather thall systemic effects [98,102,103]. 
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Detection of TNFa in the circulation may therefore reflect excessive activity of this 
mediator at the tissue level [100, I 03]. Interleukin-I B (IL-I B) shares many functions 
with TNFa: that are directed toward inflammatory responses, although less severe 
[97,100,102]. Blocking IL-W prevented some sequelae of severe endotoxemia or 
sepsis [106]. In one study [lOS], IL-IB levels were associated with patient outcome; 
however, subsequent studies did not confirm these findings [107,108]. In addition, 
IL-IB is only occassionally and transiently released into the circulation [95,97,108]. 
Unlike most other cytokines, interleukin-6 (IL-6) is more readily detected 
systemically and thus serves more of a classical endocrine function 
[97,100,101,107,109]. It has been suggested that the relative lack of toxicity of IL-6 
in experimental models argues against a major causative role in SIRS [97]. However, 
increased plasma IL-6 levels have repeatedly been found to correlate with subsequent 
organ failure(s) [110, III] and poor outcome [102,107,109,112]. In addition, Gennari 
el al. [113] recently showed that blocking of IL-6 may reduce bacterial translocation 
from the gut and improve outcome in gut~derived sepsis. Interlellkin~8 (lL-8) has also 
been suggested to playa role in SIRS [97,114]. In one study [97], plasma levels of 
IL-8 correlated with the severity of injury of multiple trauma patients. In another 
study, however, plasma IL-8 were higher in patients who survived compared to 
patients who died, suggesting a possible protective role in shock [114]. Further study 
to assess the role of this cytokine in SIRS is therefore needed. Principal effects of 
these cytokines are summarized in rable 8. Platelet activating factor (PAF) also 
appears to playa fundamental role in the pathogenesis of SIRS. Increased levels of 
PAF have been identified in animal models of endotoxemia and in human sepsis 
[91,92,115.116]. Many of the manifestations of endotoxemia, such as cardiovascular 
collapse and lethal pulmonary injury, can be mimicked by infusion of PAF [91, lIS]. 
Table 8. Abridged List of the Pathogenic Effects of Cyfokines in SIRS 
Cytokine 
TNFa 
IL-W 
IL-6 
IL-8 
Major pathogenic effects 
Neutrophil activation; amplification of mediator release (incl. itself); endothelial 
activation; increased microvascular penneability; decreased peripheral vascular 
resistence; myocardial depression; activation coagulation cascade and 
complement system; fever; lactic acidosis 
Neutrophil activation; amplification of mediator release (inc!. itself); increased 
microvascular pemleability; decreased peripheral vascular resistence; stimulates 
T~ and B-cells; fever (acts synergistically with TNFct) 
Stimulates synthesis of acute phase proteins; activates T~ and B-cclls; fever 
Recruitment and activation neutrophils and lymphocytes 
Abbreviations: SIRS, systemic inflanm1atory response syndrome; TNFa, tumor necrosis factor alpha; 
IL~lB, interleukin 1.13; IL-6, interleukin 6; IL-S, interleukin S. From [92,93,94,97,98,99,100,103,104]. 
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Use of PAF receptor antagonists in animal models attenuated many of the 
hemodynamic and metabolic sequelae of endotoxemia [91,115,116]. One important 
effect of PAF, like that of TNFa, is that it amplifies the release of various 
inflammatory mediators from cells (including cytokines and PAF), initially 'primed' 
by endotoxin [115]. PAF also strongly promotes platelet aggregation [92]. The 
complement system also participates in the inflammatory response by the generation 
and release of C3a and C5a. These factors, known as anaphyiactoxins, stimulate 
neutrophils and enhance the permeability of endothelial cells [91,92,117]. Systemic 
administration of C5a into animals induce a fall in blood pressure and leukopenia, the 
latter being due to pulmonary sequestration [117]. This may contribute to the 
development of the 'adult respiratOlY distress syndrome' (ARDS). Anaphylactoxins 
may be able to induce production of cytokines by monocytes. In one study, plasma 
levels of C3a were found to correlate with outcome in septic patients [117]. 
Activation products of the contact system of coagulation (e.g., bradykinin) have been 
found to contribute to SIRS by enhancing vascular permeability, decreasing vascular 
tone and stimulating aggregation and degranulation of neutrophils [91,92,117,118]. 
Both experimental and clinical studies have shown an early rise of bradykinin in 
septic ARDS and necrotizing pancreatitis [91,92,118]. Eicosanoids, i.e., metabolites 
of arachidonic acid (AA), are also involved in the pathogenesis of SIRS [119]. Both 
TNFa and PAF promote AA metabolism. Conversely, AA derivates can prompt 
TNFa and PAF release from cells [92,1l9]. In several studies, plasma levels of 
thromboxane A2 (TXA,) and 6-keto-prostaglandin-Ia (6-keto-PG-Ia) were found to 
correlate with patient outcome in septic shock [1l8,I20]. AA metabolites such as 
leukotrienes and TXA2 stimulate aggregation and degranulation of neutrophils, 
increase vascular permeability and produce vasoconstriction of several vascular beds. 
TXA2 also promotes platelet aggregation. Leukotrienes and TXA2 also promote the 
release of vasodilating prostaglandins (PG), i.e., PGI, and PGE" which might be a 
protective mechanism. However, it can be detrimental when these levels are excessive 
by inducing or prolonging shock [119]. Several studies have documented a circulating 
(waterRsoluble) factor responsible for myocardial depression in various forms of 
shock [92,93,121-125]. This factor or factors, however, has yet to be identified. 
Ultrafiltration of sera from these patients to determine its molecular weight yielded 
differing results; some reported a molecular weight of 500-600 Dalton willie others 
reported a molecular weight between 10 and 30 kDalton [93,121-125]. Increased 
levels of other vasoactive mediators, listed in Table 7, are also documented in both 
experimental and human shock but its precise role and relative importance in SIRS is 
less clear [91-93]. Thus it seems that all these mediators act in concert to produce 
microvascular collapse and tissue hypoxia, ultimately resulting in multiple organ 
dysfunction. However, it should also be recognized that tissue responses are 
dependent not only upon the absolute concentrations of mediators such as TNFa; and 
IL-lfi, but also upon the concentrations of cytokine inhibitors (e.g, soluble TNF 
receptors, IL-IJl receptor antagonist [100, I 06, 126]) and anti-inflammatory mediators 
[100]. 
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Specific mediatol's of renal dysfunction 
The pathophysiology of renal dysfunction in the setting of SIRS is not clearly 
understood. Patients dying of sepsis and ARF usually show no major structural 
damage at autopsy [23,127]. Renal blood flow (RBF) may be maintained because of 
renal vasodilation (i.e., autoregulation) during systemic hypotension. However, when 
blood pressure continues to decline, the renal vessels constrict due to increases in 
sympathetic activity, activation of the reninRangiotensinRaldosteron system and release 
of vasopressin [23]. In an animal model of septic ARF, however, intense renal 
vasoconstriction was observed in the absence of hypotension [128]. In addition to 
altered systemic and intrarenal hemodynamics, specific mediator activity contributes 
to the development or persistence of ARF (Table 9). 
Eicosanoids exert important (inter)actions in ARF [128-135]. In sheep with severe 
sepsis and renal impairment, urinary excretion of TXB1, i.e., the metabolite of 
TXA" correlated inversely with MAP and TX-synthetase inhibition conferred 
protection for renal function [128]. Urinary excretion of 6-keto-PG-lc<, a metabolite 
of vasodilatillg POs was also increased. Renal impairment following bile duct ligation 
in rats was also associated with increased urinary TXA2 excretion and could be 
restored by intraperitoneal administration of a specific TXA, blocker [135]. TXA, 
produces platelet aggregation, leads to a preferential afferent vasoconstriction and 
contracts glomerular mesangial cells. 
Table 9. Mechanisms Invoh'ed in the Development and Persistence of Acute Renal Failure and 
Proposed Responsible Mediators 
Mechanism 
Arteriolar vasoconstriction 
afferent 
efferent 
Mesangial contraction 
Microvascular tluombosis@ 
Recruitment/trapping ne\ltrophiis 
Mediator 
TXA2; PAF; endothelin 
Endothelin; leucotrielles 
TXA2; PGE2; leucotrienes; PAF; 
elldothelin 
TXA2; PAF; 1NFa 
TNFa; ILR 16; C3a, C5a; leucotrienes 
Abbreviations: TXA2, thromboxane A2; PAF, platelet activating factor; PGE2• prostaglandin £2; TNFa, 
tumor necrosis factor alpha; IL-W, interleukin III @: may be provoked by stimulating platelet 
aggregation (TXA2• PAF) or by stimulating the coagulation cascade (1NFa). 
From [48,115,116,127-145J 
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Systemic or intrarenal administration of leukotrienes resulted in a decrease of RBF 
and glomemlar filtration rate (GFR) by increasing efferent arteriolar resistance and 
contraction of mesangiai cells [128-135]. Adverse renal effects of endotoxemia could 
be partially abolished by the systemic administration of a nonwspecific leucotriene 
antagonist [132,134]. Neutrophil activation by leukotrienes may also playa role 
[133]. It thus seems that different AA metabolites exert opposite actions in the kidney 
and that the ratio between POI" PGE,i TXA, leukotrienes is critical. In addition, it 
should also be recognized that vasodilating PGs may induce mesangial contraction by 
stimulating the renin-angiotensin system [129,130]. PAF may also contribute to renal 
impairment in endotoxemia. PAF generation has been demonstrated in isolated 
perfused kidney and in various isolated renal cells [115,116]. PAF produces arteriolar 
vasoconstriction, contracts mesangiai cells and promotes platelet aggregation 
[115,116,136]. Infusion of PAF in normal rats decreased GFR, RBF and filtration 
fraction (FF) in the absence of hypotension [115,116]. Systemic administration of a 
PAF receptor antagonist improved GFR, RBF and FF in endotoxin-induced ARF in 
rats without inducing significant changes in MAP [115]. Endothelin, a 21-amino-acid 
(2,500 Da), is also implicated in the reduction in GFR and RBF that characterizes 
septic ARF. It causes both afferent and efferent vasoconstriction and contracts 
mesangial cells [137-141]. It is not clear whether endothelin exerts endocriene actions 
or that renal effects result from locally produced endothelin [137,138,140]. In septic 
shock patients, plasma endothelin levels correlated inversely with endogenous 
creatinine clearance, independent from MAP, suggesting that circulating endothelin 
affects adversely intrarenal hemodynamics in septic ARF [140]. LPS-induced renal 
hypofiltration was prevented by intrarenal infusion of anti-endothelin antibodies 
[141]. Hypoxia and norepinephrine are important stimuli for endothelin release from 
endothelium [137,138]. Circulating or locally produced cytokines also adversely 
affect renal function. In glycerol-induced ARF in rats, i.e. an established model of 
acute trauma, a rapid rise was seen of plasma TNFct levels which correlated with the 
development of severe renal failure [142]. Systemic administration of TNFctwantisera 
prior to glycerol injection ameliorated renal impairment. TNFct may mediate renal 
dysfunction by stimulating local endothelin or PAF release, by stimulating the 
coagulation cascade, or by increasing leucocyte adhesion molecules, thereby causing 
entrapment. of neutrophils and other inflammatory cells that release toxic mediators 
(i.e., elastaseJ reactive oxygen products, cytokines) [141,143]. In vitro, endotoxin-
induced ARF in rats was associated with increased production of TNFa and IL-6 by 
resident glomerular cells [143]. Cliuically, a correlation was found between the 
occurrence of ARF after cardiac bypass surgery and preoperative plasma levels of IL-
6 (p ~ 0.02) and sTNFR-IIII (p < 0.05), respectively [144]. Cummings and co-
workers (128] showed expression of the IL-Ill gene in tubular and vascular structures 
within kidney, removed from a trauma patient. Activated complement may also 
contribute to renal impairment by inducing neutrophil activation in the ischemic 
kidney [48]. Indeed, Linas ef al. reported that addition of endotoxin-activated 
polymorphonuclear cells to ischemic kidney, but not to non-ischemic kidney, caused 
severe renal injury [145]. Direct cellular damage may be induced by neutrophil 
products such as elastase or free oxygen radicals (133], whereas neutrophil-derived 
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vasoconstricting mediators such as TXA2 and leukotrienes may affect adversely renal 
hemodynamics [48,133,145]. 
These combined data suggest that the reduction in GFR and RBF entirely depend 
on altered glomerular hemodynamics. The latter is regulated by the tone in afferent 
and efferent arterioles and in the mesangial cells. Mediators may be produced by 
intrinsic renal cells or by macrophages infiltrating the renal parenchyme. In addition, 
circulating mediators may be involved in impairment of renal function. Therefore, 
like ARDS [91,92], ARF may represent a target organ injury resulting from 
activation of the hoses inflammatory cells and uncontrolled liberation of 
inflammatory mediators. 
The role of the kidney in medialor excretion 
Data upon the role of the kidney in mediator clearance and its clinical relevance in 
SIRS is scarce. Experimental animal data demonstrated an important role for the 
kidney in the clearance of sTNFR and TNFalTNFR complexes in mice [146]. In 
undialysed patients with chronic renal failure, plasma concentrations of TNFa, IL-IO 
and sTNFR strongly correlated with the degree of renal insufficiency, suggesting that 
inadequate renal clearance is at least partially responsible for elevated cytokine levels 
in these patients [147]. In a study of 20 septic lCU patients, it was found that TNFa 
and sTNFR-I levels increased when renal failure ensued and that these levels 
correlated with APACHE II scores and sepsis severity [148]. Graziani and co-workers 
[149] investigated the role of the kidney in cytokine elimination by comparing 
cytokine levels in septic patients with normal renal function, non-oliguric and oliguric 
ARF. Plasma IL-6 levels were significantly increased in oliguric ARF patients when 
compared to the other two groups (202 ± 13 vs 106 ± 16 and 103 ± 13 pg/mL; p < 
0.01). However, from available data one call not exclude differences in disease 
severity as a possible explanation of these findings. They also reported a weak 
inverse correlation between plasma levels and urinary excretion of IL-lfi (r2 = -0.33; 
P < 0.07) and a significant correlation between fractional urinary excretion of IL~6 
and lL-IJl (1' ~ 0.885; P < 0.0001). Froon e/ al. observed a significant correlation 
between plasma creatinine values and sTNFR-l (r' ~ 0.60; p < 0.001) and sTNFR-II 
(I" ~ 0.44; P < 0.001) levels [ISO]. No data are available upon the urinary excretion 
of other mediators in relation to plasma levels or on creatinine values in relation to 
specific plasma mediator levels. 
It has been suggested that CRRT with highly porous membranes might simulate a 
kidney-like function in removing inflammatory mediators from the blood in critically 
ill patients and that this might have a beneficial influence on the clinical course in 
these patients [151,152]. In different animal models of septic shock, isovolemic 
hemofiltration improved hemodynamics and/or gas exchange [153-158]. The 
mechanism by which this occurred, however, was not entirely clear. As the most 
pronounced beneficial effects were seen in the study using high uItrafiltrate volurnes 
(Fig 3a,b), convective removal of mediators with vasoactive and cardiodepressant 
properties might play an important role [151,157,158]. 
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Figure 3: The effect of (A) low volume (600 mUh) [153J and (B) high volume (6 liters/h) [157,158J 
hemofiltration (HF) on the course of cardiac olltput in porcine endotoxic shock. High volume HF 
resulted in a more pronounced beneficial effect on cardiac olltput as compared to low volume HF, 
Differences in e;rperimental protocol incltlded the lotal amount of endotoxin infused (0.5 mg [AJ vs 20 
mg [Bl) and the start of HF (75 min [AJ vs 30111;'/ IBJ after Ihe initiation of endotoxin infusion). Data 
(mean±SEM) of Group 2 (endoloxemia alld HF treatment) are compared to those obtained in Group I 
(control group, endotoxemia onl)~. ': p < 0.05. [From Grootel1dors/ AF, Van Bommel EFH. The role 
of hemofiltration in the critically ilIlCU patient: present and future. Blood Purij 1993; II :209~223J 
Uncontrolled clinical data support the contention that CRRT, in contrast to IHD, rnay 
improve hemodynamics and gas exchange in (non-renal) MOSF [4,151,152]. 
However, no proper designed clinical study has yet evaluated these possible 
beneficial effects of CRRT in patients with SIRS [151,152]. III addition, little is 
known as to the endogenous clearance in relation to this exogenous clearance of 
soluble mediators, the possible mechanisms (i.e., convective transfer versus 
adsorption onto the membrane) and of the impact of prolonged blood-membrane 
interaction on mediator levels. 
5. Aim and outline of the thesis 
Despite impressive advances ill the field of intensive care, patients who develop 
ARF carry a high mortality. One of the most rapidly evolving aspects of intensive 
care is the development of CRRT, which is now increasingly accepted as the 
preferred treatment modality in the hemodynamically unstable ICU patient. Indeed, 
an ever increasing number of reports have described the various aspects of different 
forms of CRRT. 
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Its superiority over conventional dialysis in terms of metabolic control, however, is 
not clearly established, In addition, despite its potentional beneficial effects. it is not 
clear whether the use of CRRT has resulted in enhanced survival of these patients, 
One explanation may be a change in patient characteristics, i,e" a shift from patients 
with isolated ARF to (older) patients who developed ARF as part of MOSF, usually 
as the result of sepsis, MOSF is characterised by an exaggerated inflammatory 
response in which the body can not control its own defense mechanisms, resulting in 
the release of many mediators into the circulation, Direct comparison of mortality 
data from diffcrent reports is hampered by the lack of objective and validated illness 
severity scores, The aim of this thesis is to assess the efficacy of CRRT, to examine 
its proposed superiority over IHD, and to investigate the mechanisms involved in the 
possible beneficial effects of CRRT on hemodynamics and gas exchange, As we used 
the APACHE II scoring system to describe disease severity to allow a meaningfull 
comparison, it was also investigated whether its use was valid in ARF patients, 
In chapter II a comprehensive review is given of the current knowledge of 
CRRT, Technical and clinical aspects of the various forms of CRRT, including their 
impact on serum drug levels and nutrient balance, are discussed, In addition, an 
attempt is made to clarify the possible beneficial role of CRRT in reducing patient 
morbidity and mortality in the ICU. 
Chapter III describes the use of the APACHE II scoring system on the day of 
ICU admission and on the day dialytic support was initiated. Using logistic regression 
analysis, a comparison of the adequacy in terms of outcome prediction is made. In 
addition, using the APACHE II scoring system, the influence of several factors on 
outcome is examined. 
In chapter IV the efficacy of the continuous treatment modality as employed in 
our hospital, i.e., CA VHD, is examined. In addition, a detailed description of the 
patient population is provided, including APACHE II scoring and examination of 
factors influencing survival, to allow a meaningful! comparison with other reports. 
In chaptel' V a direct comparison of CA VHD and IHD is made in ARF patients 
treated in the same ICU. A detailed description of the patient population, including 
biochemical and hematological data, is provided. Major variables examined are the 
control of fluid balance, acidosis and azotemia; hemodynamic tolerance; the duration 
of ARF; renal and patient outcome; and costs. 
111 chapter VI the hypothesis is tested that some of the beneficial effects of CRRT 
arc attributable to the convective removal of factors that adversely affect 
hemodynamics during endotoxemia. This was investigated with a whole-animal bio-
assay. i.e., ultrafiltrate collected under sterile conditions during hemofiltration of 
endotoxemic pigs was infused into healthy pigs and their hemodynamics were 
compared with those of pigs who were infused with ultrafiltrate from healthy pigs. 
Chapter VII describes the results of a study in which the impact of hemofiltration 
membranes on plasma cytokine kinetics (TNFa, IL-IB, and IL-6) is investigated 
during both in vitro and in vivo CRRT, with emphasis on the possible mechanisms 
involved in mediator clearance (convective transfer vs adsorption onto the membrane 
surface) and the effects hereon of prolonged filter use. 
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In chapter VIII these findings are summarized and propo~als for future research 
are given to further unravel the question whether the use of CRRT leads to irnproved 
survival of ARF patients and to provide a rational for the use of CRRT in the 
absence of conventional indications for dialytic support. 
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Chapter 2 
Abstl'act 
Despite continuous progress in intensive care during the last decades, the outcome of 
critically ill patients who develop acute renal failure (ARP) is still poor. This may be 
explained partially by the frequent occurrence of ARF as part of multiple organ 
systems failure (MOSF). In this complex and unstable patient population, the 
provision of adequate renal support with either intermittent hemodialysis or peritoneal 
dialysis may pose major problems. Continuous renal replacement therapy (CRRT) is 
now increasingly accepted as the preferred treatment modality in the management of 
ARF in these patients. The technique offers adequate control of biochemistry and 
fluid balance in hemodynamically unstable patients, thereby enabling aggressive 
nutritional and inotropic supp0l1 without the risk of exacerbating azotemia or fluid 
overload. In addition, experimental and clinical data suggest that CRRT may have a 
beneficial influence on hemodynamics and gas exchange in patients with septic shock 
and (non~renal) MOSF, independent of an impact on fluid balance. This review deals 
with both the technical and clinical aspects of the various continuous therapies, 
including their impact on serum drug levels and nutrient balance. In addition, an 
attempt is made to clarify the possible beneficial role of CRRT in reducing patient 
morbidity and m0l1ality in the ICU. 
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Intl'oduction 
Although treatment modalities for conditions predisposing to the development of 
acute renal failure (ARP) have increased and improved over the years, the incidence 
and outcome of ARF in the intensive care unit (ICU) has changed little [1,2]. This 
lack of change seems related to variations in the lCU population during the last 
decade with increasing numbers of elderly patients and patients with more complex 
conditions [1,3]. 
It is the complications associated with ARF that result largely in the death of 
patients [2,3]. Critically ill patients with ARF commonly have additional failing 
organ systems and mechanical ventilation is often required at some stage of the 
illness as a result of inadequate oxygenation due to infection, pulmonary edema 
and/or 'adult respiratory distress syndrome' (ARDS) [1,2,3]. It is likely that recent 
advances in intensive care medicine permits treatment of ARF patients who 
previously may not have been considered for renal support. 
Renal replacement therapy is one of the most rapidly evolving aspects of intensive 
care. As the traditional forms of dialysis treatment have characteristics which limit 
their use in critically ill patients with ARF, continuous renal replacement therapy 
(CRRT) has been rapidly adopted as the preferred treatment modality [4,5,6]. 
However, whether this new form of continuous treatment for ARF is superior to 
conventional dialysis can currently only be answered by reference to theoretical 
advantages, by investigations of some single factors and by a few, mostly 
retrospective studies comparing the clinical outcome of ARF patients treated with 
continuous or conventional dialysis techniques. 
We present an updated review of the various continuous renal replacement 
teclllliques, and we attempt to clarify the possible beneficial role of CRRT in 
reducing patient mortality in the ICU. To allow comparison between the procedures, 
conventional dialysis techniques are reviewed briefly. 
Intermittent Hemodialysis. 
Intennittent hemodialysis (IHD) has been used most commonly for the 
management of ARF. It is the treatment of choice for patients who are 
cardiovascularly stable or when IifeM tiueatening hyperkalemia is present. The daily 
urea clearance of IHD (urea clearance 120M l80 mUmin), calculated as the mean value 
of 4 hour, every-other-day trealment, amounts to 19 Llday. As small solutes «500 
Dalton [Da]) diffuse more rapidly than large molecules, clearance is less for solutes 
with higher molecular weights (MW). 
IHD requires specialist equipment and personnel and, despite a number of 
technical modifications, may cause cardiovascular instability and solute disequilibrium 
[4,7,8,9]. In a retrospective study of critically ill patients with ARF secondary to 
abdominal sepsis, hemodialysis led to severe hypotension (mean arterial pressure 
[MAP] <50 111111 Hg) in 52 of 163 (31.9%) procedures [8]. Fluid infused to raise the 
blood pressure may result in the patient ending dialysis more fluid overloaded than 
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pretreatment [5,7,8,9]. Possible explanations for the observed hemodynamic 
instability include impaired sympathetic response to fluid removal, the effect of 
dialysate bath components (i,e" buffer-anion used, sodium content, the presence of 
cytokine-inducing substances) and rapid volume and osmolar shifts [4,10-13]. 
Kidneys affected by acute tubular necrosis may not be able to autoregulate blood 
flow and may so be susceptible to further ischemic insults during hypotensive 
episodes associated with IHD [8,14], In addition, dialysis-induced at1erial hypoxemia 
and an increase in oxygen consumption may occur with the use of acetate-containing 
dialysate [9,13] and because of membrane incompatibility [9,15]. To allow 
hyperalimentation and to remove uremic solutes, IHD needs to be performed with 
increased frequency, However, attempts to decrease the frequency of IHD often 
results in a tendency to restrict fluids and nutritional intake, thereby aggrevating 
catabolism [5,16]. All of these problems may potentially exacerbate the already 
precarious condition of the critically ill patient. In one study [17], a significant 
increase in vital organ dysfunctions was observed during IHD in ICU patients with 
ARF. 
Recent advances in hemodialysis technology, such as bicarbonate dialysis, 
volumetric dialysis machines allowing controiJed ultrafiltration and more 
biocompatible dialyzer membranes (as used for CRRT), have reduced, rather than 
prevented, hemodynamic instability during IHD [9,16]. 
Peritoneal Dialysis 
Although less efficient in removing of fluid and waste products, acute (continuous 
or intermittent) peritoneal dialysis (PD) may be better tolerated in the critically ill 
patient [18]. PD is a relatively simple procedure and does not require the use of 
specialised equipment. The urea clearance of acute PD usually approximates 7-14 
L/day (5-10 mllmin), but may be augmented by increasing volume/exchange, 
cyclesnlf, and/or ultrafiltration/exchange [18,19,20], However, factors such as reduced 
splancimic blood flow during shock or the use of vasoconstrictors and low oncotic 
pressure due to hypoalbuminemia may compromise PD efficiency, 
According to Nolph [18], there are no absolute indications for PD other than the 
inavailabili!), of other techniques and the need for dialysis. If the hepatitis B or HIV 
status is unknown, then PD will result in less risk to medical and nursing staff than 
IHD where cross infection from the patients blood is possible, Relative indications 
include hemorrhage, for which anticoagulants are undesirable; hypotensive states, for 
which IHD is likely to exacerbate the problem; difficult blood access; and 
hypothermia, for which central core warming with intraperitoneal fluid may be 
desirable [18,20]. 
Acute PD may be contra-indicated or impossible to perform because of acute 
intra-abdominal pathology, such as recent abdominal surgery, peritonitis and the 
presence of abdominal drains, In addition, acute PD does not offer urea clearances 
sufficient to ensure adequate control of azotemia in catabolic patients and may be 
inadequate for the ultrafiltrate requirements needed to maintain fluid balance [18,20], 
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This often precludes the provIsIOn of full (par)enteral nutrition. Large volumes of 
intrawabdominal dialysis fluid may lead to respiratory compromise. Other 
complications are hypernatremia following aggressive ultrafiltration [18,20], 
, overfeeding' hyperglycemia with consecutive hypertonic exchanges [21] and, Illost 
importantly, access infection and peritonitis [18,20,22]. It is for these reasons that 
acute PD is now rarely used in the ICU. 
Continuous Renal Replacement Therapy 
CRRT has now been used in a wide variety of clinical settings. The basic 
technique involves placing a heIllofilter in the extracorporeai blood pass of the 
patient, whose systemic blood pressure provides the main driving force for 
ultrafiltration (UF). Continuous renal replacement may take one of several forms: 
continuous arteriovenous hemojiltl'ation (CAVH), first proposed by Kramer in 1977, 
depending on convective transfer of solute [23]; slow continuous ultrajiltration 
(SCUF), a technique of continuous slow ultrafiltration, most commonly performed 
without simultaneous fluid replacement [7]; continuous venovenous hemojiltration 
(CVVH). which. unlike CA VH. depends on the use of an external blood pump [24]; 
continuous arteriovenous hemodiajlltralion (CA VHD), first described by Geronemus 
and Schueider in 1984 [25]. which involves infusing sterile dialysis fluid through the 
hemofilter in a counterwcurrent direction to the blood flow, thereby enhancing solute 
movement due to convection across the membrane by diffusion; continuous 
venovenous hemodiafiltration (CVVHD), ultrafiltration and dialysis combined as in 
CA VHD, but performed with the use of a pump-assisted venovenous extracorporeal 
circuit [26]; continuous ultrafiltration periodic intermittent hemodialysis (CUPID), 
intermittent hemodialysis performed against a background of continuous pump-driven 
ultrafiltation [27]. 
Principles 
Hemofiltration was first described by Henderson el al. [28]. This technique uses 
the principle of convective transport of solutes: venous blood is pumped from the 
patient through an artificial kidney and subsequently back to the patient and an 
ultrafiltrate of plasma water is produced by a hydrostatic pressure gradient across a 
highly permeable membrane (in vitro molecular cutwoff point 40,0 kDa). Mass 
transfer occurs by convection, i.e. as water moves across the membrane 
(,ultrafiltration'), it drags with it solutes such as urea. The quantity of solute 
movement by convection depends upon molecular size, membrane penneability, 
hydrostatic pressure and the UF rate. Intravascular volume is preserved by replacing 
the ultrafiltrate with fluid that has an electrolyte composition similar to that of plasma 
[28]. 
Kramer [23.29] modified this principle by simply attaching a hemofilter to the 
femoral artery and vein, using the patient's own arterial blood pressure as a driving 
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force through the filter, thereby obviating the need for a pump to drive the system: 
CA VH. Over the last decade, this technique has gained increasing popularity as a 
way of treating critically ill patients with ARF in the ICU [4,5,6]. 
Advantages of continuous renal replacement therapy 
Several potential advantages of CRRT relative to conventional hemodialysis in 
critically ill patients with ARF have been identified. Principle among these is the 
avoidance of cardiovascular instability [8,30]. Paganini e/ al. reported in 1984 that 23 
of their patients, for whom IHD was not possible, could be treated effectively with 
CRRT [7]. CRRT is a slow, continuous form of therapy that avoids the rapid shifts in 
both blood volume status and electrolyte concentrations that result from rapid 
removal of solutes occurring with IHD [7,8,30]. The gradual, yet continuous, removal 
of intravascular water and toxic metabolites allows great flexibility in fluid and 
electrolyte management and creates 'space' for the (early) administration of full 
parenteral nutrition and intravenous medications [16,20,31]. In addition, an 
improvement of pulmonary gas exchange and cardiac performance may result from 
the readily reversal of any existing pulmonary edema and by the titration of left 
ventricular filling pressure [7,32]. Another advantage of continuous therapies is the 
metabolic 'steady state' of the ICU patients. CRRT prevents the peak/trough urea 
concentrations associated with IHD [33,34], and the steady~state urea concentration 
achieved may well reflect more adequate azotemic control [33]. By use of 
'appropiate' filtration replacement fluid the patient's electrol),te concentrations can be 
decreased or increased gradually and independently of changes in total body water 
[32·37]. Other potential advantages relative to IHD include a lower circulating 
extracorporeal blood volume, less complement activation and less need for specialised 
personnel or equipment [4,6,35]. In addition, the ability of CRRT to remove mid· to 
high MW solutes (0,50·20,0 kDa) has led to the application of this technique in 
various clinical conditions (see section 'non-renal ~ffects')[38]. The effectiveness of 
CRRT, particularly its recently developed modifications (CVVH[D], CA VHD), is 
such that adequate metabolic control can be achieved even in severely hypotensive, 
hypercatabolic patients. 
Fluid and so/ute removal 
The capability of CRRT to remove plasma water and solutes is a function of the 
net pressure gradient across the mernbrane, i.e., the difference between the 
hydrostatic and OIlCOtiC pressures present in the extracorporeal system. Positive 
hydrostatic pressure within the hemofilter is a function of the MAP but tends to be 
much lower because of resistance encountered by blood flow. This decrease is 
determined by the type of vascular access, the length and internal diameter of the 
blood tubing, the resistance of the hemofiltration membrane and the patient's venous 
pressure [35·37,39]. A MAP of 50·70 nunHg is generally required to produce an 
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adequate UF rate. A negative hydrostatic pressure component is generated by suction 
produced by the weight of the ultrafiltrate fluid column beneath the hemofilter. The 
pressure generated is equal to the height of the fluid column (cm) multiplied by 0.74 
nun Hg/cm H20 (usually 15-30 nunHg). The oncotic pressure exerted by plasma 
proteins within the blood compartment of the hemofilter opposes the forces that favor 
filtration. As UF occurs, the oncotic pressure increases along the length of the filter 
and may subsequently become sufficient to offset the hydrostatic pressure, thus 
causing UF to cease (i.e., 'filtration pressure equilibrium') [39]. However, filtration 
pressure disequilibrium (postfilter hydrostatic pressure> postfilter oncotic pressure) is 
probably present in the majority of patients [40]. As plasma water is removed, non-
proteinMbound solutes are transported across the membrane by convection. The degree 
of permeability of a hemofiltratiol1 membrane is indicated by the Sieving coefficient 
(S). The S represents the ratio of the solute concentration in the ultrafiltrate to the 
solute concentration in the retained plasma and varies from 0 to I, depending on 
particular membrane, molecular size, and proteinMbinding properties of the solute 
[6,7,35]. The Gibbs-Donnan effect on small-solute and electrolyte transfer across the 
membrane is negligible; therefore, their concentration in the uitrafiltrate is identical to 
that in the plasma (S close to 1.0) and the overall concentration of these substances 
remains unchanged [6,7,35]. For larger nonMproteinMbound solutes the concentration in 
the ultrafiltrate progressively decreases with increasing molecular size (S approaching 
O)(Figure I). 
Replacement of the ultrafiltrate with a 'balanced' electrolyte solution, which does 
not contain urea or creatinine, allows the overall clearance of these and other solutes 
from the blood. With ultrafiltrate volumes of 10-12 Ll24h being removed and 
replaced, urea clearances of approximately 9 mllmin may be achieved [35,36]. In 
hypercatabolic or severely hypotensive patients, however, urea clearances with CA VH 
may be inadequate to achieve metabolic control and additional IHD may be required 
[8,41,39]. 
Techniques for enhancing so/ute clearance 
Various modifications of CA VH have been developed to enhance solute clearance. 
These are either directed at increasing UF rate and thus convective solute transport 
(i.e., vacuum suction, predilution, use of a venovenous pumped system) or at 
enhancing solute clearance by combining diffusive and convective solute transfer 
(i.e., adding slow dialysis to CA VH). 
'SlIction assist. Applying suction (usually 150-200 nun Hg) to the UF limb of the 
filter will increase the hydrostatic pressure gradient across the mernbrane and so 
increase UF rate [42]. However, the increase in filtration fraction (sometimes 
exceeding 50%) may favor filter clotting despite adequate heparinization . 
• Prediiution. Adding replacement fluid to the blood within the extracorporeal circuit 
just before it enters the filter Cpredilution'} has the effect of reducing blood viscosity 
as it enters the filter by reducing hematocrit and plashla protein concentration and 
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Figure I: Permeability characteristics 0/ hemofiltraOon membranes (Hf) /01' solutes with different 
molecular weight (MW). The Sieving coefficient, representing the ratio 0/ the solllte concentration ill 
the IIltrafiltrate 10 the solllle concentration in the retained plasma, oj fJ}*Jnicroglohlllin (MW 11,6 kDa) 
is depicted in the figure. For comparison, the permeability profile 0/ the glomerlllar basement 
membrane (right curve) and a 10WjllO,; dialyzer membrane (left curve) are shown, Nole the progessil'e 
decline ;11 permeability 0/ hemofiltralion membranes /01' large solules with increasing molecular size 
(Sieving coefficient approaching zero), 
increasing the flow and hydrostatic pressure across the membrane [43]. In addition, 
predilution increases the availability of urea for convective transfer by favouring its 
movement from the erythrocyte [4,43). All of this will increase the UP rate and may 
lead to a better preservation of sieving properties of the membrane [4,43]. 
• Pumping. The addition of a mechanical blood pump to a venovenous extracorporeal 
circuit (i.e., CVVH) will increase blood flow through the filter (100-300 mllmin) and 
so increase the UP rate. With this technique, up to 50 litres of ultrafiltrate per day 
(urea clearance 34 mllmin) may be produced (44). Longer effective filter life may 
result from the high blood flow tlll'ough the filter. Monitoring and safety features of 
currently available systems include a venous pressure sensor, air detector and 
automatic vascular clamps. In addition, to avoid errors in fluid balance which could 
compromise the patient's clinical condition, computerwmonitored systems have been 
developed which regulate substitution fluid volume by measuring ultrafiltrate volume 
[22,45). 
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Continuous pump-driven venovenous hemofiltration may also be performed with 
volumetric dialysis machines, allowing automatic switching between hemofiltration 
and hemodialysis modes and providing automatic and accurate control of fluid 
removal: CUPID [27J. 
-Adding slow dialysis. By running dialysate through the filtrate compartment of the 
filter, additional diffusive transfer occurs, the basis of CA VHD. Counter-current 
dialysate flow should be preferred as it provides more efficient small-solute clearance 
as compared to concurrent flow [46J. If dialysate flow is slow enough «33 ml/min), 
small solutes will equilibrate completely between blood and dialysate and the urea 
clearance will approximatc dialysate flow rate [25,47]. A high dialysatc flow may 
result in declining increments in solute clearance because of incomplete solute 
equilibration. However, in contrast to Geronemus and Schneider's initial repOli [25], 
no ceiling was observed with dialysate flows up to 67 mllmin (4L1h) in a rccent 
study (urea clearance approaching 50 mllmin)[48J. As diffusive clearance with 
CA VHD is independent of blood flow in the range of 50-190 ml/min, adequate 
control of uremia can be obtained in highly catabolic patients with hypotension [47J. 
In practice, the dialysis component (typically with dialysate flow 0.5-2 Llh) is used 
for correction of uremia and hyperkalemia, whereas the filtration component is used 
for net fluid removal [47-49]. Earlier reports suggested that the presence of dialysate 
reduced the transmembrane hydrostatic pressure gradient and consequently the UF 
rate [25]. However, with use of currently available hemofilters having high hydraulic 
permeability, the UF rate with CAVHD is not reduced when compared with CA VH 
[47,49]. The combination of a pump-driven venovenous extracorporeal circuit with 
counter-current dialysate flow (CVVHD) provides excellent small-solute clearance 
[26,50J. The UF rate is usually limited to 4-7 ml/min and, as with CA VHD, the urea 
clearance is predominantly determined by the dialysate flow [26,50J. However, UF 
rate and thus convective solute transport may be enhanced significantly by increasing 
thc (pump-driven) blood flow. 
Figure 2 shows the urea clearance of the different continuous treatment modalities, 
calculated as the mean value (± SD) from 26 published reports. Both CA VHD and 
CVVH(D) compare favourably with II-ID (when calculated as the mcan value of 4 
hour, every-other-day treatment, i.e., the usual setting). In addition, the limited urea 
clearance obtained with CA VH is illustrated. Whilst urea clcarance of IHD can be 
doubled by daily treatment, the effectiveness of continuous methods can be improved 
either by increasing dialysate flow rate or by increasing daily filtration rate. 
Hemojiltl'alion membranes 
Available membranes for use in CRRT are characterized by a small internal 
volume (40-70 1111), low resistance to flow and high permeability. Because of 
increased biocompatibility, synthetic membranes (either made of polyacrilonitrile, 
polyamide or polysulphone) should be preferred [9,70J. This may especially relate to 
its use in critically ill patients. Experimentally, cuprophane membrane, but not 
polyacrilonitrile membrane, exposed blood delayed resolution of ischemic ARF [71 J. 
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Figure 2: Efficiellcy of different forms of acute renal replacement therapy. The mean (±SD) urea 
clearances of the variolls continuous treatment modalities (CAVH/CAVHD, CVVH!CVVHD) are 
calcldated from 26 published studies [l6,25,26,29,36,47~52,55-69}. Daily clearance 0/ intermittent 
hemodialysis (urea clearance 160 fill/min) is calclliated as the mean value 0/4 ho/(r (!l.'el)'-other-day 
treatment. To allow comparison, clearances 0/ 01/ treatment modalities are e.tpressed as IIII/min (black 
bars) and Uday (hatched bars). 
In addition, blood~membrane exposure significantly aggrevated the negative 
hemodynamic response to endotoxemia [72]. Recently, Davenport e( al. observed 
significant differences in cardiovascular stability during identical hemofiltration 
treatment with 2 different membranes in critically ill patients with combined hepatic 
and renal failure [73]. 
Several comparative studies evaluating filter effectiveness in terms of smal1~solute 
clearance during CRRT exist. Although low filter resistance may increase blood flow, 
it does not necessarily improve UF rate [39]. Olbricht e/ al. observed significant 
differences in UF rate, largely attributable to differences in hydraulic permeability of 
Ihe membrane [40]. The UF rate declines during treatment due to partial clotting of 
the filter, resulting in reduced available membrane surface area [74]. Small-solute 
sieving coefficients do not decrease during CRRT [75,76]. With CA VHD and 
CVVHD, the UF rate becomes less important as small-solute clearance depends 
mainly on diffusive transfer. Yohai et al. observed superior performance 
characteristics of flat plate filters compared to hollow fiber filters, attributable to 
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greater diffusive urea clearances [77]. In contrast, Ifediora el al. observed no 
influence of dialyzer membrane type, surface area or geometry on small~solute 
clearance during CVVHD [50). 
Clearance of large solutes (>500 Da) depends mainly on their convective removal 
and thus UF rate. Sieving properties of synthetic membranes for solutes up to 5,0 
kDa remain constant during CRRT [75,76). Sieving properties for larger solutes may 
decline because of protein adsorption ('secondary membrane formation') [78]. 
Membranes also differ in terms of adsorption and desorption capacity (i.e.,subsequent 
release)[75,76). If the removal of large solutes is of primary concern (e.g., 
inflanunatory mediators such as TNF-u, MW 16,8 kDa; see section 'non-renal 
effects'), it may therefore be beneficial to change filters frequently [SO). 
Filter 'survival' in most centres averages 2-3 days [6,16,35]. Although some 
suggest that flat plate dialyzers with their low resistance to flow require less heparin 
to avoid clotting [74], no comparative data exist. 
Vascular access 
Vascular access is achieved either by means of femoral artery and vein catheters 
or alternatively a Scribner shunt [6,35). Large-bore (S-IOF) femoral arterial and 
venous catheters inserted percutaneously using the Seldinger technique are routineUy 
employed in most leU's. Such catheters can be positioned quickly, requiring no 
special skill for their insertion, and are relatively simple to use, Higher blood flows 
are provided than that achieved with either Scribner shunts or arteriovenous fistulas 
[35,38,40]. Disadvantages associated with their use include an increased risk of 
infection, hemorrhage (either overt or concealed), arteriovenous fistula formation and 
limb ischemia distal to the catheter. Their use may be contra-indicated in patients 
with peripheral vascular disease or in cases of ARF complicating major vascular 
surgery because of the risk of limb ischemia [4,6,35]. Scribner shunts, inserted in the 
wrist or ankle, are an alternative to the use of femoral artery and vein catheters 
[36,38]. The risks of hemorrhage, infection and limb ischemia are less than with 
femoral catheters. The patients are more mobile which facilitates their nursing care 
and vascular access sight is more easily monitored. However, Scribner shunts 
'consume' driving force and decrease blood flow at a given MAP [35,40), In 
addition, this access may easily clot and render the vessels not suitable for future 
arteriovenous fistulas [6,35,38). 
The dangers of arterial cannulation are avoided in CVVH(D), where vascular 
access can be obtained via a double~lulllen catheter, inserted percutaneously with the 
Seldinger technique into the subclavian or femoral vein [26,SI). Indeed, fewer 
complications related to vascular access were noted with CVVHD (11 = 25) compared 
with CA VHD (1/ ~ 2S) in a recent prospective, comparative study (2 vs 10; p < 
0.025)[S2). 
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Table 1. Anticoagulant Regimcs for Use in Continuous Renal Replacement Therapy 
Agent Activity D()se Monitoring Other agents 
Heparin inhibition of thrombin, IXa, 500 - 1000 Uih APTT protamin infusion p<>stfilter 
Xa. XIa, XIIa with AT III 
LMWH anti - Xa activity < 2.5 U/kg/h anti - Xa activity PGIz (-analogues) 
PGI, inhibition of platelet 4 - 10 nglkglmin platelet aggregation after low-dose heparin or LMWH 
aggregation ADP stimulation 
PGIz-analogues inhibition of platelet 25 - 35 nidkglmin platelet aggregation after low-<1ose heparin or LMWH 
aggregation (20% of PG1J ADP stimulation 
Protease-inhibitor inhibition of thrombin, Xa, 0.1 mglkg/h APTT 
XIIa; prohibition of platelet 
aggregation 
Sodium citrate chelation of calcium prefilter 4% trisodium citrate (170 APTT calcium replacement via 
mLth prefilter) separate venous line 
(lmEq110m1 - 40 mllh) 
Abbreviations: APIT, activated partial thromboplastin time; LMWH, low molecular weight heparin: PGIz, prostacycline. From [27, 36, 86 - 93]. 
Continuous renal replacement therapy 
Anticoagulation 
Anticoagulation, usually with heparin, is necessary to prevent blood from clotting 
and occluding the filter. The main determinant of filter clotting in CRRT is blood 
flow or the lack thereof. Interruption of flow by kinking of lines or catheters will 
promote clotting. Low Anti-thrombin III levels may also contribute to filter clotting 
[83,84]. Heparin is first introduced into the system when the filter is prepared for 
clinical use. The filter is primed with normal saline to which heparin is added 
(10.000 IUI2L). A systemic dose of 2000 IU is then given, followed by constant 
infusion of heparin at a rate of 10 IU/kg/hr (500-1500 IU/hr)(Table 1). Infusion of 
heparin is controHed by an infusion pump and is given pre-filter. Although 
convective clearance of heparin might be expected in view of its MW (13,0 kDa), it 
is barely detectable in the ultrafiltrate [84]. Heparin dosages as usually instituted may 
or may not alter the partial tluomboplastin time. The purpose of measuring this 
parameter is not to achieve a given level of systemic anticoagulation but rather to 
determine if heparin is causing systemic anticoagulation in a patient who is bleeding 
[6]. With CVVH(D), less heparin is usually required because of the higher blood 
flow. Leslie ef al. noted improved filter life with CVVHD compared with CA VHD in 
a prospective, comparative study [85]. In patients with a pre-existing bleeding 
tendency or low platelet counts « 60 x 10'iL), effective filter function may be 
maintained without anticoagulation [35,82]. 
Several authors report the use of prostacyclin as an effective anticoagulant regime, 
either alone [27,44,86] or in combination with low-dose heparin [87](Table 1). 
Added beneficial effects of prostacyclin in MOSF patients may be improved tissue-
oxygenation, cytoprotection and perhaps aiding recovery of renal fnnction [88]. 
However, adverse effects of prostacyclin infusion prior to dialysis may include a 
deterioration in hemodynamics and oxygen transport, especially in ICU patients not 
adequately resuscitated [89]. Other approaches to anticoagulation include (Table 1): 
the use of sodium citrate, a rather complicated procedure with several potential 
technical problems [90]; regional heparinization via protamine infusion post-filter, a 
procedure which carries the risk of rebound anticoagulation because of difficult 
titration and differences in half-life [36]; the use of low molecular weight heparin 
[91,92]; and the use of protease-inhibitors [93]. 
The use of a heparin-coated CA VH circuit, avoiding the need for systemic 
heparinization, is currently under investigation and suggests enhanced safety and 
effieacy of the procedure [94]. 
Replacement fluids 
Fluid replacement during CRRT is needed to maintain intravascular volume and 
serves to decrease the concentration of nitrogenous wastes and creatinine by a 
dilutional effect [6,35,39]. Administration of replacement fluid is adjusted to reach 
the desired negative fluid balance. By varying the electrolyte concentration and 
volume of replacement fluid administered, it is possible to regulate the electrolyte 
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balance of a patient independently of the total fluid balance [35,37]. 
Administration of filtratiOJ.l replacement fluid may be either prefilter 
Cpredilutional') or postfilter Cpostdilutional'). As discussed (see section fluid and 
solute l'emovaf), replacement of the filtration fluid in the predilutional mode wiH 
increase the urea clearance significantly compared with that in the postdilutional 
mode [42]. In addition, predHutional fluid replacement may decrease heparin 
requirements and prolong effective filter life [45]. However, as some of the filtration 
replacement fluid administered in the predilutional mode contributes to the 
ultrafiltrate volume, ultrafiltrate chemistries may not reflect tme plasma~solute losses 
and an additional cost is associated with the increased need for replacement fluids. 
Several (commercial) filtration replacement fluids are currently available (Table 
2). They usually contain lactate or acetate as a buffering-anion. However, lactate as a 
buffer precursor mllst be metabolised to bicarbonate to achieve compensation of 
metabolic acidosis. In cases of impaired liver function, sepsis or hypoxemia in 
critically ill patients, lactate can acculllulate [95] and metabolic acidosis may be 
additionally intensified [96]. Acetate may induce adverse hemodynamic effects [13]. 
For these reasons, bicarbonate-buffered substitution fluid Illay be preferable [97]. 
However, this requires a buffer-free solution to which bicarbonate is added just 
before use to avoid precipitation of calcium- and magnesium bicarbonate [97]. 
Table 2. Typical C0Il111osilion of Rcplace01cnt/Dialysafe Fluid for Use in Continuous Renal 
Replacement Therapy 
Ringer's Replacement/dialysate fluid CAPO fluid 
solution 
Na+ (mmoUI) 130 135 - 142 134 
K' (mmol/l) 5 2.0 - 4.0 0-2.0 
Ca· (mmolll) 2 1.0 - 3.5 1.75 
Mg++ (mmolll) 0.75 - 1.5 0.5 
C!" (0111101/1) 112 110 - 118 103.5 
Bufferwanion: 
Lactate (mmolll) 27 24 - 55 35 
Acetate (mmolll) 10 - 35 
HCO)" (mmol/l) 3 t - 34' 
Glucose (g/dl) 0-2.15 1.5 
Osmolality (mosmolll) 276 284 - 320 358 
': must be added prior to use to avoid precipitation of calcium- and magncsiumbicarbonate" 
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Other forms of replacement fluids may include standard mixtures such as Ringers 
lactate solution and NaCI (0,9%) with added buffer-anions or other electrolytes. 
Since the replacement/dialysis fluid does not contain phosphate, it has to be 
substituted occasionally during prolonged continuous treatment [47,48]. In addition, 
with prolonged CA VHD potassium should usually be added to the dialysate at a 
concentration of 4 mmoVL to avoid hypokalemia [47,48]. 
Complications 
Complications of the procedure have been found to be uncommon. Clotting of the 
filter may occur and is most often due to kinking of blood lines or the catheter or 
inadvertent discontinuation of heparin infusion [38,52]. In contrast to clotting within 
the hemofilter, some patients may paradoxically hemorrhage as a result of 
heparinization andlor the presence of severe underlying coagulopathy [9,38]. Other 
complications are mostly inherent to vascular access, i.e. infection and sepsis, limb 
ischemia and arterial thrombosis requiring surgical revision [7,38,52]. However, it 
should be noted that reported complication rates related to vascular access are 
relatively low [6,33,53,54]. Tominaga e/ al. reported 3.1% (2 of 64) and 1.6% (I of 
62) arterial and venous complication rates, respectively, during a total of 309 
CA VHD days in 26 patients [54]. We noted 8 vascular access related complications 
(1 pseudoaneurysm, 3 thromboses of the venous limb of the Scribner shunt, 4 
infections [3 femoral catheters, I Scribner shunt]) during a total of 531 CA VHD days 
in 60 patients (manuscript submitted). Although rare and easily detected, filter rupture 
with blood leakage into the circuit or from a communication between the blood and 
ultrafiltrate space is a problem intrinsic to the filter [38,52]. In addition, blood leaks 
from inadvertent tubing disconnections occur and may result in significant 
hemorrhage [9,38,52]. If not closely monitored, small errors in electrolyte and fluid 
balance, while easily correctable, may lead to significant iatrogenic morbidity [38]. In 
addition, with prolonged continuous treatment patients may develop a hypochloremic 
metabolic alkalosis [98]. 
Drug removal 
Several recent reviews have described the principles and clinical findings 
regarding drug removal during CRRT [99-10 I]. As virtually all therapeutic agents 
have a MW less than 5,0 kDa, one can reasonable assume that drugs may permeate 
hemofiltration membranes [99,100]. Volume of distribution (Vd) and binding to non-
ultrafiltrable plasma proteins playa dominant role in determining convective transport 
of drugs. The removal of a drug can be measured by multiplying the UF drug 
concentration by the UF rate. Alternatively, since plasma levels are usually required 
for clinical measurement, one may calculate the UF drug concentration as the product 
of the arterial concentration times the unbound fraction [99]. Protein~binding data for 
many drugs are available, usually from healthy people [102]. 
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Many factors, however, may affect drug-protein binding including pH, molar 
concentration of drug and protein, bilirubin, uremic inhibitors, heparin, free fatty 
acids and the presence of displacing drugs [99,100]. Drug-membrane interactions may 
also affect the drug's sieving properties and thus clearance (e.g., aminoglycosides) 
[99,100], During CAVHD drug removal is 1110re complicated and, depending on the 
drug's molecular size, occurs predominantly by convection or diffusion. Few data are 
available on drug clearance in CA VHD. Although clinical guidelines for calculating 
adjustments to drug dosages during CAVHD have been published [103,104]; as for 
CA VH, it is advisable that plasma levels of drugs are monitored frequently and that 
these levels are used to alter dose regimes accordingly. 
The ability of CRRT to remove drugs may also be of therapeutic use. Because of 
its indefinite duration (e.g., for drugs with large Vd) and/or ability to remove large 
molecules, CRRT has been used in several occasions of life-threatening drug-
intoxication [105-108]. 
Nutrient and hormone balance 
Distinct metabolic alterations occur in ARF, most notably excessive protein 
catabolism and sustained negative nitrogen (N) balance [109,110]. In contrast to IHD, 
CRRT facilitates the unrestricted supply of protein and energy sources without the 
risk of exacerbating azotemia or fluid overload. The technique, however, may have 
an impact on nutrient balance itself. Urea nitrogen (UN) losses with the ultrafiltrate 
represent 70-80% of the total eliminated N [109,110]. Non-UN losses occur as a 
result of convective removal of free amino acids (AA)(MW 75-240 Da). Their 
clearance is directly prop0l1ionai to the serum concentration and UF rate and found 
to be in the range of 3-5% of nutritional input [109,112,113]. As expected from their 
MW, AA losses are greater during CAVHD and CVVHD, representing 9-12% 
(depending on dialysate flow rate) of daily protein input [111,114]. Urea kinetic 
modelling may be of value in determining nutritional needs of highly catabolic ARF 
patients [110,115-118]. In addition, identification and possibly modification of 
predictors of urea nitrogen appearance may help to reduce cumulative net N-deficit 
[110,118]. However, whether (positive) N-balance can actually be achieved in 
catabolic ARF patients undergoing CRRT is unclear [111,114,116,119] and the upper 
limit of N that should be administered has not been determined [114]. 
Convective loss of glucose relative to nutritional input is small (10% with UF rate 
IS IIday) [109]. However, when using dextrose-based dialysate in CAVHD/CVVHD, 
one has to take into account significant glucose transfer from the dialysate to the 
patient to avoid the risk of 'overfeeding' hyperglycemia [48,111]. With a dialysate 
flow rate of 16.7 ml/min (1 I/h) and use of dialysate containing 1.5 g/dl dextrose, 550 
kcal will be administered to the patient [48]. Although small amounts of insulin (MW 
5,4 kDa) may be cleared during CRRT either by convection or adsorption [120,121], 
the influence of stimuli for hormonal secretion, e.g. glucose, has by far, greater 
importance than the effects resulting from hormonal elimination [109,120,121]. The 
same holds true for other hormones involved in nutrient utilization [109,120-122]. 
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The patient's lipid status is not affected as triglycerides and cholesterol are not 
eliminated via the UF [36,111,113]. Although Davenport reported a case of 
functional camiline deficiency following prolonged CAVH [123], there is no need for 
(routine) carnitine supplementation in patients undergoing continuous treatment [124]. 
Data regarding semm levels of vitamines and trace elements and their respective 
removal via the ultrafiltrate are scarce. Only Simpson et al. addressed this issue, 
observing no depletion in both trace elements and water~soluble vitamins in ARF 
patients treated with prolonged CRRT [125]. 
NOIl-rellal ~frecls 
Recent observations have raised the potential for a beneficial effect of CRRT 
beyond that of simple renal replacement in critically ill patients. Several data suggest 
that CRRT may favourably influence the clinical course and possibly even outcome 
in these patients, even in the absence of renal failure (Table 3). 
As CRRT allows the unlimited supply of energy and protein, it may eliminate the 
effect of malnutrition on mortality of these critically ill patients [126]. Lactic acidosis 
frequently occurs in critical illness and has deleterious effects on the cardiovascular 
system [137]. Experimental data suggest that hyperlactatemia, independent of 
acidosis, also exerts adverse effects on rnyocardial contractility [137]. In addition, 
acidosis significantly contributes to the catabolic state of the ARF patient [10,113]. 
Correction of (lactic) acidosis by CRRT may therefore be beneficial in the setting of 
critical illness [134,135]. 
Table 3. Possible Influence of Continuous Renal Replacement Therapy on 
the Clinical Course in the Crilically III Patient 
Contributing factors References 
Allowance of adequate nutritional support 16,17,27,31,51,125,126 
Titration of left ventricular filling pressure 7, 32, 127, 128 
Reduction of extravascular lungwater 128,129,130,131,132,133 
Correction of lactic acidosis 134, 135, 136, 137 
Convective clearance ofinflanmmtory mediators 31, 138,139,140,141,142,143,144,145,146 
59 
Table 4. Outcome in ARF: Intermittent Hemodialysis vs Continuous Renal Replacement Therapy 
First Author [ref] Etiology Treattnent n 
Mauritz et aL [8} Abdominal IHD 22 
sepsis CAVHfCVVH 36 
Simpson et at. [27j1' Post-surgery, IHD 31 
medical CUPID 30 
paganini et al. [158}C Post-surgery, IlID 27 
medical CAVHCD) 47 
Kierdorf et al. [156] Post-surgery, IHD' 73 
medical CVVH 73 
Bastien et at. [6I} Post-cardiac IHD 32 
surgery CVVHD 34 
Bellomo et at. [157} Post-surgery, IHD 83 
medical CAVHD 84 
IHD' 24 
CAVHD 28 
van Bommet Post-surgery IHD 34 
CAVlID 60 
Apache II 
-' 
18 
19 
27 
36 
20 
25 
26 
28 
24-29 
24-29 
22 
27 
Mortality n (%) 
20 (91) 
27 (75) 
24 (77) 
17 (57) 
22 (81) 
38 (81) 
68 (93) 
57 (78)" 
24 (75) 
17 (50) 
59 (70) 
49 (59) 
21 (88) 
IS (54)"' 
15 (44) 
37 (62) 
For abbreviations see text. R: both groups comparable in terms of age, sex, need for mechanical ventilation and inotropic support: b: prospective, randomized 
study; c: no statistical analysis performed; d: retrospectively randomized from original IHD group (n=243) without knowing of outcome so that both groups 
were comparable in terms of age, sex and organ system failures; ": stratified retrospectively from original groups without knowing of outcome into groups with 
similar Apache II scores: f: unpublished data, no statistical analysis perfonne<i .• CVVH vs IHD; P <0.05; •• CA VHD vs IHD; P <0.025. 
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Net fluid removal by CRRT in severely hypervolemic patients may improve cardiac 
performance by inducing changes in preload, thereby leading to a more optimal point 
on the Starling curve [32,128]. Likewise, negative balancing may have an influence 
on interstitial pulmonary edema and hydrostatic pressure in the pulmonary circulation, 
even in the case of ARDS, thereby enhancing gas exchange [131]. 
An additional beneficial effect is ascribed to the convective clearance of 
circulating mid- to high MW (0,5-20,0 kDa) inflammatory mediators (i.e., cytokines, 
eicosanoids, allaphylatoxins etc.) involved in the pathogenesis of septic shock and 
vital organ system failures [38,138]. Uncontrolled, retrospective studies have shown 
an improvement of hemodynamics and gas exchange following the institution of 
CRRT in various clinical settings such as refractory cardiogenic and septic shock, 
ARDS and (non-renal) MOSF (Table 3). Beneficial results could not or only partially 
be explained by an impact on fluid balance. Removal of several inflarnmatory 
mediators with the ultrafiltrate, including TNF ~a, (MW 16,5 kDa) and a circulating 
cardiodepressant factor, was demonstrated [31,139,142,146]. Interim analysis of a 
prospective, randomized clinical trial evaluating the effect of isovolemic CA VH on 
the clinical course and outcome in septic ARDS patients revealed a non-significant 
trend towards improved survival in patients treated with CA VH compared to patients 
treated conventionally [147]. In animal models of septic shock, isovolemic 
hemofiltration improved hemodynamics, gas exchange and survival time [l48~155]. 
Convective clearance of several mediators, including a circulating cardiodepressant 
factor (MW 10,0-30,0 kDa), was demonstrated [15,152]. In addition, infusion of 
ultrafiltrate from septic animals into healthy animals resulted in a deterioration of 
hemodynamics and gas exchange, similar to that observed in experimental septic 
shock [152,155]. Although these data support the hypothesis that convective blood 
purification per se improves hemodynamics and gas exchange in variolls shock states, 
little is known with respect to the exogeneous clearance of mediators in relation to 
their endogenous clearance, their binding to the filter and possible subsequent release 
during treatment [80]. 
Outcome 
CRRT has significant advantages when compared to conventional modes of 
treatment and has now been established as the treatment of choice in the management 
of ARF in critically ill patients. However, despite the provision of adequate metabolic 
control and greater flexibility and facility in the control of fluid and electrolyte 
balance, it is not yet clear whether these techniques will improve overall mortality. 
In many earlier repo11ed series of ARF patients treated with PD «1980), similar 
outcome was observed compared to patients treated with IHD [20,22]. As PD is now 
rarely instituted in the ICU setting, no comparative studies exist. 
Several recent studies have compared the outcome of ARF patients treated with 
IHD and CRRT (Table 4). Most studies show a (non-significant) trend towards 
improved survival in patients treated with one of the continuous teclmiques when 
compared to patients having similar severity of disease who are treated with IHD 
61 
Chapter 2 
[8,156,157]. Improved outcome in continuously treated patients was further suggested 
by the finding of a survival rate similar to that observed in patients treated with IHD, 
despite higher Apache II scores and more organ system failmes [158]. We observed a 
higher mortality rate in surgical ARF patients treated with CA VHD compared to 
patients treated with HID. However, actual comparison is made difficult because of 
treatment selection bias resulting in marked differences in the severity of disease 
between treatment groups (Table 4). It should be noted that in most retrospective 
studies, patients treated conventionally were usually historical controls. Therefore, 
factors other than the use of CRRT per se, such as improved overall medical care, 
newer drugs or hyperalimentation may have been (more) responsible for the observed 
decline in mortality. In the only prospective, randomized study to date, a clear, 
though not significant trend towards improved survival was found in patients treated 
coutinuously (i.e., CUPID) when compared to patients treated with IHD [27]. 
Many studies reporting experience with one of the continuous techniques have 
now been published and show a wide variety in mortality rate (40~80%). This may 
pal1ially be explained by differences in underlying diseases or differences in the 
severity of the disease that led to the development of ARF. Combining 32 published 
reports comprising Illore than 1600 patients, no significant difference is observed in 
the outcome of ARF patients treated with one of the continuous treatment modalities 
(Figure 3). 
CAVH 
(>0600 
CAVHD 
n=4IXJ 
CVVH 
n=400 
CVVHD 
n=131 
Figure 3: Outcollle (mean ± SD) in acute renal failure patients (11 = 1614) treated with d(fferent 
forms of continuolls renal replacement therapy (CAVHICAVHD, CVVHICVVHD), shoWing no 
significant difference in mortality rate. Pooled data from 32 studies {17,29,36,4/,44,47,49,51,52,55· 
69.85,/59-/65]. 
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Table 5. Outcome in ARF: Low-volume vs High-volume HemofiUrafion 
Author Mode of UF (Uday) Survival (%) Recovery of renal 
treatment function (%) 
Storck el al. [166] CAVH 7.0 12.5 
PDHF 15.7' 29.4" 
Mauritz et 01. [8} CAVH 14.6 II II 
PDHF 38.4' 29.6 48 
JouOlois e/ 01. [167} CAVH 18.4 
PDHF 22.3' 
correlation UF-recovery 
diuresis' 
Sieberth el al. [17] CVVH Survivors vs Non-survivors; 
17.8 vs 10.7" 
For abbreviations see text. '; p < 0.05; "; p < 0.01; "; Correlation UF - survival, p < 0.05 
Several data, however, suggest a positive correlation between the ultrafiltrate volume 
and survival as well as ullrafiltrate volume and recovery of renal function (Table 5). 
While some suggest that this represents greater clearance of circulating inflammatory 
mediators involved in the pathogenesis of septic shock and MOSF [166], others 
suggest that this may represent more adequate metabolic control [17]. 
However, as the severity of disease in critically ill patients who develop ARF is in 
the most part independent of the problems of acute uremia, correction of the uremia 
itself will not necessarily lead to any improvement. 
Which treatment is best? 
During the last years, CRRT has been established as the preferred treatment 
modality in the management of the oliguric patient with hemodynamic instability 
and/or severe fluid overload. The distinct advantages of CRRT relative to 
conventional dialysis are illustrated in Table 6, which surnmarizes the major features 
of the various renal replacement therapies. CRRT creates space for the provision of 
early, aggressive nutritional support, antibiotics and inotropic dmgs. Although limited 
clearances are obtained with CA VH, adequate metabolic control can now be achieved 
with its recent modifications (CA VHD, CVVH[D], CUPID). The choice of which 
form to use is mainly influenced by personal preference and the availability of 
equipment. There are no studies clearly demonstrating the superiority, in terms of 
improved outcome, of CRRT over conventional modes of treatment or the superiority 
of one continuolls treatment modality over the other. 
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Table 6. Major Features of Various Renal Replacement Therapies. 
IHD PD CRRT 
Hemodynamic stability + ++ 
Fluid removal ++ + +++ 
Correction of acidosis ++ + +++ 
Unlimited (par)enteralnutrition ++ 
Clearances 
small solutes (MW <500 Oa) ++ + +++ 
large solutes (MW >500 On) + ++(+)' 
Access morbiditl + ++ +(+)' 
Anticoagulation needs + +(+)d 
Simplicity + +++ ++ 
Abbreviations: lHD, intennittent hemodialysis; PO, peritoneal dialysis; CRRT, continous renal 
replacement therapy; ': clearance of larger solutes may be augmented by increasing ultrafiltration 
rale; b: relates to angio (lHD, CRRT) and peritoneal cavity (PD) access; ': may be decreased by 
using veno-venous hemofiltration; d; lTlay be decreased by using predilution hemofiltration or pump-
driven hemofiltralioll. 
However, several authors have recently propounded the view that CVVH(D) should 
be the preferred treatment modality [33,58,59,82,168,169]. The constant UF rate with 
CVVH(D) simplifies fluid and electrolyte management and the high blood flow rate 
contributes to the low heparin doses required to prevent clotting. The need for large-
bore at1erial access with its inherent complications is obviated. In addition, a high UF 
rate may lead to significant convective clearance of mid- to high M\V inflammatory 
mediators, which may have a beneficial influence on the clinical course and possibly 
even outcome in critically ill patients. Although some suggest that use of a blood 
pump adds complexity to the procedure, it has been shown that with close 
supervision of the nephrologist, CVVH(D) is safe, easily implemented and managed 
efficiently by the ICU nursing staff [26,57,82,169,170]. However, although CRRT 
allows control of biochemistry and fluid balance in patients who were previously too 
unstable for satisfactory dialysis by conventional techniques, further studies are 
needed to assess long-term effects of CRRT on morbidity and mortality and to 
establish the preferred continuous treatment modality unequivocally. In addition, 
further research is warranted to provide a rationale for the use of CRRT in critically 
ill patients in the absence of conventional indications for dialytic support. 
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Abstract 
Objective: To determine the applicability of the Acute Physiology and Chronic 
Health Evaluation (APACHE) II score in surgical patients with acute renal failure 
(ARF) requiring dialytic support, and to assess its utility in evaluating data from this 
specific disease group. 
Desigm Retrospective, partly prospective follow-up study of patients who developed 
ARF during their course of stay on the surgical intensive care unit (ICU) of a Dutch 
university hospital from January I, 1986 to January 31, 1994. 
Patiellts alUl methods: A total of III patients were identified, of whom 104 patients 
were considered eligable for this study. Data for the individual APACHE II scores 
were calculated from the most deranged values during the initial 24 h of ICU 
admission (APACHE III) and on the day dialytic support was instituted (APACHE 
II,). The ratio between both APACHE II scores was also calculated for each patient 
(AP2/AP1-ratio). Receiver operating characteristic curves (ROC) were constructed. 
Other variables evaluated included age, sex, serum creatinine, diagnostic category, 
time from ICU admission to start of dialytic support, and the type of dialytic support. 
Results: Of these 104 patients (median age 64; range 23-85 yrs), 51 (50%) survived 
to leave the ICU, of whom 47 (46%) survived to leave hospital. The APACHE II, 
score (27.0 ± 4.4 l'S 22.4 ± 3.5; p < 0.001) and AP,IAPI-ratio (1.12 ± 0.09 l'S 0.97 ± 
0.06; p < 0.001) were significantly higher for non-survivors as compared to 
survivors. The ROC curve was most discriminative for the AP/AP1-ratio (area under 
the curve 0.92) and to a lesser extent for the APACHE II, score (area under the 
curve 0.78). Estimated risk of death with the APACHE II equation did not improve 
predictive power. Multivariate analysis of various variables revealed the AP/AP]-
ratio as the single most important factor predicting death (odds-ratio 13.8, p < 0.001). 
Adjusting for the AP/AP]-ratio, no impact on outcome was observed for age, 
diagnostic category, time from lCU admission to start of dialytic support, and the 
type of dialytic support. Above a value of 1.0 of the AP,/API-ratio, logistic 
regression revealed a sharp increase in death probability with increasing AP/AP1-
ratio. 
COllciusiollS: APACHE II, when used at the time of initiation of dialytic support, 
proved to be a valid way in our surgical ICU to stratify ARF patients by the severity 
of their illness. Moreover, use of the AP/AP]-ratio further improved the usefullness 
of this severity-index and may help to identify patients who have little chance of 
survival. Estimating the risk of death with the APACHE II equation did not improve 
predictive power. 
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Introduction 
Despite continuous progress in intensive care medicine, the incidence and outcome 
of critically ill patients who develop acute renal failure (ARF) has changed little [I]. 
Some authors, however, suggest that progress- has been made but is masked by a 
change in patient characteristics [1,2,3]. One major reason for our failure to show 
unequivocal evidence of progress in outcome of ARF patients on the intensive care 
unit (lCU) is the failure of most studies to provide information in a form that allows 
meaningful comparison [2,3]. While this problem is closely studied in the intensive 
care field, little is known in nephroIogical circles. Indeed, from most reports, it is 
difficult to determine if outcome variables were related to therapeutic efforts (e.g., 
renal replacement therapy) or to a difference in case mix [2,3,4]. 
Recently, the need for a severity-of-disease scoring system for use in ARF patients 
was emphasised [1,4,5]. An accurate scoring system would allow us to risk-stratify 
patients, to compare patient risk from different units and to compare outcome of ARF 
patients subjected to different interventional strategies [6]. Although several risk 
models for use in ARF patients have been developed, none of these are widely 
adopted and most of them have not been formally validated [4,5]. Furthermore, 
recent data suggest that these risk models may be institution-specific [7]. In contrast, 
the Acute Physiology and Chronic Health Evaluation (APACHE) II scoring system is 
now used routinely in most ICU's and is familiar to most physicians involved in the 
care of critically ill patients [8,9,10]. However, while validated for use in the general 
and surgical ICU population [8-11], it is not clear whether use of APACHE II is 
valid in specific disease groups such as those with ARF. 
The purpose of this study was to examine the APACHE II system as an outcome 
predictor in ICU patients with ARF receiving dialytic supp0l1. We also evaluated the 
lenght of time patients were in the ICU before renal replacement therapy was started, 
the type of dialytic support, the change in APACHE II scores between ICU 
admission and the start of dialytic supp0l1, and whether these variables are predictive 
for mortality. 
Patients and Methods 
Records of patients admitted to the surgical ICU receiving dialytic support during the 
period January I, 1986-August 31, 1992 were retrospectively reviewed. From 
September I, 1992 untill January 31, 1994, patients receiving dialytic support were 
studied prospectively. Patients with pre~existing chronic renal failure treated with 
hemodialysis prior to leu admission were excluded from this study_ The University 
Hospital 'Dijkzigt' is a tertiary care, 800-bed teaching hospital with separated 
medical and surgical lCU's and as such, it receives patients referred from peripheral 
hospitals for specialized care. A total of III patients were identified for the study 
from dialysis and lCU records; however, insufficient data were available from 7 
patients to calculate accurately the APACHE II score, either at the time of ICU 
admission or at the time dialytic support was instituted. Therefore, results of this 
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study were based on the records of the remammg 104 patients. The decision to 
initiate dialytic support was made conjointly by the critical care staff and consulting 
nephrologist. Indications for dialysis were azotemia (serum urea > 40 mmolfL), 
severe hyperkalemia, refractory acidosis andlor severe fluid overload. Patients 
received either intermittent hemodialysis (IHD) or continuous arteriovenous 
hemodiafiltration (CA VHD). lHD was performed approximately every-other-day 
using a high-flux cellulosic-triacetate membrane (CT IIO-G, Baxter, USA) and 
bicarbonate as a buffering anion. Vascular access was achieved by inserting a single-
lumen catheter (Medcomp, Harleysville, USA) into the femoral, jugular or subclavian 
veins or by the surgical creation of a Scribner shunt (Quinton instruments Co., Seattle 
WA, USA). Dialysate flow was 500 mLimin; mean blood flow 150-175 mLimin. 
CAVHD was performed using a hollow fiber polyacrilonitrile membrane (AN 69-HF, 
Hospal Ltd., France). Vascular access was by means of either large-bore catheters 
inserted into the femoral artery and vein (Medcomp, Harleysville, USA) or by means 
of a Scribner shunt. Bicarbonate-buffered dialysis fluid (Schiwa GmbH, Glandorf, 
Germany) was pumped counter-current to blood at a rate of ILih (16,6 mLlmin). 
Mean ultrafiltration rate during CA VHD averaged II Llday (8 mLlmin). During the 
study period, CA VHD was increasingly used in the Ill.ore severely ill patients when 
compared to IHD. All patients who required continued renal support after discharge 
from the ICU were converted to, or maintained on, IHD. The APACHE II score was 
calculated as described in the original publication [8]. Briefly, the APACHE II 
system evaluates 3 aspects of health status: the patients' age, the patient's chronic 
health status, and a calculated acute physiology score (APS). The APS evaluates II 
routine physiologic measurements and assigns points for each based on the variations 
on the norm. In addition, points were added based on the Glasgow Coma Scale score 
to give the total APS. Finally, the points assigned because of the patient's age and 
health status were added to the APS to get the APACHE II score. The risk of death 
(%) for individual patients was calculated according to the equation: In (Rfl-R) ~ 
-3.517 + (APACHE II score x 0.146) + 0.603 (only if postemergency surgery done) 
+ (diagnostic category weight), where R is the estimated risk of death (ERD)[8]. The 
predicted death rate for groups was calculated by summing the individual risks and 
dividing them by the total number of patients. Data for the individual patient 
APACHE II scores were calculated from the most deranged values during the initial 
24 hours of admission to the ICU (APACHE II,) and on the day dialytic support was 
instituted (APACHE II,). The differences in the two scores were reviewed and an 
APACHE II/APACHE II, (AP,/AP,) ratio calculated [12]. Patients were divided into 
specific subgroups according to their underlying disease andlor according to the 
surgical procedure performed: poly trauma, major vascular surgery, gastrointestinal 
surgery, hepatobiliary surgery, pancreatitis, or miscellaneous. The following 
information was also obtained: age, sex, serum creatinine, duration of ICU stay, type 
and duration of renal replacement therapy, time interval from ICU admission to start 
of dialysis treatment and both ICU and final (alive on discharge from hospital) 
survival. 
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Statistical analysis 
Percentages were compared using the Chi-square test or tested for trend where 
appropriate. Comparisons of continuous variables were done using Mann-Whitney's 
test. Correlation coefficients given are Pearson's. Logistic regression was used to 
evaluate various variables simultaneously regarding the probability of death. Receiver 
operating characteristic (ROC) curves, graphically depicting the sensitivity versus the 
specificity in predicting death of various cut-off levels, were constl1lcted for each 
severity-index, death risk and the AP,IAP,-ratio [13]. The area under the curve, being 
a measure of the power of the predictive model, was also calculated [13]. P-values 
:::;0.05 (two-sided) were considered statistically significant. Data are given as mean ± 
standard deviation (SD), or median and range if indicated otherwise. Analysis was 
done in duplicate (i.e., ICU death and hospital death). As both analysis gave similar 
results, only the analysis of ICU death is presented. 
Results 
Respiratory failure (46%) was the most conunon primary indication for ICU 
admission, followed by cardiac failure (22%) and intra-abdominal sepsis (20%). 
Other baseline characteristics of the patients are given in Table 1. Of the 104 
patients, only 13 (13%) were dialysed immediately or on the day of ICU admission. 
In 38 (37%) patients, dialytic support was initiated more than 5 days after ICU 
admission. Overall, 51 (50%) patients survived' to leave the ICU, of whom 47 (46%) 
survived to leave hospital. Table 2 represents the univariate analysis of different 
variables in comparing non-survivors and survivors. Non-survivors did not differ 
significantly from survivors with respect to age, gender, serum creatinine, APACHE 
III' ERD, or type of dialytic support. There were also no differences between 11on-
survivors and survivors in terms of diagnostic categories (p := 0.74). The mean time-
interval from ICU admission to start of dialytic support was significantly longer in 
those who died as compared to those who survived. Patients who were dialysed 
within 4 days after admission had a better survival as compared to those who were 
dialysed after this period (60% vs 38%; p ~ 0.03). The mean APACHE II, score, 
ERD2 and AP2/AP,-ratio were significantly higher in those who died compared to 
those who survived (Table 2). Observed number of deaths did not differ significantly 
from the number of deaths predicted at the time of st3l1 of dialytic support, i.e., 
ERD, (53 vs 48.9 patients; p ~ 0.36). The APACHE ", and APACHE II, score were 
strongly correlated (Fig I). It is also evident from Figure I that most patients who 
had an increased APACHE " score at the time of initiation of dialytic support as 
compared to the score at admission, i.e., the patients located above the line of 
identity, had died. In contrast, there were only a few deaths among those who had a 
decreased APACHE" score at that time. ROC curves were generated by using each 
severity-index and death risk as decision criteria to predict ICU mOI1ality. 
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Table I. Baseline Characteristics of Study Population 
Variable 
Age (years) 
Sex ratio (M:F) 
Diagnostic category 
poly trauma 
gastrointestinal surgery 
hepatobiliary surgery 
acute pancreatitis 
vascular surgery 
miscellaneous@ 
Creatinine (Junol/l) 
APACHE II,' 
APACHE 112" 
AP2 1 API - ratio 
Time-interval (days)~ 
Dialytic support 
IfID 
CAVHD 
Median (range) 
64 (23 - 85) 
83 (80%) : 21 (20%) 
15 (14%) 
21 (20%) 
8 (8%) 
7 (7%) 
48 (46%) 
5 (5%) 
578 (172-1086) 
24 (14-35) 
25 (14-37) 
1.04 (0_88-1.30) 
4.5 (0-25) 
36 (35%) 
68 (65%) 
Abbreviations: IHD, intenniltent hemodialysis; CA VHD, continuous artcriovenous 
hemodiafillration; @: urosepsis following nephrectomy (n = 2), Iivcr transplantation (n = I), 
pulmonary embolism (n = 1), gastrointestinal bleeding (1/ = 1); . APACHE lJ score at the time of 
ICU admission; ": APACHE II score at the start of dialytic support; ~: time-interval from leU 
admission to start of dialytic support. 
These curves were in a discriminating position for APACHE Il2, ERD2, and most 
pronounced for the AP,IAPI-ratio, but not for APACHE III or ERDI (Fig 2). 
Observed In0i1ality rates calculated within index intervals of the AP,IAPI-ratio are 
shown in Table 3. There was a significant increase of the mortality rates when the 
AP,IAPI-ratio was larger (test for trend; p < 0.001». 
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Table 2. Univariate Comparisons of Non-survivors and Survivors Regarding 
Various Characteristics 
Variable Non-survivors Survivors Significance 
(n ~ 53) (n ~ 51) 
Age (years) 62 ± 15 61 ± 16 P ~ 0.77 
Male (%) 43 (81) 40 (78) P ~ 0.56 
Creatinine (1lIlloI/1) 569 ± 207 641 ± 208 p ~ 0.08 
APACHE 1I1@ 24.2 ± 4.2 23.0 ± 3.3 P ~ 0.26 
APACHE n/ 27.0 ± 4.4 22.4 ± 3.5 P < 0.001 
ERDI (%)@ 47.2 ± 18.8 38.6 ± 20.2 P ~ 0.09 
ERD2 (%l 55.6 ± 20.3 36.9 ± 20.7 P < 0.001 
AP2 / API - ratio 1.12 ± 0.09 0.97 ± 0.06 p < 0.001 
Time-interval (days)' 6.8 ± 5.6 4.5 ± 4.7 p ~ 0.01 
Dialytic support 
IHD 15 (28%) 21 (41%) 
CAVHD 38 (72%) 30 (59%) P ~ 0.24 
Abbreviations: IHD, intennittent hemodialysis; CA VHD, continuous arteriovenous 
hemodiafiltratioll. ': time from ICU admission to start of dialytic support; @: at the time of ICU 
admission; N: at start of dialytic support. Data are given as mean ± SD or percentage, where 
appropriate. 
Table 3. Relationship Between AP2 I API - ratio and ICU Mortality 
s; 1.00 
1.01 . 1.09 
~ 1.l0 
No of patients 
28 
40 
36 
Observed mortality rates (%) 
45 
94 
Abbreviations: see text. #: proportions of the number of patients who died to the total of numbers 
within each index interval; @: difference between the observed mortality rates in significant (test for 
trend, p <0.001). 
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Using multiple logistic regression analysis to evaluate variables which were found 
significant on univariate analysis, it appeared that the AP,IAP,-ratio was the most 
important factor predicting ICU mortality. Adjusting for the AP,IAP,-ratio, none of 
the other variables evaluated were of additional prognostic value. Results of 
multivariate analysis of the variables age, AP2/AP,Mratio, time-interval and type of 
dialytic support are shown in Table 4. The association between outcome and timeM 
interval, found on univariate analysis (Table 2), could not be confirmed (Table 4). 
This could be explained by the observed correlation of time-interval with the 
AP,IAP,-ratio. Patients who were dialysed within 4 days after admission generally 
had lower AP,IAP,-ratios than those who were dialysed after this period: 1.03 ± 0.09 
vs 1.08 ± 0.12 (p ~ 0.04), respectively. Univariate analysis revealed no significant 
difference in outcome between patients receiving different types of dialytic support 
(CA VHD 56% death l'S IHD 42% death; p ~ 0.24), but significant differences were 
observed for each severity-index and risk of death between groups (Table 5). 
Table 4. Multivariate Analysis of Various Factors Regarding the Probability of ICU Death 
Factor No of patients Odds-ratio 95% CI Significance 
Age (yrs) 
~ 50 23 I' 
51-70 46 0.4 0.1 - 2.0 P ~ 0.25 
> 70 35 0.8 0.2 - 4.3 p ~ 0.80 
AP2 / API-ratio 104 13.8~ 4.7 - 40.2 P < 0.001 
Time-interval (days)' 
<5 52 I' 
> 5 52 1.2 0.3 - 4.2 P ~ 0.77 
Dialytic support 
IHD 36 I' 
CAVHD 68 0.9 0.2 - 3.9 P ~ 0.94 
Abbreviations: 95% CI, 95% confidence intervals; lHD, intennittent hemodialysis; CA VHD, 
continuous arterivenous hemodiafiltration; #: denotes the reference category; @: as compared to 
patients in whom the AP2 / API-ratio is 0.1 points smaller. ': timeMinterval from ICU admission to 
start of dialytic support. Data given are the ratios of the odds for ICU-death against survival «I 
indicates a decreased probability of death; > I an increased probability). 
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Table 5. Characteristics of Patients Receiving IHD 01' CA VHD 
Variable IHD CAYHD Significance 
(II ~ 36) (II ~ 68) 
Age (years) 63 ± 17 61 ± 15 p ~ 0.71 
Male (%) 29 (81) 54 (79) P ~ 0.52 
Creatinine (~ullolJl) 685 ± 186 557 ± 210 p < 0.001 
APACHE II,@ 21.4 ± 3.8 24.9 ± 3.3 P < 0.001 
APACHE n/ 22.1 ± 3.8 26.5 ± 4.3 P < 0.001 
ERD[ (%)@ 30.9 ± 17.9 49.9 ± 17.6 P < 0.001 
ERD2 (%Y' 32.9 ± 18.9 54.4 ± 20.5 P < 0.001 
AP2 I API ~ ratio 1.04 ± 0.13 1.06 ± 0.09 P ~ 0.11 
Time-interval (days)' 4.8 ± 4.2 6.2 ± 5.8 P ~ 0.34 
Abbreviations: lHD, intennittellt hemodialysis; CA VHD, continuous arteriovenous hemodia-
filtration, @: at the time ofICU admission; #: at start of dialytic support; ': time from lCU 
admission to start of dialytic support, Data given as mean ± SD, or percentage where appropriate, 
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However, also after adjusting for these factors, no significant difference in outcome 
was observed between the CA VHD and IHD group. Outcome correlated with the 
AP,IAP,-ratio, independent from the type of dialytic supp0l1 (Table 4). That the 
AP,IAP,-ratio strongly relates to outcome may also be demonstrated by plotting the 
estimated probability of death, as found by logistic regression, againsts the AP,/AP,-
ratio (Fig 3). Below a value of 1.0 the estimated probability of death is less then 
about 20%. Above this value, there is a sharp increase in the probability of death 
with increasing AP/API-ratio. 
Discussion 
Since its introduction in 1981, the APACHE II scoring system system has gained 
general acceptance as a measure of disease severity and in outcome prediction of 
general lCU patients [8-11]. It has been used extensively in controlling for case mix 
in clinical studies and assessing quality of care among lCU's [12,14,15]. In recent 
years, use of APACHE II to describe disease severity or to risk stratify lCU patients 
with ARF to allow comparison of outcome among different centres or to compare 
different treatment strategies has been proposed by several authors [11,16-20]. 
However, the APACHE II system has been validated for large groups of patients with 
mixed diagnosis but as yet not for specific disease groups such as those with ARF 
[4,5, I 0]. In addition, APACHE II has been developed for use during the first 24 h 
following lCU admission and may not be automatically transferable for use in ARF 
patients receiving dialytic support at one particular time during their course of stay 
on the lCU [8]. 
Our results demonstrate that the APACHE II scoring system can be used without 
modification in surgical ARF patients. However, use of APACHE II at the time of 
initiation of dialytic support provided a more reliable index of severity of illness and 
likelihood of survival as compared to its use on lCU admission. It may be that the 
physiologic derangements observed within the first 24 hours of lCU admission do not 
accurately reflect the subsequent clinical course and outcome of patients who develop 
ARF. Today, many patients develop ARF as part of multiple organ systems failure 
[1,2,21]. As renal failure usually develops later than failure of other vital organs, 
particularly the cardiovascular and pulmonary system [21], calculation of APACHE II 
on leu admission may lead to some bias. Indeed, in a prospective study it was 
shown that subsequent development of various organ failures in surgical patients 
could not be foreseen from scores calculated during the first 24 hrs of ICU admission 
[22]. This may also explain the findings of Maher el al. [16], who observed that 
patients with ARF had a lower chance of survival compared to general ICU patients 
at comparable admission APACHE II scores. Our findings contrast with those of 
Schaefer el al. [23], who found the system to be inaccurate in medical lCU patients 
with ARF receiving dialysis. They did not observe differences in median APACHE II 
scores between survivors and non-survivors. In addition, the overall accuracy at a 
death risk of 50% and 70% was only 57.5 and 53.7, respectively. As surgical patients 
have multiple, specific risk factors (e.g., anesthesia, trauma, surgical complications) 
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that do not pertain to medical lCU patients, our results may not apply to this group 
of ARF patients. 
Calculating the risk of death by combining the raw APACHE II score with a 
diagnostic weighing did not improve predictive power in our study. Paganini and co-
workers [II] recently suggested use of the ratio between the APACHE II score at the 
time of renal consult and at the time of ICU admission (i.e., AP/API-ratio) to select 
the appropiate renal replacement therapy, i.e., IHD or continuous renal replacement 
therapy (CRRT)[II]. If this ratio was greater than I, patients were best served with 
CRRT. Our study showed that this ratio strongly correlated with ICU outcome and 
that its use significantly improved predicted power of the APACHE II system. The 
higher the ratio, i.e., the greater the increase in APACHE II score, the lower was the 
chance of survival. This suggests that ultimate outcome is related to the degree of 
reversibility of physiologic derangements that led to the development of ARF. Use of 
the AP,IAP,-ratio may help to risk-stratify patients, by unabling us to classify patients 
within the group of ARF patients in which those who have stabilised but who have 
isolated renal failure and those who have developed renal failure as part of MOSF 
represent two sides of the spectrum. 
Dobkin el al. [17] suggested use of APACHE II to identify patients who would 
not benefit from dialytic therapy. Using this system in ARF patients who received 
dialytic support from combined medical, surgical and pulmonary lCU's of 2 different 
hospitals (/1 ~ 100), they reported a correct prediction of 100% specificity at a death 
risk of 70% regardless of what interventions were carried out. Sensitivity and 
predictive negative value were low in all cases, indicating a poor predictability of 
those who will survive. The authors suggested that if dialysis were withheld from 
those patients who were predicted to die, this would not change the overall outcome 
but would achieve considerable cost reduction [17]. Despite the accuracy of the 
APACHE II system, when used at the start of dialytic support, and the AP,IAP,-ratio 
in our study, we suggest that this approach be taken with great caution. Once 
undertaken this method becomes self-fulfilling: patients not expected to survive are 
not treated and therefore survival is precluded. In addition, an accurate estimate of 
the number of patients expected to die among a group of similar patients will not tell 
us which pal1icular patient will actually die [3,9]. Furthermore, outcome is to some 
extent hospital specific and results from one hospital cannot be directly applied to 
other hospitals [10]. 
No consistency exist in the literature as to the impact of age on outcome in ICU 
patients with ARF [5,24]. We did not find age to be an independent predictive factor 
of death, suggesting that renal replacement therapy should not be withheld solely on 
the basis of advanced age. The same holds true for the different diagnostic categories. 
Irrespective of a patient's age or type of underlying disease and/or surgical procedure 
performed, outcome was determined by the patient's illness severity at the onset of 
dialytic support. Using the APACHE" system, we also evaluated whether the type 
of dialytic support affected patient survival. Several authors have recently propounded 
the view that CRRT is superior to IHD for the treatment of ARF on the ICU 
[1,16,24]. Comparative data, however, is scarce and potentionally confounding 
variables are present in these studies [25]. In our study, CA VHD treated patients had 
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a higher severity-index and death risk as compared to UID treated patients, which 
probably resulted from treatment selection. However, outcome did not differ between 
groups. Although this may suggest a survival advantage in those treated with 
CA VHD, logistic regression could not confirm an influence of the type of dialytic 
support on outcome. The same was tme for the moment of timing of dialytic support. 
In conclusion, the APACHE II scoring system, when used at the time of initiation 
of dialytic support, proved to be a valid way in our surgical ICU to stratify ARF 
patients by the severity of their illness. Moreover, use of the AP2/AP I-ratio further 
improved the usefullness of this index of severity-of-disease and may help to identify 
patients who have little chance of survival. Using this index as described, we could 
not detect an influence of age, time-interval from lCU admission to start of dialytic 
support, or the type of dialytic support, on patient survival. Despite the accuracy of 
APACHE II, we do not recommend its use in individual decision making. As stated 
by Smithies and Cameron [3], 'one remembers - perhaps all to well - our exceptional 
patients who survived against the odds'. 
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Abstract 
Objective: The outcome aud metabolic control was studied in 60 critically-ill patients 
with acute renal failure (ARF) treated by continuous arteriovenous hemodiafiltration 
(CA VHD) in a single surgical intensive care unit. In addition, the influence on 
outcome of various factors was determined, 
ReslIlts: Meau age (± SEM) was 60 ± 2 years with a male predominance (80%). The 
majority of patients required mechanical ventilation (83%) and/or vasopressor support 
(70%) and suffered from mliltiMorgan failure (mean number of organ system failures 
3.3 ± 0.2 [range I - 6)). CA VHD resulted in a rapid decline of serum urea and 
creatinine levels during the first 72 hours (urea 47.4 ± 2.3 to 30.3 ± 1.4 mmol/I; p < 
0.05, and creatinine 572 ± 27 to 361 ± 23 l.unol/I; p < 0.05); thereafter, controlled 
steady-state levels were achieved with serum urea levels kept below 30 mmol/l with 
full protein alimentation and often despite hypotension, surgery and septicemia, 
Significant electrolyte derangements could be easily corrected and maintained within 
normal limits, Bicarbonate homeostasis could be restored within 48 hours in patients 
with severe metabolic acidosis (HC03' < 20 nmlOl/l) with use of bicarbonate as a 
buffering anion (17 ± 0.5 to 23.2 ± 0.6; p < 0.05). CA VHD allowed rapid removal of 
excess body and lung water (up to 5 I/day) without hemodynamic instability. Despite 
a mean pretreatment APACHE II score of 26.5, 26 patients (43%) survived until 
discharge from the ICU, of whom 23 (38%) survived to leave hospital. Requirement 
of mechanical ventilation or vasopressor support, higher APACHE II scores and 
septicemia were all associated with a poor prognosis, Although prognosis was 
inversely correlated with the number of organ system failures, 24% of patients with 3 
or more organ system failures survived to leave hospital. 
Conclusions: Data suggest that CA VHD represents a significant advance in the 
management of criticallYMiIl patients with ARF and may have contributed to improved 
survivaL 
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Introduction 
Despite many advances in the care of the critically-ill patient, acute renal failure 
(ARF) continues to be associated with a high mortality, attributed in pm1 to a change 
in patient characteristics [1,2]. Today, ARF is often but one of several failing organs, 
leading to a complex and unstable patient population. As the traditional forms of 
hemodialysis treatment have characteristics which limit their use in these patients [3], 
continuous renal replacement therapy has been rapidly adopted as the treatment of 
choice [3,4]. Although the first to be introduced, continuous arteriovenous 
hemofiltration (CA VH), proved very useful in the management of these precarious 
patients, its capacity in terms of uremic control was limited and often insufficient. To 
overcome this shortcoming, continuous arteriovenous hemodiafiltration (CA VHD), 
combining the advantageous aspects of CA VH and intermittent hemodialysis (HD), 
was developed as a more versatile alternative [5,6]. 
We report herein our experience with CA VHD in 60 consecutive critically-ill 
patients with ARF treated in a single surgical intensive care unit, with emphasis on 
the efficacy of treatment and clinical outcome. In addition, the influence on outcome 
of various clinical and laboratory features present at the time of initiation of or 
during CA VHD treatment was determined. 
Material and methods 
Records of patients admitted to the surgical intensive unit receiving CA VHD during 
the period January I, 1986 - August 31, 1992 were retrospectively reviewed. From 
September 1992, patients receiving CA VHD were studied prospectively. The 
following information was obtained: age, sex, pre-existing medical conditions 
(chronic obstructive pulmonary disease, diabetes mellitus, cardiovascular disease, 
hypertension, chronic liver disease, chronic renal insufficiency, and malignancy), 
underlying disease and surgical procedures performed for each patient, need for 
vasopressor support or artificial ventilation, provision of total parenteral nutrition 
(TPN), systolic and diastolic blood pressure, heart rate, arterial blood gas, FiO, 
requirements, presence of suspected or proven sepsis, bleeding complications, renal 
and patient outcome and cause of death. Renal recovery was defined as return of 
renal function sufficient to discontinue dialytic support. To aid comparison with other 
studies, both ICU survival and final survival (alive on discharge from hospital) are 
discussed. The Acute Physiology and Chronic Health Evaluation (APACHE) II score 
at the start of dialysis treatment and the number of organ system failures (OSF's) at 
the time of initiation of or whilst on CA VHD were calculated according to the 
pertinent literature [7,8,9]. In a subgroup of 10 patients, cardiorespiratory parameters 
were reviewed prior to the initiation of CAVHD, and 1, 4 and 24 hI'S, respectively, 
after the initiation of treatment. 
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Table 1. Composition Of Dialysis Fluid @ 
Solute 
Na' 
K' 
CI' 
lactate 
mmollL 
140.1 
2.01 
1.75 
0.60 
112.31 
2.90 
31.40 
5.80 (1.04 giL) 
@: Composition of 4.5 L acidic solution and 160 mL sodium bicarbonate 8.4%; lactic acid is added 
to prevent precipitation of Ca++ and Mg++ carbonate. 
Continuous arteriovenous hemodiajiltration 
The decision to initiate CA VHD was made conjointly by the critical care staff and 
consulting nephrologist. CA VHD was performed using polyacrilonitrile hollow-fibre 
filters (AN-69HF, surface area 0,6 m', Hospal Ltd, France) connected to the arterial 
and venous vascular access devices in a pumpless circuit with the use of 1.25 mtr 
extracorporeal tubings with luer lock fittings. Vascular access was either by means of 
large bore catheters (MedComp, Harleysville PA, USA), introduced in the femoral 
vessels with the Seldinger technique, or the surgical creation of a Scribner shunt 
(Quinton Instrument Co., Seattle W A, USA) when cannulation of the femoral vessels 
was precluded because of severe atherosclerosis or the presence of a vascular 
prosthesis. Warmed bicarbonate-buffered dialysis fluid (Schiwa Combi-Pae, Sehiwa 
GmbH, Glandorf, Germany), the composition of which is depicted in Table I, was 
pumped counter-current to blood through the ultrafiltrate compartment of the filter 
(dialysate inflow rate, Qd) at a rate of 1000 ce per hour (16,6 mllmin) with a 
calibrated, volumetrie pump (3M, A VI inc., St Paul, USA). In severely catabolic 
patients, a Qd of 2 IIhr (33,2 mllmin) was used. The combined ultrafiltrate and 
dialysate was collected in a graded collection bag and the volume measured hourly. 
The ultrafiltration rate (Q,f) was calculated by subtracting the hourly dialysate volume 
(typically 1000 cc) from the total volume of effluent in the collection device. Because 
the production of ultrafiltrate was Iypically much greater than the desired rate of 
volume contraction, replacement fluid (Ringer's lactate) was administered into the 
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arterial limb C'predilution lt) of the extracorporeal circuit. Standard anticoagulation 
consisted of 2000 U of heparin as a loading dose followed by continuous infusion of 
500-700 Ulhr into the arterial line. Low-dose « 250-500 U/hr) or no heparin was 
used in the presence of severe underlying coagulopathy or severe thrombocytopenia 
« 60'10'/1). The filters were changed when there was objective evidence of 
inadequate filter function (i.e., a sustained reduction in UF volume [< 300 mllhr]) or 
evidence of filter clotting. Access devices were not routinely changed unless there 
were clinical signs of infectious (or other) complications. Routine investigations while 
on CA VHD included daily measurement of serum urea and creatinine, electrolytes, 
calcium and phosphate. magnesium, glucose, full blood cell count and the activated 
partial thromboplastin time (APTT). Technical data collected for analysis included 
ultrafiltrate volume (lIday), vascular access and vascular accesswrelated complications, 
duration of CA VHD treatment and number of filters used for each patient. 
Biochemical analysis 
Serum urea and creatinine levels were recorded during the first 7 days on CA VHD. 
Other variables recorded for analysis were serum levels of sodium, potassium, 
calcium, phosphate and bicarbonate tlu'oughout CA VHD treatmeu!. Urea and 
creatinine clearances (CI) were calculated iu 8 raqdomly selected patients studied 
prospectively by using the formula: CI = Cd" QdjCp;, where Cd, = dialysate outlet 
solute (urea, creatinine) concentration, Qdo = dialysate outflow rate, comprising 
dialysate inflow rate and net ultrafiltration flow rate (Qd + Quf), and Cpi = plasma 
inlet solute (urea, creatinine) concentration [5,6J. In addition, different variables were 
randomly measured at 6 different occasions in both serum and ultradiafiltrate to asses 
solute saturation of dialysis fluid at Qd 16,6 ml/min. Variables were measured by 
routine clinical laboratory methods. 
Statistical analysis 
Data are expressed as mean ± standard error (SEM) or percentage, where appropiate. 
For biochemical data, a two-factor mixed design ANOVA (group by repeated 
measures [timeD was used. For analysis of patient characteristics, a one-way 
between-subjects ANOV A (group) was used. When significant differences occurred 
between and/or within groups, these differences were further analyzed with a Student-
Newman-Keuls test. Statistical significance was accepted at p < 0.05. 
Results 
Patient population 
Sixty patients were included in this study (Table 2). There were 12 female and 48 
male patients, whose ages ranged from 17 to 83 years (mean 60 ± 2 yrs). 
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Table 2. Characteristics of 60 Critically m Patients with Surgical ARF Treated by CA VHD 
Etiology of ARF No of Age(yrs)1 Male APACHE II No ofOSF's Renal function Survival (%) 
patients recovery (%) 
Polytrauma 8 48 ± 717 27.1 ± 2.1 3.8 ± 0.7 37 25 
Gastrointestinal surgery 17 60 ± 4/10 25.6 ± 0.7 3.3 ± 0.3 53 35 
Hepatobiliary surgery 6 47 ± 7/5 26.3 ± 1.4 3.3 ± 0.6 83 67 
Pancreatitis 5 52 ± 4/4 26.6 ± 0.6 4.4 ± 0.5 60 40 
Vascular surgery 22 71 ± 2121 27.4 ± 1.0 2.6 ± 0.3 27 45 
Other" 2 60 ± 2211 22.0 ± 3.0 3.0 ± 1.0 100 100 
Total 60 60 ± 2/48 26.5 ± 0.5 3.4 ± 0.2 48 43 
Abbreviations: ARF, acute renal failure; No of OSF's, number of organ system failures (including ARF) as defmed according to the pertinent literature [7,8.9]; 
@: Livertransplantation (n = 1), urosepsis (n = 1). Data expressed as mean ± SEM, or percentage where appropriate. 
Continllolls arteriovenolls hemodiafiltration 
Thirty patients were aged 65 or older. Pre~existjng chronic disease was present in 31 
patients (52%). Four of these patients had pre~existent impaired renal function (semm 
creatinine> 180 flmolll). Mean alierial pressure (MAP) at the initiation of CA VHD 
was 75 ± 3 mm Hg (range 45 - 144 mm Hg). The majority of patients required 
artificial ventilation (83%) andlor vasopressor support (70%) at the start of treatment. 
All but 4 patients (93%) were oligo-anuric (diuresis < 400 mllday). The etiologies of 
ARF were varied and often multifactorial. The mean pretreatment APACHE II score 
was 26.5 ± 0.5 (range 19 - 32). The mean number of OSF's during CA VHD 
treatment was 3.3 ± 0.2 (range I - 6), with 27 patients (45%) having ~ 4 failing 
organs. TPN was given in 76% of patients. In the majority of patients (71%), 
suspected Or proven sepsis was present either at the start of (43%) or during CAVHD 
(28%), with several patients experiencing more than one septic episode.lndications 
for stmiing CA VHD included azotemia (91%), severe fluid overload (21%), 
hyperkalemia (8%) and/or severe metabolic acidosis (23%). CAVHD was performed 
via femoral cannulae in 44 (73%) and via a Scribner shunt in 16 (27%) patients 
(forearm, n = 12; ankle, n = 4). 
Hemodynamic tolerance 
Seven patients failed initial attempts at hemodialysis (defined as hypotension 
complicating volume removal necessitating discontinuation of dialysis) prior to the 
initiation of CA VHD. CA VHD was hemodynamically well tolerated. No significant 
differences in systolic blood pressure, MAP, heart rate and PaO/Fi02-ratio were 
observed during treatment. During the first 24 Ius of CA VHD, no significant 
differences were observed in cardiorespiratory parameters when compared to 
pretreatment values. Significant lIel fluid loss (up to 5 L/day) could be obtained with 
no significant drop in MAP and in several patients with a concomittant decrease in 
oxygen requirements and vasopressor support. 
Melabolic cOlllrol 
These 60 patients were treatcd with CA VHD for a total of 531 days (mean 8.9 ± 0.7; 
range I - 25 days). Mean UF volume was 11.5 ± 0.3 IIday (range 8.9 - 14.7). The 
mean serum urea and creatinine levels at the initiation of CA VHD were 47.4 ± 2.3 
nunolll (range 18.0 - 94.2 mmolll) and 572 ± 27 flmolll (range 172 - 1113 flmolll) 
respectively. Overall, a significant decline of both parameters was observed during 
the first 72 h of treatment (urea 47.4 ± 2.3 to 30.3 ± 1.4 nU11olll; p < 0.05, and 
creatinine 572 ± 27 to 361 ± 23 ~molll; p < 0.05); thereafter, controlled steady-state 
levels were achieved with serum urea levels kept below 30 mllloi/l (Fig I). 
Insufficient uremic control with Qd I IIhr was observed in 9 patients (15%), all of 
whom were hypercatabolic and suffering from refractory septic shock. 
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Figure I: DecUne of serum urea and creatinine levels over time following the initiation ofCAVHD in 
60 patients. Data expressed as mean ± SEM; ': p < 0.05. ANOVA for repeated measllrements. 
Figure 2: Decline of serum /lrea level OWl' time following the il/itiation of CAVHD in surviving (n = 
26) and lIoJl-sUtvivillg (n = 34) patients. There was no significant difference betll'een groups. Data 
etpressed as meall ± SEM. 
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Mean urea and creatinine clearances with Qd 1 l/hr amounted to 24.6 ± 0.4 and 24.3 
± 0.4 mUmin. Mean urea and creatinine ultradiafiltrate to plasma ratios were 0.95 ± 
0.45 and 0.94 ± 0.51 respectively. There were no significant differences in serum 
urea and creatinine levels between surviving and non~surviving patients at the start of 
or during CA VHD treatment (Fig 2). No difference was observed in azotemic control 
between the 2 modes of vascular access. During treatment, serum sodium (Na ") and 
potassium (K+) were maintained within the normal range in most patients; however, 
supplemental potassium-chloride was required in some patients following prolonged 
CA VHD to prevent or correct hypokalemia. Serum calcium and magnesium were also 
maintained within the normal range throughout therapy. Senun phosphate fell below 
the normal range in several patients following prolonged CA VHD necessitating 
supplemental intravenous phosphate administration. Significant electrolyte 
derangements could be easily corrected and maintained within normal limits ([Kf] 6.5 
± 0.1 to 4.2 ± 0.4 mmolll; /I ~ 5; [Na'] 130 ± 0.9 to 140 ± 0.5 mlllolll; /I ~ 5; 155 ± 
0.3 to 139 ± 1.7 mmolll; /I ~ 2). In patients with severe metabolic acidosis (HC03' < 
20 mmol, /I ~ 14), bicarbonate homeostasis could be restored (HCOT 17 ± 0.5 to 
23.2 ± 0.6; P < 0.05) within 48 hours with use of bicarbonate as a buffering-anion. It 
was only occasionally necessary to administer additional intravenous supplementation 
of bicarbonate, this being mostly associated with an acute septic episode. 
Complications 
There were no cornplications related to the extracorporeal circuit itself apart from 
filter clotting. Overall, 261 filters were used during the total of 531 days of CA VHD 
treatrnent, i.e. a mean number of 4.4 ± 0.4 filters were used per patient. The mean 
life span of the filter per patient was 51.2 ± 1.2 Ius but there were marked inter~ 
individual differences (mean filter life ranging from 16 to 96 hrs). Although the 
femoral catheters were removed 8 times because of bacteremia of unknown origin, 
documented infection (as evidenced by positive culture of the catheter) was present in 
only 5% (Table 3). One patient developed a false aneurysm at the site of the femoral 
arterial catheter insertion requiring surgical repair. Surgical revision of the Scribner 
shunt or the creation of a new one in the contra~lateral extrernity, either because of 
(recurrent) thrombosis or infection was required 4 times in 3 patients. No distal 
ischaemic cornplications were seen with either access device. Overt bleeding 
complications requiring the temporary discontinuation of anticoagulation or 
subsequently CA VHD were seen in 6 patients, all of which were from the digestive 
tract. Three of these patients had severe concommitant thrombocytopenia « 60'10'/1) 
(Table 3). 
Outcome 
Twenty-six patients (43%) survived until discharge from the ICU. Three of these 
patients subsequently died on the general ward a mean of 40 days (range 25-64) 
following discontinuation of CAVHD. Twenty-three patients (38%) ultimately 
survived and were discharged from the hospitaL 
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Table 3. Hemorrhagic And Vascular Access Related Complications 
Observed During CA VHD Treatment 
Complication 
Access Infection 
localized 
systemic 
Shunt thrombosis 
Pseudo-aneurysm 
Overt bleeding 
No 
3 (Klebsiella, 1/ = I; Serratia, 11 = 2) 
I (Pseudomonas, n = I) 
3 (venous limb) 
I (femoral artery) 
6' 
#: All from the digestive tract: oesophageal ulceration, n = J; ulcus ventriculi, n = 2; bowel 
perforation, n = I; unknown focus, n = 2. Mean platelet count in these 6 patients was 69 x 109/1 
(range 31-1 10); mean heparin dosage was 533 Vlhr (range 500-700 Vlhr). 
There was no difference in age or gender between survivors and non-survivors (Table 
4). Similar survival (40% vs 37%) was observed in elderly patients (2: 65 yrs) when 
compared to younger patients « 65 yrs). There was no difference in the duration of 
CAVHD treatment between survivors and non-survivors as a group (8.7 ± 0.7 vs 9.3 
± 1.1 days; NS). Forty-two percent of patients receiving 2: 10 days CA VHD survived 
to leave the ICU compared to 44% of those who received < 10 days CAVHD. There 
was no difference in the prevalence of pre-existing chronic disease between survivors 
and non-survivors (54% liS 50%). The non-surviving group had higher APACHE II 
scores, more additional OSF's, and a more frequent requirement for mechanical 
ventilation and/or inotropic support as compared to survivors. Of patients with an 
APACHE II score > 30, none survived. The incidence of sepsis was significantly 
highcr in the non-surviving group (Table 4). All patients with non-oliguric ARF 
survived. Survival of patients who required mechanical ventilation was significantly 
lower when compared to those who did not (32% vs 70%; p < 0.05). Outcome was 
particularly poor in patients with ARF complicating poly trauma (Table 2). Prognosis 
was inversely related to the number of OSF's (Table 5). None of the patients with 
isolated ARF died. Of those patients with 3 or more OSF's (including ARF) 24% 
survived. Death was most often due to refractory septic shock and/or progression to 
irreversible multiple organ failure (70%). Other causes were myocardial infarction (11 
= 4). ventricular fibrillation (11 = 3), massive pulmonary embolism (n = 1), coma 
vigil (/I ~ I), and stroke (/I ~ 2). Seventy-six percent of those who survived had 
recovery of renal function, while this occurred in only 23% of those who died (p < 
0.05). The mean semm creatinine level of these patients, either at the time of death 
or on discharge from the hospital, was 127 ± 13 pmoVI (range 44 - 269 J.unoVI). 
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Table 4. Characteristic Features or Survivors and NOli-Survivors from Surgical ARF Treated 
by CAYHD 
Survivors Non-survivors Significance 
(/I ~ 26) (n ~ 34) 
Age (yr') 59 ± 3,5 61 ± 3 NS 
Male (%) 20 (80) 28 (80) NS 
APACHE II 24,2 ± 0,7 28,1 ±0,7 P < 0,05 
No ofOSF's 2,2 ± 0,2 3,9 ± 0,2 P < 0,05 
Sepsis (%) 12 (48) 30 (86) P < 0,05 
Artificial ventilation (%) 18 (72) 32 (91) P < 0,05 
Inotropics (%) II (44) 30 (86) P < 0,05 
Pretreatment urea (mmol/L) 45,8 ± 4,0 48.5 ± 2,6 NS 
Pretreatment creatinine (mmol/L) 641 ± 46 523 ± 32 NS 
Duration CAVHD (days) 8,7 ± 0,7 9,26 ± l.l NS 
ARF, acute renal failure; CAVHD, continuous arteriovenous hemodiafiltration; No of OSF's, 
number of failed organ systems (including ARF) (7, 8, 9). Values are expre-ssed as mean ± SEM or 
percentage, where appropriate, 
Table 5. Mortality of High-Risk Surgical ARF Patients Treated by 
CAYHD 
No of organ systems failed @ 
2 3 
No of patients 7 II 15 
Died o 3 8 
Mortality (%) o 27 53 
24 
27 
23 
85 
ARF, acute renal failure; CA VHD, continuous arteriovenous hemodiafiltration; @; number of organ 
system failures (including ARF) as defined according to the pertinent literature [7,8,9J, 
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None of the patients with pre-existing chronic renal failure (serum creatinine> 180 
J1molll; n :=; 4) recovered renal function and required continued renal support. The 
chance of renal recovery was particularly low (27%) in patients who underwent 
major vascular surgery (Table 2). 
Discussion 
Present data demonstrate that CA VHD provides efficient renal support for 
critically ill patients. The majority of our patients (85%) reached consistent and 
controlled steady-state urea and creatinine levels within 72 hrs, with no protein 
restriction and often despite surgery, hypotension and septicemia. In addition, 
satisfactory correction of acidosis and plasma electrolyte concentration was obtained. 
The urea and creatinine clearances corresponded to the ultrafiltrate/dialysate flow 
rate, being approximately 24 mllmin, because of almost complete (> 94%) dialysate 
solute saturation. Even in severely hypotensive, inotropic-dependent patients excellent 
tolerance to fluid removal was observed, thereby enabling aggresive nutritional 
support together with intravenous infusions, yet still attaining an overall negative 
fluid balance if needed. The complication rate was relatively low. Access-related 
complications occurred 8 times. Gastrointestinal bleeding occurred in 6 patients, in 
which the continuous heparinization may be assumed to be a contributing factor. 
However, some cases of overt bleeding will always occur in poly trauma and 
postoperative patients, and this incidence of gastrointestinal bleeding is not different 
from that reported in ARF patients treated with intermittent hemodialysis (IHD) 
[9,10]. Nevertheless, reducing the dose or even avoiding heparin in patients at risk of 
bleeding is of utmost importance. 
As noted by others [4], prolonged duration of renal support was not associated 
with a poor prognosis. No difference was observed in metabolic control between 
surviving and non-surviving patients, suggesting that the outcome is in the most part 
determined by the underlying disease process and not by uremia per se. This is 
further supported by the marked differences in severity of illness between nona 
survivors and survivors (Table 4). Like Maher et at [4], we noted an increased risk of 
dying with higher APACHE II scores. A patient's age or sex did not affect outcome. 
No consistency exists as to the impact of age on prognosis. Some related age to 
increasing mortality [I], while others did not [4,10,12]. As in others studies [11,12], 
premorbid conditions did not seem to have an imp0l1ant impact on acute outcome. 
However, it may exert deleterious effects on long-term survival [12]. 
Present data underline [1,12] the importance of sepsis as being the major cause of 
death in surgical ARF patients. Overall patient survival in the present series was 
38%J the majority of which with recovery of renal function. Direct comparison with 
mortality data from other rep0l1s is hampered by the fact that each series contains 
patients of varying qualifications (usually a case-mix of medical, surgical andlor 
obstetrical ARF), not all of whom required dialysis or stay on the ICU. In addition, 
many studies lack validated and objective illness severity scores (e.g., APACHE II 
[13]). However, our data do compare favourably with sevcral studies specifically 
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dealing with ARF patients on the surgical I CU treated by conventional dialysis 
(mortality ranging from 81% to 94%)[1,10,11,12,14]. When analyzing subgroups of 
patients considered to have an unfavourable prognosis, CA VHD treated patient 
outcomes also compares favourable to other repOlis. Recently, Spiegel e/ al. [10] 
reported a 100% mortality of ARF patients treated with intermittent hemodialysis, 
who also required artificial ventilation. In our series, mortality rate of ventilated 
patients was 70%. Similar results of ventilated ARF patients treated by CA VHD were 
reported by others [15,16]. We also [1,4] noted an inverse correlation between 
survival and the number of OSF's. However, 24% of patients with 3 or more OSF's 
still survived to leave the hospital. Outcome of our multiple organ failure patients 
compared favourably with those of Pry e/ al. [16], who reported mortality rates of 79 
and 100% for 3 and 4 OSF's, respectively, in postoperative patients, and those of 
Pine e/ al. [18], who found a 100% mortality in patients with 3 or more OSF's. 
While this apparent increase in survival may at least in pat1 be explained by 
advances in general intensive care medicine (e.g., more potent antibiotics, vasopressor 
agents, improved monitoring and ventilation techniques etc), the use of CA VHD per 
se may have also contributed to a better prognosis of these critically ill patients. As 
illustrated, CA VHD avoids dialysis-related complications such as (aggrevation of) 
hypotension, cardiac arrhythmias, and an increase in oxygen consumption [4,19]. 
Conunonly observed cardiac and/or pulmonary system failure may be exarcerbated 
(or provoked) by overhydration. In one study [14], all but oue postoperative patients 
were grossly overhydrated. In the present study, severe fluid overload was present in 
21 % of patients. In this complex and unstable patient population, CA VHD offers the 
potential of continuous fine tuning of intravascular volume and left ventricular filling 
pressure. Indeed, Lauer el al. [20] observed a significant rise in cardiac index after 
gradual volume reduction during CA VH, attributed to changes in preload thereby 
leading to an improved position on the Starling curve. In addition, while use of IHD 
usually leads to a tendency to restrict fluids and protein, CA VHD enables the 
provision of unlimited amounts of energy and proteins without the risk of 
exacerbating azotemia or fluid overload. In our study, serum urea levels were 
consistently below 30 mmolll in a population of which the majority (76%) received 
TPN. Prolonged proteinKcalorie malnutrition can precipitate or worsen ventilatory 
failure [21]. There is some evidence to suggest that high calorie feeding results in 
better outcome than low caloric feeding in surgical ARF [19]. With CA VHD, unlike 
IHD, it may be possible to counter~act excessive catabolism. and, at least in sOllle 
patients, to establish positive nitrogen balance [22]. Of note, however, one should 
take into account an aminoacid loss with the ultradiafiltrate of approximately 9% of 
daily protein load and the upper Iirnit of nitrogen that should be administered to these 
patients has not been determined [23]. In addition, when using high~dextrose 
containing CAPD fluid as dialysate, significant glucose uptake occurs which must be 
taken into account when prescribing nutritional support to avoid the risk of 
'overfeeding' hyperglycemia with its detrimental effects on metabolism and 
respiratory function [15,24]. 
As shown in this study, beneficial effects may also result from the adequate 
correction of metabolic acidosis. \Ve routinely use bicarbonate~buffered dialysis fluid 
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as the use of lactate as a buffering anion in the critically ill may lead to 
hyperlactatemia and worsening acidosis, probably because of impaired lactate 
conversion by the reduced liver flow [25]. Severe acidosis may result in decreased 
cardiac contractility, vasodilation and hypotension, decreased hepatic and renal flow 
and increased susceptibility to ventricular arhythmias [26]. In addition, acidosis 
significantly contributes to the catabolic state of the ARF patient [27]. Recent 
experimental and uncontrolled clinical data suggest that the initiation of continuous 
hemo(dia)fi1tration in septic shock and (non-renal) multi-organ failure may result in 
improved hernodynamics and gas exchange, independent of the fluid balance, 
attributed to the convective removal of inflammatory mediators (e.g., cytokines) from 
the circulation [28]. However, this proposed beneficial effect awaits further 
investigation. 
In summary, CA VI-ID proved to be a safe and efficient mode of renal replacement 
therapy in our critically-ill patients with surgical ARF. In addition, a comparatively 
favourable outcome was observed, However, it does not yet seem possible to identify 
with any degree of certainty those patients most likely to benefit from prolonged 
intensive care treatment (including renal support) nor those in whom additional organ 
failure will adversely determine the outcome of ARF. There has been a tendency to 
be pretty grim as to the treatment and outcome of ARF in the ICU setting [2,11]. 
Present data, however, suggest that CA VHD represents a significant advance in the 
management of these patients and may have contributed to improved survival. 
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Abstract 
Objective alld design: There is still debate about whether continuous renal 
replacement therapy is superior to intermittent hemodialysis (IHD) as dialytic support 
for the critically ill patient with acute renal failure (ARF), mainly because of lack of 
comparative data. We sought to address this issue by reviewing the medical records 
of such patients admitted to a single surgical intensive care unit (ICU) treated with 
either continuous arteriovenous hemodiafiltration (CA VHD) or IHD between january 
1, 1986 and august 31, 1993. 
Results: Of 94 consecutive patients who received dialytic support for severe ARF, 34 
(36%) patients were treated with IHD and 60 (64%) patients with CA VHD. Patients 
were comparable in terms of age or gender and represented a similar case-mix. 
Patients treated with CA VHD were more severely ill as manifested by a lower mean 
arterial pressure (75 ± 3 vs 86 ± 5 mm Hg; p < 0.05), higher APACHE II score (26.5 
± 0.5 vs 22.2 ± 0.3; p < 0.05), and a higher number of organ system failures (3.4 ± 
0.2 vs 2.6 ± 0.3; p < 0.05). Despite greater illness severity and a higher probability of 
death (55 ± 2.6% vs 33 ± 2.5%; P < 0.0001) in those treated with CAVHD, no 
difference in outcome was observed between groups (CAVHD 26/60 [43%] vs IHD 
20/34 [59]%; NS). The mean APACHE II score of patients treated with CAVHD 
who survived was similar to that of patients treated with IHD who died (24.5 ± 0.3 
vs 24.2 ± 0.4; NS). CA VHD was associated with improved hemodynamic stability, 
better control of fluid balance and biochemistry, increased nutritional intake, and a 
shorter duration of ARF (p < 0.05). 
COllc/usiom Data suggest that CA VHD offers several distinct advantages over IHD, 
which may translate in improved survival, particularly in the more severely ill 
patient. 
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Intl'oduction 
Despite impressive advances in the field of intensive care medicine, the mortality 
rate of critically ill patients who develop acute renal failure (ARF) is still uniformly 
high [I]. As traditional forms of hemodialysis treatment have characteristics which 
limit their use in these patients, continuous renal replacement therapy (CRRT) has 
been rapidly adopted as the preferred treatment modality [2,3]. However, there is still 
debate about whether CRRT is superior to intermittent hemodialysis (IHD), especially 
in terms of metabolic control and clinical outcome [4,5,6,7]. While many publications 
exist concerning the technique of CRRT, relative advantages offered by the various 
systems, and mortality rates of critically ill patients with ARF on the intensive care 
unit (ICU) [3,8,9], few studies have directly compared CRRT and IHD [10,11]. 
The purpose of this study was to compare the efficacy of metabolic control and 
clinical outcome in critically ill ARF patients treated with either continuous 
arteri~venous hemodiafiltration (CA VHD) or IHD in the same surgical ICU. 
Material and methods 
The medical records of 94 consecutive patients admitted to the surgical ICU between 
January I, 1986 and August 31, 1993 who had severe ARF requiring dialytic support 
were reviewed. Patients with preMexisting chronic renal failure treated with 
hemodialysis prior to ICU admission were excluded from this study. Mean age was 
61 ± 2 years (range 17 -85 yrs) and 46 patients (49%) were aged 65 or older. There 
was a male (83%) predominance. The etiologies of ARF were varied and often 
multifactorial. SixtYMseven (71%) patients required mechanical ventilation, 55 (59%) 
patients received vasopressor dmgs at the start of dialysis treatment. All but 9 
patients (90%) were oligo-anuric (diuresis < 400 mllday). F0l1y-six patients (49%) 
survived until discharge from the ICU, of whom 42 (45%) could be discharged from 
the hospital. Indications for dialysis were azotell.1ia (serum urea> 40 mm01l1), severe 
hyperkalemia, refractory acidosis and/or severe fluid overload. Patients received 
either IHD (11 ~ 34) or CA VHD (/1 ~ 60). During the study period, CA VHD was 
increasingly used in the more severely ill patients when compared to IHD. All 
patients who required continued renal replacement therapy after discharge from the 
ICU were converted to, or maintained 011, IHD. The following information was 
obtained: age, sex, preMexisting medical conditions (chronic obstructive pulmonary 
disease, diabetes mellitus, cardiovascular disease, hypertension, chronic liver disease, 
chronic renal insufficiency, and malignancy), underlying disease and surgical 
procedures performed for each patient, need for vasopressor support or aliificial 
ventilation, provision of full (par)enteral nutrition, systolic and diastolic blood 
pressure, heati rate, arterial blood gas, Fi02 requirements, PaO/Fi02Mratio [12], 
presence of suspected or proven sepsis, bleeding complications, renal and patient 
outcome and cause of death. Renal recovery was defined as return of renal function 
sufficient to discontinue dialytic support, either during the course of stay on the ICU 
or on the general ward. To aid comparison with other studies, both ICU survival and 
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final survival (alive on discharge from hospital) are discussed. Serum urea, creatinine 
and bicarbonate levels were recorded during the first 7 days on dialytic supp0l1. 
Other biochemical and hematological variables recorded for analysis were serum 
levels of potassium, albumin, the white blood cell count and platelet count at the time 
of initiation of dialytic support. Technical data collected for analysis included 
ultrafiltration rate, type of vascular access and vascular access-related complications, 
duration of treatment and number of filters used for each patient. The mea and 
creatinine clearance with CA VHD were assessed according to standard formulas [13]. 
To assess severity of illness and to establish whether the lHD and CA VHD groups 
were tmly comparable, the Acute Physiology and Clu-onic Health Evaluation 
(APACHE) II score at the start of treatment and the number of organ system failures 
at the time of initiation of or whilst on dialytic support were calculated according to 
the pertinent literature [14,15,16]. For each individual the probability of death (%) 
was calculated according to the APACHE II equation [14], which incorperates a 
weighing factor for the diagnostic category or major organ system failure leading to 
ICU admission. This is important as death rate varies according to the principal 
underlying disease [14]. The mean predicted values were then assessed for both the 
CA VHD and IHD group. In a subgroup of inotropic-dependent and ventilated patients 
(IHD, 11 = 10; CA VHD, 11 = 10) cardiorespiratory parameters were reviewed prior to 
the initiation of dialytic supp0l1, and 1, 4 and 24 It, respectively, after the initiation 
of treatment. The costs of both lHD and CA VHD were also estimated for providing 
one week of dialytic support. lIsing standard accounting techniques. 
Intermittent hemodialysis 
IHD was performed using high-flux cellulose-triacetate hollow-fiber membranes (CT-
1I0G, surface area 1.1 m', Baxter Healthcare, USA) and standard dialysis machines 
with volumetric controlled ultrafiltration (Fresenius A 2008 C, Bad Homburg, 
Germany). Vascular access was achieved by inserting a single-lumen acute dialysis 
catheter (MedComp, Harleysville, USA) into the femoral, subclavian or jugular veins 
with the Seldinger technique (11 = 31), or by the surgical creation of a Scribner shunt 
(Quinton instnnnents Co., Seattle WA, USA)(n ~ 3). Dialysate sodium content varied 
from 140-145 mmoVL and potassium content from la2 mmollL; bicarbonate was 
used as a buffering-anion (BC-F 8.4%, Fresenius AG, Bad Hoburg, Germany). 
Dialysate flow was set at 500 mLimin, mean blood flow at 150-175 mLimin. Using 
these flow rates. the ill vitro urea clearance with the CT -11 OG dialyser is 160 
mL/min (Manufacturer's data; Baxter healthcare, USA) . \Vhere neccesary, sequential 
ultrafiltration and isovolemic dialysis was performed. Albumin, saline. and dopamine 
infusions were used for hemodynamic support during dialysis as clinically required. 
Standard anticoagUlation consisted of a heparin loading dose (1000-1500 U) followed 
by continuous infusion of heparin (l000-1500 Un,). In case of a bleeding diathesis, 
regional heparinisation was instituted (l000-1500 un, heparin prefilter 1'S 500-1000 
un, protamine postfilter). 
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Continuous arleriovenous hemodiaflltration 
CAVHD was performed using polyacrilonitrile (PAN) hollow-fiber filters (AN-69HF, 
surface area 0,6 m2, Hospal Ltd, France) connected to the arterial and venous 
vascular access devices in a pumpless circuit with the use of 1.25 III extracorporeal 
tubings with luer lock fittings. Vascular access was either by means of large bore 
catheters (MedComp, Harleysville PA, USA), introduced in the femoral vessels with 
the Seldinger technique (n :=: 44), or by the surgical creation of a Scribner shunt 
(n :=: 16) when carumlation of the femoral vessels was precluded because of severe 
atherosclerosis or the presence of a vascular prosthesis. Warmed bicarbonate-buffered 
dialysis fluid (SH 44-HEP, Combi-Pac, Schiwa GmbH, Glandorf, Germany) was 
pumped counter-current to blood flow through the uitrafiltrate compmiluent of the 
filter (dialysate inflow rate, Qd) at a rate of 1000 mL per hour (16,6 mLimin) with a 
calibrated, volumetric pump (3M, A VI inc., St Paul, USA). In severely catabolic 
patients, a Qd of 2 Llh (33,2 mLimin) was used. The ultradiafiltrate was collected in 
a graded collection bag and the volume measured hourly. The ultrafiltration rate (Q,,) 
was calculated by subtracting the hourly dialysate volume (typically 1000 mL) from 
the total volume of effluent in the collection device. Replacement fluid (Ringers 
lactate) was given as clinically indicated, administered into the arterial limb 
Cpredilution') of the extracorporeal circuit. Standard anticoagulation consisted of 
2000 U of heparin as a loading dose followed by continuous infusion of 500-700 Ulh 
into the arterial line. Low-dose « 250-500 U/h) or no heparin was used in the 
presence of severe underlying coagulopathy or severe thrombocytopenia « 60·IO'/L). 
The filters were changed when there was objective evidence of inadequate filter 
function (i.e., a sustained reduction in UF volume [< 300 mLlh)) or evidence of filter 
clotting. Access devices were not routinely changed unless there were clinical signs 
of infectious (or other) complications. 
Statistical analysis 
Data are expressed as mean ± standard error (SEM) or percentage, where appropiate. 
The Wilcoxon signed-rank test and Kruskal-Wallis test were used to analyse 
nonparametric data. Repeated measures ANOV A test and the unpaired I-test were 
used to analyse normally distributed data. The Chi-square test, including Yates' 
continuity correction where appropiate, was used to assess nominal differences 
between two groups. Statistical significance was accepted at a p < 0.05 level. 
Results 
Patielll population 
Thirty-four patients (36%) treated with IHD were compared with 60 patients (64%) 
treated with CAVHD. All patients were treated in the same surgical ICU. Groups 
were comparable in tenus of age or gender and represented a similar case~mix. 
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Table 1. Characteristics of High-Risk ARF Patients Upon Initiation of Dialytic Support 
IHD CAVHD Significance 
(/I ~ 34) 
Age (yrs) 62 ± 3 
Male (%) 82 
MAP (mmHg) 86 ± 5 
APACHE II 22.2 ± 0.7 
No of OSF's 2.6 ± 0.3 
Sepsis (%) 67 
Arteficial ventilation (%) 50 
Inotropic support (%) 41 
(/I ~ 60) 
60 ± 2 
80 
75 ± 3 
26.5 ± 0.5 
3.4 ± 0.2 
71 
83 
70 
NS 
NS 
P < 0.05 
P < 0.05 
P < 0.05 
NS 
P < 0.05 
P < 0.05 
ARF, acute renal failure; IHO, intemlittcnt hemodialysis; CA VHD, continuous arteriovenous 
hemodiafiltration; No of OSF's, number of failed organ systcms (including ARF) [14,15,161. Values 
are given as mean ± SEM or percentage, whcre appropriate. 
Table 2. Biochemical and Hematological Variables of High-Risk ARF Patients 
Upon Initiation of Dialytic Support 
IHD CAVHD 
(/I ~ 34) (/I ~ 60) 
Urea (mmoVI) 39.1 ± 1.9 47.4 ± 2.3 
Creatininc (~lInol/l) 695 ± 36 572 ± 27 
Potassium (mmolll) 4.8 ± 0.1 4.9 ± 0.1 
Bicarbonate (mmolll) 23.2 ± 0.6 21.8±0.6 
Albumin (gil) 24.6 ± 0.8 25.2 ± 1.0 
Platelel count (x 10'11) 140 ± 12 105 ± 9 
IVBC (x WII) 13.3 ± 1.3 17.2 ± 1.4 
Significance 
p < 0.05 
P < 0.05 
NS 
NS 
NS 
P < 0.05 
P < 0.05 
ARF, acute renal failure; IHD, inlennittent hcmodialysis; CA VHD, continuous arteriovenous 
hClllodiafiltration; WEC, white blood cell count. Values expressed as mean ± SEM. 
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There were significant differences in the severity of illness between groups (Table 1). 
Patients treated with CAVHD had a lower MAP, higher APACHE II score, more 
additional organ system failures and a more frequent requirement of mechanical 
ventilation and vasopressor support as compared to patients treated with IHD. The 
prevalence of ARF as the only vital organ dysfunction differed significantly between 
groups (CAVHD 6/60 [10%] vs IHD 14/34 [41%]; p < 0.05). In addition, there was a 
significant difference in the white blood cell and platelet count between groups 
(Table 2). There was no significant difference in the prevalence of pre-existing 
chronic disease (CA VHD 52% vs IHD 56%), including the presence of pre-existing 
impaired renal function (CAVHD 7% vs IHD 18%). Four patients (7%) in the 
CAVHD-group had non-oliguric ARF compared to 5 patients (15%) in the IHD 
group. Forty-six patients (76%) in the CA VHD-group received full (par)enteral 
nutrition compared to only 10 patients (34%) in the IHD-group (p < 0.05). 
Hemodynamic tolerance 
Severe hypotension occurred in 25 of 130 (19%) HD-procedures. Thirteen of 130 
(10%) HD-procedures were complicated by cardiac arytlunias (rapid supraventricular 
tachycardia, n = 12; ventricular fibrilation, 11 = I). \Vhen patients with isolated ARF 
were excluded, the frequency of severe hypotension was 26% (22 of 84 HD-
procedures) and the frequency of cardiac arrytlullias 14% (12 of 84 HD-procedures). 
Hemodynamic instability often led to premature termination of IHD and/or inability 
of effective fluid removal. Subgroup analysis of inotropic-dependent and ventilated 
patients (Fig 1) showed a significant decrease in MAP (77.3 ± 5.2 to 63.2 ± 4.7 mm 
Hg; p < 0.05) and a trend towards a concomittant decrease in the PaO/FiOz-ratio 
(2.2 ± 0.2 to 1.7 ± 0.2; NS) during the first hour of IHD when compared to 
pretreatment values. No differences were observed in these parameters 4 hand 24 h, 
respectively, after the initiation of IHD compared to pretreatment values (Fig 1). 
CA VHD was hemodynamically well tolerated. No significant differences in heart 
rate, systolic blood pressure, MAP (Fig 1) and PaO,iFiO,-ratio were observed during 
treatment. Significant net fluid loss (up to 5 Llday) could be obtained with no 
significant drop in MAP and in several patients (11 = 9) with a concomittant decrease 
in oxygen requirements and vasopressor support. 
Metabolic contra/ 
There was no significant difference in the duration of dialytic support during the 
course of stay on the ICU (CAVHD 8.9 ± 0.7 [range 1 - 25] vs IHD 8.1 ± 1.0 [range 
2 - 27] days; NS). During a total of 531 days of CA VHD, the mean life span of the 
filter was 51.2 ± 1.2 h. A mean of 3.8 ± 0.5 IHD-procedures were performed during 
this period of 8.1 ± 1.0 days, giving an average of alternate-day treatment (1 :2.1 
days). Average duration of a dialysis session was 4 h (range 1-5 h). The mean serum 
urea level was higher and creatinine level lower upon initiation of dialytic support in 
patients receiving CA VHD as compared to those receiving IHD (urea 47 ± 2.3 vs 
39.1 ± 1.9 mmollL; p < 0.05, and creatinine 572 ± 27 vs 695 ± 36 pmollL; p <0.05). 
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Figure 1: Effects of intermittent hemodialysis (IHD) and continllolls arteriovenous hemodiafiltratioll 
(CAVHD) 011 mean arterial pressure (MAP) in inotropic-dependent and ventilated patients with acute 
renal failure (CAVHD, n = 10,' IHD, II = 10). There was a significant decline of MAP during the first 
hour of IHD. Ultrafiltration volume during IHD was 1.1 ± 0.4 L (mean ± SEM),' net ultrafiltration 
volume during CAVHD was 3.7 ± 0.3 Uday. Values of MAP are expressed as percent cliangejrom 
pretrealment values. *: p < 0.05 vs previous time point. 
Overall, no significant changes in senllll urea or creatinine levels were observed 
during treatment with IHD (Fig 2a,b). In patients receiving CA VHD, a significant 
decline of both parameters was observed during the first 72 h of treatment (urea 47.4 
± 2.3 to 30.3 ± 1.4 mmollL; p < 0.05, and creatinine 572 ± 27 to 361 ± 23 IlmolfL; 
p < 0.05, respectively). Thereafter, controlled steady-state levels were achieved with 
serum urea levels kept below 30 mmoliL (Fig 2a,b). Mean urea and creatinine 
clearances with CA VHD (Qd I Llh) were 24.6 ± 0.4 and 24.3 ± 0.4 mLimin 
respectively. Mean UF volume during CAVHD was 11.5 ± 0.3 Llday (range 8.0 -
14.7 Llday). In patients with severe metabolic acidosis (HC03' < 20 mmolfL), 
bicarbonate homeostasis was restored more adequately with CA VHD when compared 
to IHD (Fig 3). 
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Figure 2a,h: Course of serum urea (a) and creatinine (b) levels (CAVHD,fI; IHD,o) following the 
iflStilulion of dialytic support. In patients receivitlg CAVHD (11 = 60), a significant decline of serum 
urea and creatinine levels was obsen'ed during the first 72 h of treatment,' thereafter, steady-state 
levels were achieved. No changes in these levels were seen in patients treated wilh IHD (1/ = 34). The 
peak/trough levels that are normally seen with IHD are smoothed alit by the graph. Values are 
etpressed as mean ± SEM. *: p < 0.05 Vs previous lime points; #: p < 0.05 vs IHD. 
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Figure 3: Serum bicarbonate levels (CAVHD,u; IHD,o) following the initiation of dialylic support in 
patients with severe metabolic acidosis (HC03' < 20 mmolll), mew'bonate homeostasis was restored 
more adequately in patients treated wilh CAVHD (1/ = 14) when compared 10 those (rea/ed with IHD 
(11 = 8). Vailles are expressed as mean±SEM. *: p< 0.05 \'S previolls time poinls; #: p < 0.05 vs IHD, 
Complications 
Apart from hemodynamic deterioration as observed during IHD, no difference in the 
(hemorrhagic- or vascular access related) complication rate was observed between 
groups (Table 3). No distal ischemic complications were seen with either femoral 
cannulation or Scribner shunt insertion. Despite continuous heparinization during 
CA VHD, no difference in the incidence of overt bleeding complications (all of which 
were from the digestive tract) were observed (Table 3). 
Outcome 
Twenty-six patients (43%) treated with CAVHD survived to leave the ICU, of whom 
23 (38%) could be discharged from the hospital, compared to 20 (59%) and 19 
(55%) patients, respectively, treated with IHD. These differences were not statistically 
significant. The calculated probability of death (%), however, was significantly higher 
for the CAVHD group compared to the IHD group (55 ± 2.6 l'S 33 ± 2.5; p < 0.001). 
In addition, the mean APACHE II score of patients treated with CA VHD who 
survived was similar to that of patients treated with IHD who died (Fig 4). None of 
the patients with ARF as the only vital organ dysfunction (CAVHD, fI = 6/60 [10%]; 
IHD, 11 = 14/34 [41%]) died. 
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Table 3. Complications of Different Forms of Dialytic Support 
Complication 
Hypotension 
Cardiac arrythmias 
Vascular access-related: 
shunt thrombosis 
infected shunt site 
pneumothorax 
infected dialysis catheter 
false aneurysm femoral artery 
Overt bleeding 
IHD 
(/I ~ 34) 
25 (19)' 
13 (10)' 
4 (12) 
o 
2 
2 (6) 
CAVHD 
(/I ~ 60) 
o 
o 
8 (13) 
3 
3 
6 (10) 
#: given as number of hemodialysis procedures (11 = 130). Values between parentheses are 
percentages. 
For the group as a whole, duration of stay on the ICU was longer for patients treated 
with CAVHD compared to patients treated with IHD (22.1 ± 2.0 vs 15.5 ± 1.8 days; 
p < 0.05). Time-interval from ICU admission to stmi of dialysis treatment did not 
differ between survivors and non-survivors for patients treated with IHD (Fig 5). In 
patients treated with CA VHD, however, this interval was significantly shorter for 
those who survived compared to those who died (Fig 5). There was no difference in 
the pretreatment creatinine levels between survivors and non~sUl'Vivors treated with 
CAVHD (641 ± 46 vs 523 ± 32; NS). In both groups, death was most often due to 
refractory septic shock and/or progression to irreversible multiple organ system 
failure (MOSF), followed by cardiovascular causes. FOI1y-seven percent of patients 
receiving CA VHD regained renal function compared to 53% of patients receiving 
IHD. Mean senllu creatinine levels of these patients, either at the time of death or on 
discharge from the hospital, differed significantly between groups (CAVHD 127 ± 13 
vs IHD 185 ± 12 fImollL; p < 0.05). In addition, the time from start of dialytic 
support to dialysis independency was significantly sh0l1er in patients treated with 
CAVHD compared to patients treated with IHD (10.9 ± 1.6 [range 3 - 52] vs 17.6 ± 
3.4 [range 5 - 73] days; p < 0.05). 
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Figure 4: Mean APACHE II score of surviving (IHD, 11 = 20; CAVlfD, II = 26) and flail-surviving 
patienls (IHD. 11 = 14; CAVHD. II = 34). The mean APACHE II score of nOll-surviving patients 
treated with IHD was similar to that of surviving patients treated with CAVHD. There were significant 
differences between aff other groups ill the mean APACHE II score (p < 0.05). 
Costs 
The weekly costs of IHD were calculated by assuming a dialysis frequency of 1:2.1 
days (i.e., 3.3 treatments/wk), with an average duration of 4 h each. The costs of 
dialysis machines, water treatment systems and physicians were not included. The 
weekly costs of CA VHD were calculated by assuming a Qd of 16.6 mLimin (I Llh) 
and a mean life span of the filter of 51.211 (i.e., 7 x 24 11/51.2 ~ 3.3 filters/wk). 
No requirement to change access was assumed for both treatments. There was a 
difference in apparent costs of approximately $400 per week in favour of IHD 
(Table 4). 
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Figllre 5: Time interval (days) between admission to the intensive care IInit (ICU) and initiation of 
dialytic support. In patients treated with CAVHD, slln'ival was more likely when treatment was started 
earlier during the course of stay 011 the ICU. *: p < 0.05 vs nOli-survivors. 
Discussion 
In recent years, CRRT has been rapidly adopted as a viable alternative to IHD for 
the treatment of ARF in the critically ill patient. However, whether continuous 
treatment modalities are superior to IHD is still debated, m,ainly because of lack of 
comparative data [6,7]. In addition, because of its high efficiency (urea clearance 120 
- 180 ml/min), single-vessel access and less risk of bleeding, several authors have 
stated that IHD should still be considered as first line therapy in ARF [4,5,6]. We 
sought to address this important issue by comparing the continuous treatment 
modality as employed in our hospital, i.e., CA VHD, with IHD, not only in terms of 
control of biochemistry and fluid balance, but also in term,s of morbidity, m0I1ality 
and costs, \Ve are aware that the current study suffers in being retrospective and non-
randomized, and that treatment selection bias became evident during the study period. 
However, carefull assessment of disease severity with use of clinical and laboratory 
data, including calculation of the APACHE II score and the number of failed organ 
systerns, allowed a meaningfull comparison between both groups. 
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Table 4. Weekly Cost of Therapy' 
CA VHD costs (7 days) 
Dialysateb 
Catheters 
Replacement (8 I/day) 
Hcmofiltcr (3.3 @ $78 eachY 
Renal nurse time ($20/hr x 30 min. x 3.3)d 
Total 
IHD costs' (3.3 treatments, 4 Ius each) 
Dialysate ($12 x 3.3) 
Catheters 
Lines ($3 x 3.3) 
Dialyzer (3.3 @ $26 each) 
Renal nurse time ($20fhr x 5 Ius x 3.3) 
Total 
$ 454 
87 
112 
257 
32 
$ 932 
$ 40 
42 
10 
86 
330 
$ 508 
• Costs of dialysis machines, watcr treatment systems, and physicians not included; b Qd 16.6 
ml/min (I l/hr); , assuming filterlife of 51.2 Ius; d renainUfse time involved in priming of the filter 
and set-up CA VHD system; • assuming dialysis frequency 1 :2.1 days (= 3.3 Irealment/wk), average 
duration 4 Ius each. 
One of the major findings of our study was the superior metabolic control 
obtained with CA VHD. We observed a significant decline of serum urea levels with 
CA VHD, achieving controlled steady-state levels within 72 h, whereas no significant 
changes were seen in serum urea levels with (alternate-day) HD. Others have also 
fouud more effeclive coutrol of azotemia with CRRT when compared to IHD [10,11]. 
The peak/trough urea concentrations as seen with IHD are avoided and the 'steady-
state' urea achieved may well be a more appropriate measure of the uremic status [7]. 
CA VHD was also associated with more adequate correction of bicarbonate 
homeostasis. This may be of importance as acidosis significantly contributes to the 
catabolic state [17], attenuates the response to (exogenous) catecholamines [18], and 
exerts deleterious effects on hemodynamics and cardiac performance [19]. 
Using acetate-buffered dialysate and cellulosic membranes, Mauritz et al. [lO] 
observed severe hypotension in 31.9% of dialysis procedures performed in patients 
with ARF secondary to abdominal sepsis. Despite the performance of more 
'contemporary' IHD with often sequential ultrafiltration/isovolemic dialysis [20], use 
of bicarbonate-buffered [21], high sodium [22] dialysate and use of a modified 
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cellulosic membrane, hypotension and the inability of effective fluid removal was still 
a major problem. It may be that circulating vaso~active mediators, the presence of 
'leaky capillaries' and the presence of low serum albumin levels (Table 2), as 
frequently observed in critically ill patients with MOSF [23], contributed to a 
diminished plasma refilling rate and the prohibition of adequate compensatory 
peripheral venoconstriction during (rapid) ultrafiltration, By contrast, CA VHD 
afforded great ease in volume control and irnproved hemodynamic stability was 
noted. In addition, subgroup analysis of mechanically ventilated patients revealed a 
trend towards a decrease in the PaO,iFiO"ratio [12] concomillant with a fall of MAP 
following I h of IHO, whereas no changes were seen in these parameters during the 
first 24 h of CA VHD, Impaired gas exchange may be explained by a decrease in 
venous oxygen tension as a result of a decrease in cardiac output, an increase in 
oxygen consumption (V02), or both. An increase in V02 during IHO, independent of 
the membrane or buffer~anion used, has been demonstrated in ventilated ARF patients 
on the ICU [24], During CRRT, YO, is unchanged or even reduced [25,26] and an 
increase in cardiac performance may occur as a result of gradual volume removal 
[27] or by the removal of circulating mediators with cardiodepressant properties [28]. 
The ample water and solute removal with CA VHD facilitated the administration of 
full parenteral nutrition without the risk of exacerbating azotemia (steady-state urea 
levels < 30 mmollL) or fluid overload, Allempts at full parenteral nutrition in patients 
treated with IHD, however, were frequently thwarted by the problems of fluid 
overload or severe hypotension induced by rapid ultrafiltration. Excessive catabolism 
is frequently present in the critically ill patient with ARF and adversely affects 
prognosis [17,25]. It is associated with impaired healing rate and depressed immune 
response [25]. In addition, prolonged protein~calorie malnutrition may precipitate or 
worsen respiratory failure [29], With CA VHD, unlike IHD, it is possible to reduce 
the protein catabolic rate and to achieve, at least in some patients, positive nitrogen 
balance [9], 
There was no difference in the number of patients who recovered renal function 
between groups. However, senUH creatinine levels of patients treated with CA VHD, 
either at the time of death or upon discharge from the hospital, were lower compared 
to those of patients treated with IHO. In addition, the duration of ARF was 
significantly longer in patients who were treated with IHO when compared to patients 
who were treated with CA VHD. One effect of ischemic ARF may be to impair renal 
autoregulation [30,31]. It is possible that recurrent episodes of hypotension, as 
occurred during IHO, may be accompanied by a prop0l1ionate fall in renal perfusion 
pressure, thus potentially prolonging renal failure by inducing repeated ischemic 
insults [3 I]. 
Several findings suggest that CA VHO contributed to improved survival. Despite 
significantly greater illness severity and a higher probability of death in those treated 
with CA VHD, no difference in outcome was observed between groups. The finding 
of a similar APACHE II score of surviving patients treated with CA VHD and non, 
surviving patients treated with IHO fmiher suggest an improved outcome in 
continuously treated patients. Others have also noted improved survival for patients 
treated with CRRT compared to patients, matched for the severity of disease, treated 
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with IHD [11,32]. 
However, differences in the type of membrane used (i.e., modified cellulosic 
membrane [IHD] vs synthetic membrane rCA VHD]) may have been confounding 
variables in the present comparative study. Experimentally, cellulosic membrane, but 
not synthetic (PAN) membrane, exposed blood delayed resolution of ischemic ARF 
in rats [33]. In addition, preliminary data from a randomized, clinical study 
comparing cellulosic membranes and synthetic (polymethylmethacrylate) membranes 
in the treatment of ARF suggested enhanced recovery of renal function and improved 
outcome in patients dialyzed with the biocompatible synthetic membrane [34]. 
Therefore, use of the (more) biocompatible PAN membrane in the CAVHD group 
may have contributed to the observed difference in the duration of ARF and outcome 
behveen groups, independent of the mode of dialysis. 
In the present study, survival was more likely when CA VHD was instituted earlier 
during the course of stay on the ICU. This difference was not observed in patients 
treated with IHD. There was no difference in serurn creatinine levels between 
survivors and non-survivors upon initiation of CA VHD. It may be that patients 
treated later developed ARF with a more protracted course or developed ARF as part 
of MOSF. Otherwise, one might speculate that earlier intervention with CRRT may 
have a favourable irnpact on outcome. Commonly observed cardiac and/or pUlmonary 
system failure accompanying postoperative ARF may be exacerbated (or provoked) 
by overhydration [35] and increases the risk of dying [36]. Therefore, prevention or 
the rapid reversal of any existing overhydration with the early institution of CRRT 
may lead to a diminution of additional vital organ dysfunctions. In addition, it gives 
the oppol1unity for early and aggressive nutritional supp0l1, thereby counter-acting 
the often excessive catabolism with its adverse effects [16]. Yet another beneficial 
effect of (early) CRRT may be a down-modulation of the body's exaggerated 
response to septicemia by the removal of soluble inflammatory mediators with 
vasoactive and cardiodepressant properties [28]. 
Finally, the cost of ARF support was also considered. There was an apparent 
difference in cost of approximately $400 per week in favour of IHD. The actual 
difference is reduced somewhat as the costs of dialysis machines and water treatment 
systems were not considered. Moreover, to achieve azotemic control similar to that 
achieved with CA VHD, the frequency of IHD would have to be increased, thus 
increasing its costs. The apparent prolongation of ARF with IHD represents a fiu1her 
increase in total costs. However, had equal cost been attained with more frequent 
hemodialysis, survival might have been different, i.e., higher in the IHO group. The 
costs of CA VHD were largely dependent upon the use of large amounts of sterile 
dialysate, which is inevitable, and the use of synthetic hemofilters. Maximizing filter 
life may thus be an important issue pertaining to these costs. One factor may be that 
a more appropiate timing of investigations or procedures that require discontinuation 
of CRRT is performed. 
In conclusion, the present comparative study suggests that CAVHD offers several 
distinct advantages relative to IHD. It is associated with superior control of 
biochemistry and fluid balance; avoids hemodynamic instability and deterioration of 
gas exchange, as often observed with IHD; enables the provision of full (par)enteral 
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nutrition; and reduces the duration of ARF. All of these factors may have contributed 
to the apparent improved outcome in patients treated with CA VHD. Although 
CA VHD may be more expensive, effectiveness rather than costs should determine the 
technique employed. With all the limitations of a retrospective study, we think the 
present data add weight to the contention that CRRT is superior to IHD as dialytic 
support for the critically ill patient with ARF and may contribute to improved 
survival. 
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Chapter 6 
Abstract 
Object;,'e alld desigll: A beneficial effect of hemofiltration on the hemodynamics of 
cndotoxic shock pigs has recently been shown (see chapter 1. 4), To test the 
hypothesis that this effect of hemofiltratioll is caused by convective removal of 
factors that adversely affect hemodynamics during endotoxemia, we infused 
ultrafiHrate from endotoxic shock and normal pigs into healthy pigs. Twelve 
anesthetized and ventilated pigs were hemodynamically monitored for 150 minutes 
following the infusion of 2 liters of ultrafiltrate from 12 donor pigs, The acceptor 
pigs were randomly divided into two groups; group 1 received uitrafiltrate from pigs 
who were hemofiltered after the infusion of 0.5 mglkg endotoxin over 30 minutes; 
group 2 served as a control group, receiving uItrafiltrate from. healthy donor pigs. 
Results: Group 1 showed a decrease in mean arterial pressure of 28 ± 7 mmHg 
[mean ± SEM] versus an increase of 17 ± 3 mmHg in group 2 (p < 0,04), Mean 
pulmonary artery pressure increased in group 1 compared to group 2 (9 ± 2 nmlHg 
vs 1 ± 1 mmHg; p < 0.04). The decrease in cardiac output in group 1 was greater 
than in group 2 (3,3 ± 0,2 IImin I'S 0,3 ± 0,3 IImin; p < 0,02) and was due to a fall 
in stroke volume. The fall in right ventricular ejection fraction was also greater (0.15 
± 0,02 I'S om ± 0,00; P < 0,0 I), Systemic vascular resistance, right atrial pressure, 
right ventricular end diastolic volume, pulmonary wedge pressure and heat1 rate did 
not differ between groups. 
COllclusion: In contrast to ultrafiltrate from healthy pigs, ultrafiltrate from endotoxic 
shock pigs contains soluble, filtrable factors that increase pulmonary artery pressure 
and depress cardiac performance. 
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Introduction 
Septic shock and multiple organ system failure (MOSF) carry a high mortality rate 
[l]. The availability of new antibiotics, inotropic agents and teclmiques to replace the 
function of failing organ systems does not prevent the high mortality of these 
patients. Novel approaches in the treatment of these patients include optimization of 
oxygen delivery and the administration of monoclonal antibodies against endotoxins 
and tumor necrosis factor (TNFu) [2]. 
Another approach is the convective elimination of mediators of sepsis by 
hemofiltration (HF) [3-5]. In intensive care unit (leU) patients with acute renal 
failure treated by HF, a relation between ultrafiltrate volume and survival has been 
observed [6], suggesting that toxic substances are removed from the circulation with 
this technique. Animal studies revealed only minimal effects of low volume (600 
mllh) HF on cardiac performance [7-9]. We recently reported that high volume HF 
(ultrafiltrate flow 6 literslh) had a beneficial effect on left [10] and right [II] 
ventricular performance in porcine endotoxic shock. The discrepancy between our 
results and those obtained by others suggests a relationship between the ultrafiltrate 
volume and hemodynamics. This may indicate that the beneficial effect of HF is 
based on convective elimination of factors responsible for myocardial dysfunction via 
the ultrafiltrate. 
To further test this hypothesis, we infused uitrafiltrate, obtained from endotoxic 
shock pigs, into healthy acceptor pigs and compared the hemodynamic response to 
that after infusion of ultrafiltrate from healthy pigs. 
Materials and methods 
The protocol was approved by the local ethical conunittee for animal experiments. 
Twenty-four pathogen-free pigs from our own herd were used. Average age was 12 
weeks and weight varied from 28 to 32 kg. All pigs were fasted overnight and 
allowed free access to water. The pigs were randomly assigned to serve as donor or 
acceptor. Thereafter, the donor was randomly assigned to a controle group or a group 
receiving endotoxin (E. coli 0.111 :B4, Sigma, St.Louis, USA). 
Donor pigs 
The pigs were premedicated with 300 mg ketamine intramuscularly. They were 
intubated and mechanically ventilated, using a volume-controlled ventilator (Oxylog, 
Draeger, Luebeck, Germany) with Fi02 0040, ventilator minute volume 4.0 liters and 
frequency 12 breath/min. A double-lumen catheter (DL6K, Impra. Inc., Tempe, AZ) 
was introduced into the superior caval vein, using the Seldinger technique. 
Thereafter, the pigs received 180 mg pentobarbital Lv., followed by a continuous 
infusion of pancuronium bromide (0.2 mgikglh) and pentobarbital (6.0 mg/kg/h). 
After a stabilization period of 30 min, endotoxin (0.5 mg/kg in 60 ml Ringer's 
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lactate), or 60 ml Ringer's lactate was infused over 30 min. Thereafter, pigs were 
subjected to zero-balanced hemofiltration, exchanging 2.0 liters ultrafiltrate over 30 
min. The ultraflltrate was collected under sterile conditions. The hemofiltration set-up 
consisted of a roller pump, air detector and pressure limiter (Gambro AK 10, Lund, 
Sweden). The pump flow was set at 250 mUmin, the pressure limiter was set at 250 
mmHg. A 0.6 m' polysulphon hollow fiber filter with a cut-off point of 30,000 
Dalton (Diafilter 30, Amicon Corp., Lexington, USA) was used. Prior to experiments, 
the filter was rinsed with 2 liters Ringer's lactate containing 5000 U heparin. Zero-
balanced HF was achieved using a balance (BS I.Gambro, Sweden). The substitution 
fluid (HF 21 hemofiltration solution, Fresenius, Bad Homburg, Germany) was 
warmed and infused before the filter. After collection of uitrafiltrate, the pigs were 
sacrificed. 
Acceptor pigs 
The pigs were premedicated with 300 mg ketamine Lm. After 15 min, they were 
orally intubated and ventilated (FiO, 0.40; 12 breath/min), using a blender (SJO I, 
Ohio medical products, Minneapolis, USA) and a volume-controlled ventilator 
(Siemens 900A, Elema, Sweden). The minute volume was adjusted to obtain an 
arterial pCO, of 38-42 mm Hg. Thereafter, ventilation was kept constant during the 
experiment. Anesthesia was maintained with 6 mg/kg/h phenobarbital and 0.2 
mglkg/h pancuroniul11 bromide, via a continuous intravenous infusion. A 30 cm F5 
cannula (Cavafix, 417375/9, Braul1, Melsungen, Germany) was advanced into the 
femoral artery after cutdown and connected to a pressure transducer (PIN 966025/07, 
Baxter, Irvine, USA), positioned at the level of the left atrium. Arterial blood 
pressure was measured by connecting the transducer to a monitor (Hewlett Packard, 
78342A), after calibration and zeroing to atmospheric pressure. A 7F rapid response, 
balloon-tipped thermodilution catheter (TD) (type 93A-431H-7, Baxter Healthcare 
Corp., Irvine, USA) was introduced into the superior caval vein via a percutaneous 
puncture using the Seldinger technique. Under monitoring of pressure wave forms, 
the catheter was advanced into the pulmonary m1ery until the inflated balloon 
wedged, and the injectate port positioned 3 cm above the tricuspid valve. This 
position was checked by pressure tracing before each set of cardiac output 
measurements. The catheter was connected to a cardiac output monitor (REF-I, 
Baxter Healthcare Corp., Irvine, USA) and to a pressure transducer (type PIN 
966025-07, Baxter Healthcare Corp., Irvine, USA) connected to a Hewlett-Packard 
monitor (type 78342A). The transducer was positioned at the level of the left atrium 
and pressures were measured after calibration and zeroing to atmospheric pressure. 
Right atrial pressure (RAP) and pulmonary artery wedge pressure (PA WP) were 
measured intermitttentIy. Cardiac output (CO) and right ventricular ejection fraction 
(RVEF) were measured by the thermodilution teclUlique. The injectate was cooled 
using an injectate coil (type 93-500, Baxter Healthcare Corp.). The injectate 
temperature was measured on line. Each injection was started at the end of a 
ventilatory cycle and for each variable the average of 3 measurements was taken. The 
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arterial pressure and pulmonary artery pressures were recorded continuously on a 
multichannel recorder (WS-682G, Nihon Kohden Co. Tokyo, Japan). RAP and 
PA WP were recorded before the start of ultrafiltrate infusion and subsequently every 
15 min. Values were calculated from pressure tracings. After instrumentation, the 
pigs were allowed to stabilize for 75 min, during which they received 500 ml Ringers 
lactate. In this period, the donor pigs were instrumented. Thereafter, baseline 
measurements were made, followed by the infusion of 2 liters of ultrafiltrate over 2 
h. After baseline measurements, hemodynamic .measurements were repeated every 15 
min during 150 min. At each hemodynamic measurement, arterial and mixed venous 
blood samples were taken simultaneously for measurement of pH, blood gases, 
hemoglobin (Hb) concentration and white blood cell count (WBC). Blood gases (pO" 
pe02) were measured with an IL-1306 analyser (Instrumentation Laboratories, Milan, 
Italy). A Contraves 8016 Analyzer (Contraves AG, Zurich, Switseriand) was used to 
determine WBC and Hb concentration. 
Calculations 
Stroke volume: 
SV~COIHR, 1111 
Systemic vascular resistance: 
SVR~(MAP-RAP)x80ICO, dynes. sec. CIII" 
Left ventricular stroke work: 
L VSW~(MAP-PA WP)xSVxO.O 136, gill 
Right ventricular stroke work: 
RVSW-(MPAP-RAP)xSVxO.0136, gill 
Right ventricular end diastolic volume: 
RVEDV~SV/RVEF, 1111 
Right ventricular end systolic volume: 
RVESV~RVEDV-SV, 1111 
Statistical analysis 
To compare data of groups at different time points, statistical analyses were 
performed on all variables. We lIsed the ante-dependence method for repeated 
measurements, as described by Kenward [12,13]. This method can decompose 
observations into independent components, so that it is possible to identify the first 
moment at which a new significant difference between the groups occurs. In addition, 
this method provides a cumulative overall test for comparison of hemodynamic 
profiles. Moreover, Fisher's least significant difference (LSD) was performed, 
comparing the values for each parameter at the start of the experiments to those at 
the end of the experiments. This test shows the least difference between two effects 
that is significant as a measure of precision of the estimated difference [13]. Results 
are given as mean ± SEM; p < 0.05 is considered statistically significant. 
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Table 1. Values of Variables at Different Time Points in Group laud 2" 
Tune (min) 
0 IS 30 45 60 75 90 lOS 120 135 ISO 
HR (bpm) 
Group 1 152 ± 3.2 151 ± 12.3 150 ± 15.2 133 ± 11.0 139:t 12.8 134 ± 9.9 128 ± 9.3 125 ± 93 114 ± 7.7 112 ± 7.4 113 ± 9.6 
Group 2 151 ± 4.0 149 ± 4.5 156 ± 49 147 ± 6.8 141 ± 7.& 141 :':7.& 141 ±6.7 132±95 124 ± lOS 125 ± 125 124 ± 11.1 
SVR (dyness.cm·$) 
Group 1 1483 ± 31 1618 ± 12& 1967 ± 30& 2041 ± 236 2114 ± 142 2390 ± 29& 2108 ± 16& 2020 ± 257 2233 ± 269 2413 ± 274 2415 ± 325 
Group 2 1709 ± 74 1562 ± 91 1523 ± 79 1707 ± 90 172&± 103 1741 ±72 179& ± 70 1943 ± 65 2203 ± 200 2191 ± 252 2158 ± 182 
PAWP (romHg) 
Group 1 5±0.7 10 ± 1.6 9 ± 13 8 ± 1.6 7 ± 1.9 6±1.2 5± 1.4 4 ± 1.0 5± 1.4 5 ± 1.4 5 ± 1.8 
Group 2 5 ± 0.6 & ± 1.5 8± 1.1 7 ± 0.4 7 ± 0.7 6 ± 0.& 5 ± 0.9 6 ± 1.0 6 ± 1.1 6 ± 0.8 5 ± 0.8 
RAP (romHg) 
Group 1 2±0.5 3 ± 0.& 3 ± 12 2 ± 1.1 3 ± 1.2 2 ± 0.& 2 ± 0.9 2 ± 1.1 2 ± 1.0 2 ± 0.& 2 ± 1.0 
Group 2 1 ±03 3 ± 1.0 3 ± 0.7 3 ± 0.4 1 ± 0.5 1 ± 03 1 ± 0.3 1 ± 0.5 2±0.8 1 ± 0.4 I ±03 
RVSW (g) 
Group 1 8±03 14 ± 1.1 13 ± 0.& 13 ± 1.4 II ± 1.4 9 ± 0.7 9 ± 0.9 13 ± 1.9 10 ± 0.5 10 ± 1.2 9 ± 1.0 
Group 2 6±0.6 10 ± 1.9 10 ± 1.5 9 ± 1.5 10 ± 1.8 6±1.2 9 ± 0.9 & ± 0.8 8 ± l.l 9 ± 0.9 8 ± 0.6 
RVEDV (mL) 
Group 1 80 ± 4.0 79 ± 3.1 7&±25 77 ± 4.4 69 -=.4.8 73 ± 5.8 71 ± 6.1 76 ± &.8 77 ± 6.4 79 ±89 7& ± 9.8 
Group 2 86 ± 3.4 86±33 &6 ± 3.4 86 ± 3.6 83 ± 3.6 86 ± 3.6 86 ± 3.8 85±4.1 84 ± 4.4 83 ± 4.& 80 ± 4.5 
RVESVIRVESP 
Group 1 1.6 ± 0.6 0.7 ± 0.9 0.7 ± 0.9 l.l ± 03 1.1 ± 0.2 1.2 ± 02 1.2 ± 0.5 1.1 ± 0.2 1.5 ± 0.7 1.4 ± 0.4 1.5 ± 0.6 
Group 2 1.9 ± 0.5 1.7 ± 0.5 1.7 ± 0.6 1.& ± 0.5 1.9 ± 0.6 1.7 ± 0.2 1.8 ± 03 1.8 ± 0.4 1.9 ± 0.6 1.9 ± 0.5 2.1 ± 03 
Hb (mmollL) 
Group 1 5.6 ± 02 63 ±03 6.4 ± 03 6.5 ± 0.4 6.& ± 0.4 7.0 ± 0.4 73 ± 0.3 73 ± 03 72 ± 0.4 72 ± 0.4 6.9 ± 0.4 
Group 2 6.1 ±03 6.0 ± 0.4 5.9 ± 0.3 5.& ± 0.2 5.& ± 03 6.0 ± 02 6.0 ± 03 5.7 ± 03 5.9 ± 02 5.9 ± 03 5.7 ± 03 
WEe (xIO·!l.) 
Group 1 &.1 ± i.3 7.4 ± LO 9.&± 1.4 10.8 ± 1.8 8.9 ± 1.5 7.6 ± 1.& 8.1 ±2.1 8.4 ± 2.2 &.5 ± 2.4 7.7 ± 23 7.8 ± 2.6 
Group 2 7.8 ± 0.6 &.0 ± 0.9 7.0 ± 0.7 6.6 ± 0.7 6.8 ± 0.6 6.4 ± 0.& 6.8 ± 1.0 6.9 ± 0.9 6.9 ± 1.0 7.0 ± 1.1 6.0 ± 1.6 
Arterial pH 
Group 1 7.41 ± 0.01 737 ± 0.02 735 ± 0.01 736 ± 0.01 736 ± 0.01 736 ± 0.02 736 ± 0.02 7.40 ± 0.02 738 ± 0.02 73& ± 0.02 738 ± 0.02 
Group 2 7.43 ± 0.02 7.42 ± 0.02 7.41 ± 0.01 739 ± 0.02 7.3&±0.01 73& ± 0.02 737 ± 0.02. 7.36 ± 0.02 735 ± 0.02 735 ± 0.01 7.36 ± 0.02 
For abbreviations see text ": Values not significantly different over time (Antedependence method). 
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Figllre I: The cOllrse 0/ cardiac oU/pm (CO), mean arterial pressure (MAP), left ventricular stroke 
work (LVSW) and stroke \'olllme (SV) after the in/lis ion of 2 liters 0/ IIltrofiltrate from elida/oxic shock 
pigs (Group I,' n = 6) or healthy pigs (Group 2,' 11 = 6). The meall ± SEM values are shown. The 
probability value results from the overall tests of profiles. The asterisks indicate the occurrence 0/ a 
new significant difference between groups (p < 0.05), using the anfedependence method. 
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Results 
All pigs survived till the end of the experiment. No filter clotting occurred, in all 
pigs a blood flow of 250 ml/min through the filter was achieved and venous pressure 
of 200 mmHg was never exceeded. In all donor pigs 2 liters of ultrafiltrate could be 
obtained over 30 min. The hemodynamic and blood gas data are shown in Table 1 
and depicted in Figures 1-3. 
Table 2. Fisher's Least Significant Difference Test 
Group 2-1 LSD 2·1 
HR 12.3 41.6 
Cardiac output 3.01' 0.987 
SV 18.0' 9.90 
MAP 47.4' 21.9 
PCWP 0.50 3.50 
SVR 1029 1602 
MPAP 8.0' 5.17 
RAP 0.67 1.63 
LVSW 54.8' 17.81 
RVSW 0.6 3.19 
RVEF 1.33' 0.072 
RVEDV 15.1 22.5 
RVESV/RVESP 0.188 0.307 
Hb 1.8' 1.18 
WBC 1.6 8.99 
Arterial P02 53' 51.5 
Arterial PC02 2.5 5.59 
Arterial pH O.oJ8 0.08 
Note: TIle decrease or increase between baseline values and values at ISO minutes for each variable 
ill group 2 is compared with the change in that variable in group 1. Considering P <.05 significant, 
the value under 'Group 2-1' that should be exceeded to reach significance was calculated (least 
significant difference, 2-1). For abbreviations see text. 'p < .05. 
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Global hemodynamics 
Cardiac output decreased more in Group 1 than in Group 2 due to a fall in SV and 
not in HR. This difference occurred inunediately after the start of ultrafiltrate 
infusion (Fig 1). MAP increased in Group 2 and decreased in Group I, a significant 
difference occurring at 45 min. LVSW increased in Group 2 and decreased in Group 
1, a significant difference occurring at 15 minutes. Overall, cardiac output, SV, MAP 
and L VSW were significantly lower in Group 1 than in Group 2 (Fig 1), as were 
their values at 150 min compared to those at the start of the experiments (Table 2). 
MPAP increased significantly more in Group 1 than in Group 2. This difference 
occurred at 15 min. PAWP, RAP, HR and SVR did not differ between the groups. 
RighI ventricular volumes and peliormance 
RVEF gradually fell in Group 1, in contrast to a very small change in Group 2. At 
15 min, a significant difference in this variable occurred, while a concomitant 
increase in MPAP was observed (Fig 2). Overall, RVEF was lower and MPAP was 
higher in Group 1 than in group 2, as were their values at 150 min compared to those 
at 0 min. No overall difference was found in the RVESV/peak systolic pulmonary 
pressure ratio between hath groups. 
o 15 30 45 60 75 90 lOS 120 135 150 
Figure 2: The course of right venlriClllar ejection fraction (EF) and mean pulmonary arterial pressl/re 
(MPAP) after the infusion of 2 liters of ultra filtrate from endotoxic shock pigs (Group i,' II = 6) or 
healthy pigs (Group 2; 11 = 6). The meall ± SEAl values of RVEF and MPAP are shown. The 
probability value results from the o\'eral/ tests of profiles. The asterisks indicate the occurrence of a 
lIew significant difference (p < 0.05) between groups, using the antedependence method. 
135 
Chapter 6 
"0 
"0 
110 0 15 30 (5 00 75 00 105 1.0 135 150 
~me(min) 
i 
~4S 
I 
35 0 15 30 (5 00 75 00 105 110 135 1M 
I,ma(min) 
Figure 3: The course of arterial pCO] and pOl after infllsion of 2 liters of IIllrajillrale from elldotoxic 
shock pigs (Group i,' 11 = 6) or healthy pigs (Group 2; II = 6). The mean ± SEM values are shown. 
The probability value results from the overall tests of projiles. The asterisks indicate the occurrence of 
a new significant difference (p < 0.05) hetween groups, using the antedependence method. 
Biochemistry 
At 15 min, arterial peol was higher in Group I than in Group 2; this difference 
disappeared at 105 minutes (Fig 3). Comparing arterial pCO, at 150 minutes to the 
baseline values, no difference was found between the groups; overall arterial pC02 
was higher in Group 1 than in Group 2, Comparing Hb concentration and arterial p02 
of Group I with Group 2 at 150 minutes, Hb concentration was higher, while arterial 
pOl was lower; no overall differences in these variables between the groups were 
seen. WBC and pH did not differ between the groups. 
Discussion 
Our results show that ultrafiltrate of endotoxic shock pigs induces pulmonary 
hypertension and decreases cardiac performance in healthy pigs. These findings 
suggest that ultrafiltrate of endotoxic shock pigs contains filtrable factors, responsible 
for these deleterious effects. The cause of the fall in cardiac output is probably 
multifactorial. We measured RVEF and derived right ventricular end systolic volume 
using the rapid response thermodilution technique [14]. This technique has been 
shown to correlate well with gated blood pool techniques. The difference in RVEF 
between the groups should be interpreted with care. The decrease in RVEF in Group 
1 needs not reflect a decrease in right ventricular function, but may be caused at least 
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partially by the increase in pulmonary artery pressure, as supported by the absence of 
differences in the right ventricular end-systolic volume/peak pulmonary pressure 
relation [15]. In Group I an increase in RVEDV would be expected in response to 
the increase in MPAP [16]. The absence of right ventricular dilatation in this group 
indirectly suggests a fall in venous return. An increase of the venous capacitance is 
consistent with a septic circulation [2] and may have contributed to the drop in 
cardiac output in Group 1. The difference in L VSW in the absence of significant 
differences in PA WP between the groups suggests an adverse effect of ultrafiltrate 
infusion on LV function. However, as we did not measure LV end-diastolic volume, 
differences in L VSW between the groups may also be caused by a decreased LV 
compliance in Group I. However, RVEDV did not differ between the groups, so that 
a fall in LV compliance due RV distension is unlikely. Therefore, the fall in cardiac 
output may result from both a decreased venous return and decreased left ventricular 
function. 
The cause of the transient difference in arterial pC02 is unclear. It may either 
reflect increased CO2 production by the action of infused mediators of sepsis or a 
deterioration of pulmonary function. This latter is further suggested by the lower pO, 
in this group at the end of the experiment. It was previously demonstrated [17] that 
continuous arteriovenous hemofiltration improved survival time and arterial p02 of 
pigs infused with S. allrells. Infusion of ultrafiltrate of endotoxic shock pigs into 
healthy pigs induced lung injury, similar to that seen after S. alll'eus infusion. 
The cause of the increase in pulmonary and systemic pressure in the control group 
is unclear. Contributing factors may be volume infusion, the presence in the 
ultrafiltrate of vasoactive mediators resulting from extracorporeal circulation [18] and 
the presence in the ultrafiltrate of ketamine or catecholamines, released by the donor 
pig as a result of the instnunentation. As we did not study the effect of volume 
infusion alone, no data are available to substantiate this point. 
Myocardial depression during septic and endotoxic shock is well-documented. 
Decreased Or uneven myocardial perfusion [19,20] and myocardial edema [21] have 
all been suggested to play a role in its pathogenesis. The role of circulating 
substances that depress myocardial performance during sepsis has been studied for 
many years [22-27]. Attempts to reveal the identity of myocardial depressant factor(s) 
(MDF) have focused on identification of production site and molecular weight [22-
24,28]. TNFa induces myocardial depression in in vitro assays of rat myocardial cells 
[29]. In human experiments, interleukin-2 [30] and endotoxin [31] administration 
resulted in cardiovascular abnormalities analogeous to tI~e hemodynamics of human 
septic shock. TherefOl'e, the (inter-)action of many mediators may be involved in 
producing cardiac depression during sepsis. We did not measure levels of important 
mediators of sepsis, such as TNF-a and interleukins, in Sel"lllll or uitrafiltrate, because 
no reliable, quantitive tests for assaying these mediators in pigs are available in our 
area. Nevertheless, our findings do support the hypothesis [10, II] that the 
improvement in cardiac performance during HF is caused by the removal of factors, 
responsible for cardiac depression after endotoxin infusion, via the ultrafiltrate. 
Therefore, it can be expected that the positive effect of HF on cardiac performance of 
endotoxic shock pigs is related to the ultrafiltrate volume. This may explain our 
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previous findings [10,11) of a more pronounced effecl of high volume HF (6 lilers/h) 
than was seen in olher sludies on Ihe effecl of low volume HF (600 ml ultrafiltrale/h) 
on cardiac performance of endotoxic shock pigs [7,9]. 
Several other investigators have addressed the question if hemoflltration could 
reduce the cardiac depression during septic shock by elimination of the causative 
subslances. Gomez ef al. (8) demonslraled Ihal E. Coli infusion resulted in 
myocardial dysfunction, as measured by myocardial contraction velocity and end w 
systolic pressure-volume relation. Hemofiltration using an Amicon filter (molecular 
cuI-off point 30.000 dalton) resulted in an improvement of these parameters. In 
addition, plasma of septic dogs reduced isometric tension of isolated right ventricular 
trabeculae. This effect was not seen when plasma of dogs after HF was used. This 
study indicates that circulating factor(s), responsible for cardiac dysfunction during 
sepsis, can be removed by ultrafiltration. In patients with refractory cardiogenic shock 
(32) or acute respiratory failure following open hearl surgery (33), hemofiltration 
(Amicon diafilter 20; molecular cutoff point 50.000 Da) has been shown to improve 
cardiac output and MAP. Subsequent in vitro experiments showed that ultrafiltrate 
from these patients reduced isometric tension of isolated papillary muscle. Parrillo et 
al. [28] demonstrated that serum of septic shock patients depresses contractility of 
isolated rat myocytes. The quantity of depression of the in vitro myocyte was shown 
to correlate with the reduction in the left ventricular ejection fraction in septic shock 
patients. Molecular filtration experiments with Amicon filters by this group of 
investigators produced somewhat contradictory results as to the molecular weight of 
MDF, some experirnents suggesting a molecular weight between 500 and 5000 Da, 
others a molecular weight of greater than 10,000 Da [28,34,35). These studies 
confirm that both plasma of septic animals and ultrafiltrate of septic patients are 
capable of reducing the contractile propeliies of isolated papillary muscle and 
myocytes. 
Concerning the clinical relevance of these findings, many questions remain to be 
answered. Most animal studies are short term studies on the effect of HF on 
hemodynamics of pigs in the acute phase of endotoxic shock. The potential role of 
hemofiltration in the treatment of septic shock lies in its ability to remove mediators, 
kJlO\Vll to playa causative role in its development. Several studies demonstrated that 
filters with a cut-off point of 30.000 are able to remove PGE, [4], Thromboxane 8, 
[4,9,36), B-endorphin (4) and TNFu [36,37]. Other mediators, for instance 6keto 
PGFlu, were shown to be bound to the filter. We previously showed that high 
volume hemofiltration impn;>ves hemodynamics of endotoxic shock pigs [10,11]. Our 
present study shows that uitrafiltrate from these pigs contains factors that adversely 
affects hemodynamics. Therefore, convective blood purification by hemofiltration 
seems to be at least partially responsible for the improvement in hemodynamics 
during endotoxemia in pigs. 
Translation of these experimental results into the clinical setting of septic shock, 
however, is difficult as we performed a short term study using ultrafiltrate volumes 
that may be difficult to achieve on a continuous basis. Given the low clearance of 
some key mediators of sepsis in man, such as TNFa [37], and the progressive decline 
in sieving properties of hemofilters over time, it is therefore unclear whether 
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clinically achieveable ultrafiltrate volumes are capable of clearing adequate amounts 
of mediators to improve hemodynamics or survival of septic shock patients, Only 
prospective, clinical trials might answer the question if high volume HF is of any use 
in the management of septic shock patients. 
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Abstract 
Objective: To determine whether the clinical improvement noted in some critically ill 
patients undergoing continuous renal repacement therapy (CRRT) is in part due to the 
removal of inflammatory mediators, we assessed the impact of hemofiltration 
membranes on cytokine kinetics (TNFa, IL-l13, IL-6) during both in vitro and in vivo 
hemofiltration (HF). 
Design: In vitro HF was performed using a closed-loop recirculation model 
containing Ringers lactate with human albumin in which recombinant human 
cytokines were added in consecutive experiments. Cytokine kinetics in humans were 
assessed in 20 patients suffering from the systemic inflammatory response syndrome 
and acute renal failure undergoing CA VH-D. To assess sieving characteristics, the 
dialysate pump was stopped IS min prior to sample collection so as to obtain 'pure' 
ultrafiltrate (UF). 
Results: Appreciable sieving of TNFa was observed in vitro only for the AN69 
membrane. In addition, initial sieving of TNFa was masked by its rapid adsorption 
onto the AN69 membrane. Significant sieving of IL-W was observed for all 
membranes tested. Significant sieving of IL-6 occurred with the AN69 membrane but 
less than that for TNFa and IL-IB. No appreciable adsorption was noted for IL-IB 
and IL-6. All patients had detectable TNFa and IL-6 levels; none of the patients had 
detectable IL-lil levels. In contast to our in vitro experiments, lye noted no 
appreciable sieving of TNFa ill vivo; this cytokine being detected in only 17 of 60 
UF specimens (8.9 ± 0.8 pg/mL [mean ± SEM)). Mean ultrafiltrate clearance (K",) 
was 0.1 ± 0.02 L/day. No significant change over time was observed in plasma 
TNFa levels during CA VH-D. Mass transfer of TNFa from blood was greater than 
that appearing in the UF suggesting membrane adsorption. Clearance from blood (Kb) 
of TNFa differed significantly with filter duration (17.7 ± 4.6 [I-2h]; 3.0 ± 3.8 [4-
6h]; -30.6 ± 11.8 mLimin; p < 0.05). Significant amounts of IL-6 were detected in 
all 60 UF specimens (304 ± 28.6 pg/mL). The mean sieving coefficient of IL-6 was 
0.26 ± 0.04. Mean K", was 3.4 ± 2.2 Llday. Plasma IL-6 levels decreased over time 
(796 ± 163.2 [pre] to 548 ± 82.2 [24h] pglmL; p < 0.05). Kb ofIL-6 with filters used 
for for'; 6 h was significant (5.3 ± 3.4 [I-2h]; 2.6 ± 2.68 [4-6h] mLlmin), but 
became negative over time (-4.7 ± 4.4 [20-24h] mLlmin). Mass transfer of IL-6 from 
blood did not differ from that appearing in the UF for any given filter duration. 
COIlc/usions: Cytokines can be removed from the circulation with CRRT, either by 
their adsorption or by their removal via the UFo Differing sieving properties of TNFa 
in vitro and in vivo may be explained by the fact that this cytokine exists in the 
circulation as a trimer or that circulating TNFa is rapidly bound to soluble TNF 
receptors. Prolonged blood-membrane interaction seemingly affects adversely 
cytokine clearances, possibly by desorption and/or by increased generation. If 
removal of cytokines is of primary concern, high UF volumes and frequent filter 
change are needed to extract significant amounts of cytokines from the circulation, 
144 
Cylokine kinetics dllril1g continuous hemofillraliol1 
Introduction 
The development of acute renal failure (ARF) in intensive care unit (ICU) 
patientsj usually as part of multiple organ systems failure (MOSF), carries a poor 
prognosis [1,2]. Although continuous hemo(dia)filtration is now increasingly accepted 
as the preferred treatment modality for the critically ill patient with ARF, it is not 
clear whether its use has an impact on outcome of these patients [2]. 
Both experimental [3,4] and uncontrolled clinical data [2,5,6] suggest that CHF 
may improve hemodynamics and gas exchange in patients with septic shock and 
(non-renal) MOSF, independent of an impact on fluid balance. These beneficial 
effects are ascribed to the removal from the circulation of middle- and large 
molecular weigth (>500 Dalton [Da]) inflammatory mediators, particularly cytokines, 
responsible for the cardiorespiratory and metabolic alterations leading to MOSF [7-9]. 
Indeed, (persistently) elevated levels of TNFex and IL-6 have been associated with 
progressive inflammatory illness and poor outcome in both septic and non-septic 
shock [7,8]. However, few and controversial data exist concerning the removal of 
cytokines from the circulation with continuous renal replacement therapy (CRRT) 
[10,11]. 
The aim of the present study was to investigate whether cytokines are removed 
from the circulation with CRRT both under in vitro conditions and in vivo, i.e., in 
patients with ARF suffering from the 'systemic inflammatory response syndrome' 
(SIRS)[12]. In addition, it was investigated whether these cytokines were sieved 
through or adsorbed to the hemofiltration membrane. 
Material and methods 
III vitro 
Continuous hemofiltration was conducted in vitro using an experimental set-upj 
consisting of a 'blood' reservoir containing Ringers lactate with human albumin (15 
gIL), a synthetic hemofilter with standard arterial, venous and ultrafiltrate tubings, 
and roller pumps (Rhone Phoulenc, France) to regulate blood and ultrafiltrate rates. 
The venous outflow and uitrafiltrate were returned to the blood reservoirj thus 
minimizing changes in blood volume during the experiment. Polyacrilonitrile (AN 
69-HF, Hospal Ltd, France [O.60m2]), polyamide (PAM)(FH66-D, Gambro BV, 
Sweden [0.60 m2]) and polysulphone (PS)(BL-624, Sorin biomedica, Germany [1.0 
m2]) hollow-fibre hemofilters were used. In consecutive experiments using a single 
mediator. recombinant human tumor necrosis factor-a (TNFa, 16,5 kDa) and 
interleukin-IB (IL-IB, 16,5 kDa), respectively, were added to the blood reservoir and 
allowed to equilibrate for 15 min. The pumps were calibrated to deliver a blood flow 
(Qb) of 150 mLimin and an ultrafiltrate flow (Q,,) of 30 mLimin. During initial 
experiments, samples (2 mL) were taken from the arterial, venous and ultrafiltrate 
line at t = 15, t = 60j and t = 120 min. At t = 0 min and t = 150 min, samples were 
taken from the reservoir. Because these results suggested that the sieving properties 
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of cytokines were masked by their initial adsorption and that the binding capacity of 
the AN69 membrane was not saturated for TNFa, we subsequently performed 
continuous hemofiltration with the AN69 membrane during a 24~hrs period, again 
using a single mediator (TNFa, IL-lfl, and IL·6 [22,0 kDa], respectively) in each 
experiment. Samples were taken immediately prior to and at 5, 10, 15, 30, 60, 120, 
240, 360, 480, 720 and 1440 min, respectively, after the start of continuous 
hemofiltration. The amount of cytokine left unbound was calculated from the 'blood' 
volume (corrected for sample collection) and final cytokine concentration. The 
amount of cytokine bound is equal to the amount added initially minus the amount 
remaining unbound. Samples were drawn in ethylenediamine (EDT A) tubes and 
immediately stored at -70°C until assays were performed. 
ill vivo 
Patients 
Twenty critically ill patients with ARF who were treated by continuous arteriovenous 
hemodiafiltration (CA VH-D) in a single surgical ICU were included in a prospective 
study during the period August I, 1992 - January 31, 1994. All patients suffered 
from SIRS, as manifested by 2 or more of the following conditions: temperature> 
38°C or < 36°C; heart rate> 90 beats/min; respiratory rate> 20 breaths/min or Pa02 
< 4.3 kPa « 32 torr); WBC >1 2,000 cells/mm', < 4000 cells/mm', or > 10% 
immature (band)forms [12]. All patients required mechanical ventilation and inotropic 
support prior to the institution of CAVH·D. The following information was obtained: 
age, gender, underlying disease(s) and surgical procedures performed, presence of 
systemic infection, severity of illness as calculated from the Acute Physiology and 
Chronic Health Evaluation (APACHE II) score [13] and the number of failed organ 
systems [12,13], outcome and calise of death. Cardiorespiratory and acid~base 
variables were monitored prior to the start of CAVH~D and 1, 4, and 24 h, 
respectively, after the stati of treatment. 
Continuous arteriovenous hemodiajiltratioll 
CA VH·D was performed using a hollow-fibre polyacrilonitrile hemofilter (AN 69-
HF) connected to the arterial and venous vascular access devices in a pumpless 
circuit. Vascular access was by means of large~bore femoral catheters (Medcomp, 
Harleysville, USA)(n ~ 17) or by means of a scribner shunt (Quinton, USA; n ~ 3). 
Warmed bicarbonate-buffered dialysis fluid (SH 44·HEP, Schiwa GmbH, Glandorf, 
Gerrnany) was pumped counter~current to blood through the ultrafiltrate compartment 
of the filter at a rate of I Ln, with a calibrated, volumetric pump (3M, A VI inc., St 
Paul, USA). Lactate~based replacement fluid was given as clinically indicated, 
administered into the arterial limb of the extracorporeal circuit. The extracorporeai 
circuit was anticoagulated with heparin (500·700 UIh) unless there was severe 
coagulopathy 01' thrombocytopenia « 60 . 10'1L). The filters were changed when 
there was objective evidence of inadequate filter function (i.e., a sustained reduction 
in ultrafiltrate volume [< 300 mLn,] or evidence of filter clotting. Net ultrafiltration 
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rate at each time point was measured from timed volumetric collections (Qur 
[mLlmin]). 
Sample collection 
Both blood and ultrafiltrate levels of the cytokines TNFa, IL- In, and IL-6 were 
measured in these patients (11 = 20). Blood samples were taken from a port on the 
arterial tubing prior to the infusion of predilution fluid and, as such, represent the 
patient's systemic levels. Simultaneously, samples were drawn from the ultrafiltrate 
port. To assess cytokine sieving properties (i.e., no dilutioll of ultrafiltrate by dialysis 
fluid), the dialysate line was clamped and dialysate pump stopped 15 min prior to 
collection so as to obtain 'pure' ultrafiltrate, i.e., convective solute transfer occurs 
only (CA VH). To assess cytokine mass transfer across the membrane, clearances of 
cytokines from blood and the impact of prolonged blood-membrane interaction on 
these characteristics, blood samples were also taken from a port immediately 
postfilter in 10 of these patients. To calculate the blood flow pre- (Qbm) and postfilter 
(Qb"J, hematocrit (Hct) levels were measured simultaneously at the filter inlet and 
outIet (Hct""Hct"J in these patients (n ~ 10). For each patient, samples were taken 
immediately prior to and I, 4 and 24 h, respectively, after the initiation of CA VH-D. 
Postfilter values were corrected for hemoconcentration as a result of ultrafiltration. 
The 'age' of the filter was recorded at each sampling time point because filter 
replacement was required within 24 h in some patients as a result of filter clotting. 
Samples were placed in EDT A tubes and held on ice until centrifugation. The plasma 
was removed and stored at -70°C until assays were performed. Ultrafiltrate samples 
were drawn in EDTA tubes and held on ice until storage at -70°C. 
Calcllialions lUJ: 
Blood flow: 
Qbin = Qur . Hcteul(Hctou' - Hctin), mllmin 
Qbeu! = Qbin - Qu() 11111min 
Sieving coefficient: 
S = 2 . Cu/Cin + Cpu! 
Clearance (filtrate): 
Kur = Cur' Qui Cin, 11111111ill 
Clearance (blood): 
K. ~([Qb" . C"l - [Qb,,, . C"J)/C,", 1II1/lIIin 
Mass transfer (J) across the membrane from blood: 
J, ~ (Qbm • C,,) - (Qb,,, . C"J, pg/min 
Mass transfer into ultrafiltrate: 
Juf = Qur . Cur, pg/min 
Mass balance: 
Jbin - Jbou ! = Juf 
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TNF a concentration (%) 
lW~------------------------------1 
AN69HF Potyamlde Polysu~one 
Fig 1: TNFa elimination (monomeric form; 16,5 kDa) during in vitro hemo/iltratiolJ (HF) over 150 
min wifh 3 different membranes. Bolh the ul(ra/iltrate and wnolls outflow were retllrned to the 'blood' 
reservoir; there/ore, mass lost fi'OlJl 'blood' could only be due to adsorption. Results are 8.\pl'essed as 
percent 0/ total TNFa measured in the blood reservoir be/ore the start o/recirculation. Only the AN69 
membrane exhibited appreciable adsorption. 
Sieving coefficient 
0.1 
0.08 
AN69HF Polyamide Polysulfone 
Fig 2: Sieving coefficient 0/ TNFa (16,5 kDa) during in vitro HF wifh 3 di//erent membranes at 15 
min (black bars), 60 min (hatched bars), and 120 min (dotted bars), respecti\'ely. No appreciable 
sievillg 0/ TNFa was absen'ed during the /irst 60 min 0/ HF; thereafter, sieving properties 0/ the 
AN69 membrane increased with the sieving coefficient o/TNFa approaching 0,/ (10%). 
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Assay procedures 
Blood and ultrafiltrate concentration of cytokines were measured by commercially 
available enzyme-linked immunosorbent assays (ELISA) and performed according to 
the manufacturers instructions. TNFct concentrations were measured with a one-step 
"sandwich" type inununoassay (Immunotech S.A'J Marseille, France). The lower 
detection limit of TNFa was 7.8 pg/mL. The coefficient of variation was less than 
10% in the range of 115-1000 pg/mL. No cross reactivity appears with TNF3, IL-Ill, 
IL-2, IL-6, or the p55 and p75 forms of the TNF receptor. IL-Ill concentrations were 
measured using a two-step immuno~assay (Immunotech S.A., Marseille, France). 
Analytical sensitivity of the assay was 5 pg/mL. Coefficient of variation was less than 
8% in the range of 50-1000 pg/mL. No cross reactivity occurs with IL-a, IL-6, or 
TNFo:. IL-6 concentrations were measured with a tluee-step inununo-assay, lIsing the 
human (hu) IL-6 ELISA compact kit (C.L.B., Amsterdam, The Netherlands). 
Analytical sensitivity of the assay was 5 pg/mL. Coefficient of variation was less than 
10% in the range of6.5 - 400 pg/mL. No cross reactivity occurs with either IL-Ill or 
TNFct. Samples were assayed in duplicate and all cytokine levels assayed in the same 
run. Cytokine concentrations, where necessary, were corrected for dilution. The mean 
of the duplicate measurements is reported at each time period. 
Statistical allalysis 
Data are expressed as mean ± standard error of the mean (SEM) or percentage, where 
appropriate. The Wilcoxon signed-rank test was used to analyse non-parametric data. 
Repeated measures ANOV A test was used to analyse normally distributed data. 
Statistical significance was accepted at a p < 0.05 level. 
Results 
III vitro 
Different membranes 
Significants amounts of TNFa (3.5 fLg) disappeared from the blood compartment 
with the AN69 membrane (Fig I) with only minimal amounts detectable in the 
uitrafiltrate. The only plausible explanation for the observed mass balance error in the 
closed-loop recirculation model is that TNFa is bound to the membrane. No 
appreciable adsorption of TNFa was noted for the polysulfone (0.15 fLg) and 
polyamide (0.3 ~g) membrane (Fig I), steady-state blood levels occurring after 15 
min. There was no appreciable sieving of TNFo: during these shorHerm 
hemofiltration experiments (Fig 2). However, sieving properties of TNFo: with the 
AN69 membrane seemed to increase over time with a concomittant increase of 
convective clearance (K,f 0 mLimin [15 min]; 0.8 mLimin [60 min]; 2.9 mLimin 
[120 min]). Only minimal convective clearance occurred with the 2 other membranes 
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(K", [PS] 0.96 mLimin; [PAM] 0.24 mLimin at 120 min). The adsorption capacity of 
all 3 membranes for IL-lll was less compared to that seen for TNFu (AN 69 1.0 Ilg; 
PAM 0.03 Ilg; PS 0.06 Ilg). However, significant sieving of IL-lll was seen with all 
3 membranes, again with increasing sieving properties over time with the AN69 
membrane (S [AN69J 0.96; [PSJ 0.67; [PAMJ 0.62 at 120 min). This resulted in 
significant convective clearances of IL-lll (K" [AN 69J 28.8 mLimin; [PSJ 20.1 
mLimin; [PAM] 16.5 mLimin at 120 min) with all 3 membranes. 
Twenty-jollr hours hemofiltration with the AN69 membrane 
During the 24-hrs hemofiltration experiments with the AN69 membrane, the 
adsorption capacity of the membrane became saturated for all 3 cytokines, as 
indicated by steady-state arterial (i.e., prefilter) cytokine levels (Fig 3). Calculated 
adsorption capacity of the membrane for TNFu was 4.5 f'g, IL-lll 1.6 Ilg, and for 
IL-6 1.9 Ilg. Sieving capacities of the different cytokines were masked by their initial 
adsorption. \Vhen the binding capacity of the membrane became saturated, the sieving 
coefficient of all cytokines increased significantly (TNFu 0.0 I ± 0.003 to 1.0 ± 0.0 I; 
IL-lll 0.12 ± 0.01 to 1.0 ± 0.14; IL-6 0.01 ± 0.004 to 0.32 ± 0.031; P < 0.05 [n ~ 
3]). 
100 
c IL-1tl 0 
'p g 
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0 50 IL-6 c 8 
.1Y 
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0 120 1440 
Time (min) 
Fig 3: Arterial (i.e., prefilter) cytokine levels (FNFa, IL-Ift, /L·6j over time during continuous 
hemojiltratioll. Both the ul/raftllrate alld venous outflow were refumed to the 'blood' reservoir; 
therefore, mass lost from 'blood' could only be due to adsorption. A single mediator was added ill 
each e;'(periment. Results are e.tpressed as percen! of total cytokine measured in the 'blood' before the 
start of recirculatiol/. For the purpose of clarity, steady-state cylokine mllles between 240 and 1440 
min are 1101 shown. 
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III vivo 
Patients 
Mean age of the patients was 54 ± 3,8 yrs (range 17-83 yrs) with a male 
predominance (75%), The mean pretreatment APACHE II score was 27 ± 0,7 (range 
19-34) and the mean number of OSFs was 3,3 ± 0,3 (range 1-6), MAP upon 
initiation of CA VH-D was 73 ± 1.8 mm Hg (range 55-86 mm Hg), Eight patients 
(40%) survived to leave the ICU, of whom 7 (35%) survived to leave hospital. Nine 
patients (69%) died in refractory septic shock complicated by MOSF, 3 patients 
(23%) died from irreversible MOSF following multitrauma, and I patient (8%) died 
from myocardial infarction, All patients had detectable TNFa and IL-6 plasma levels, 
The plasma TNFa levels in non~survivors were higher than in survivors (Fig 4a). No 
difference in plasma IL~6 levels was observed between survivors and non~survivors 
(Fig 4b), None of the patients had detectable IL-13 plasma levels, Hemodynamic, gas 
exchange, and acid-base variables prior to and during 24 h of CA VH~D treatment are 
shown in Table 1. There was a non-significant trend to improved hemodynamics and 
gas exchange after 4 h of treatment, which could at least in part be explained by fluid 
removal. In addition, a significant increase in serum bicarbonate levels was observed 
after 24 h of treatment. 
500 TNV.-.(wlnl) 2500 Il6(~') 
400 2000 
300 1500 
200 1000 
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Fig 4 a,b: Individual plasma TNFa (a) and IL-6 (b) cOllcentrations in surviving (S) and non-surviving 
(NS) patienls. TNFOI. levels were higher in non-sllrviving patients (p < 0.05). 
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Table 1. Cardiorespiratory And Acid-Base Variables Prior To And During CAVH-D 
Treatment 
Time (h) 
Variable 
Pre 4 24 
MAP (mmHg) 73 ± 1.8 76 ± 2.0 84 ± 2.1 78 ± 1.8 
CO (Umin) 5.8 ± 0.5 6.1 ± 0.4 6.5 ± 0.4 6.0 ± 0.3 
HR (beats/min) 108 ± 2.3 106 ± 2.1 101 ± 1.8 104 ± 1.7 
SVR (dynes.sec.cm-s) 724 ± 82.1 732 ± 61.2 884± 121.1 801 ± 112.3 
MPAP (mmHg) 27 ± 2.5 29 ± 2.1 26 ± 2.0 28 ± 0.4 
PCWP (mmHg) 15 ± 1.1 13 ± 0.8 15 ± 1.1 14 ± 0.8 
PaO/Fi02-ratio 2.3 ± 0.3 2.4 ± 0.4 2.6 ± 0.3 2.6 ± 0.4 
pH 7.36 ± 0.3 7.38 ± 0.3 7.40 ± 0.4 7.39 ± 0.3 
Bicarbonate (mmol/L) 16.2 ± 0.7 17.4 ± 1.6 17.5 ± 0.9 18.9 ± 0.4' 
Abbreviations: MAP, mean arterial pressure; CO, cardiac output; HR, he-rut rate; SVR, systemic 
vascular resistance; MPAP, mean pulmonary arterial pressure; PCWP, pulmonary capillary wedge 
pressure. All patients required artificial ventilation and inotropic support (n=20). Daily ultrafiltrate 
volume 12.6 ± 0.42 Uday; Net ultrafiltration was 3.2 ± 0.1 Uday. Net 24 hours fluid balance was 
plus 1208 ± 564 mL. Results are expressed as mean ± SEM. ': p < 0.05 vs pretreatment value. 
Table 2. Ultrafiltra(e Clearances of Cytokines During CAVH-D 
Variable TNFa IL-6 
Plasma concentration (pg/ml) 153 ± 7.3 (26-475) 796 ± 163.2 (265-2097) 
Ultrafiltrate 8.9 ± 0.8 (2.1-48) 304 ± 128.6 (34-1294) 
concentration (pg/ml) (/I ~ 17 [28%]) (/I ~ 60 [100%]) 
Daily UF Clearance (Uday) 0.1 ± 0.02 3.9 ± 1.8 
Daily mass transfer UF (pg/day) 0.03 ± 0.01 3.4 ± 0.3 
Abbreviations: CAVH-D, continuous arteriovenous hemo(dia)filtration; UF, ultra filtrate. Mean UF 
volume during CAVH·D was 12.6 Uday (range 7.8-14.8 Uday); mean blood flow through the filter 
was 92 ± 3.8 mUm in. Data expressed as mean ± SEM (/I = 20). 
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Ultrajiltrate clearances (Table 2) 
Mean ultrafiltrate volume during CAVH-D was 12,6 Llday (range 7.8-14.8 Llday). 
Mean blood flow through the filter was 92 ± 3.8 mLimin. Overall, the mean plasma 
TNFa level upon initiation of CAVH-D was 153 ± 7.3 pg/mL. TNFa could be 
detected in only 17 of 60 (28%) ultrafiltrate specimens, resulting in only minimal 
daily mass transfer of TNFa into the ultrafiltrate (Table 2). Mean daily ultrafiltrate 
clearance of TNFa was 0.1 ± 0.02 Llday. No significant change in the plasma TNFa 
level was observed over time following the initiation of CA VH-D (pretreatment 
TNFa 153 ± 7.3 I'S 24h TNFa 170 ± 41.7 pg/mL; NS). The mean IL-6 concentration 
upon initiation of CAVH-D was 795 ± 163.2 pglmL. Significant amounts of IL-6 
were detected in all 60 ultrafiltrate specimens with significant daily mass transfer of 
IL-6 into the ultrafiltrate (Table 2). Mean daily ultrafiltrate clearance was 3.9 ± 1.8 
L/day. There was a significant decrease of plasma IL-6 level over time following the 
initiation of CAVH-D (pretreatment IL-6 level 796 ± 163.2 I'S 24h 548 ± 82.2 
pg/mL; p < 0.05). 
Filter duration 
No differences were found between the mean sieving coefficient of TNFa., when 
correlated to the age of the filter (SC 0.02 ± 0.01 [1-2h], 0.01 ± 0.01 [4-6h], 0.02 ± 
0.01 [20-24h]; NS). Postfilter TNFa levels, corrected for hemoconcentration, were 
significantly lower with filters used for 1-2h (prefilter TNFa 152 ± 43.2 l'S postfilter 
TNFa 126 ± 36.7 pg/mL; p < 0.05). No difference between pre- and postfilter levels 
of TN Fa were observed with filters used for 4-6h (178 ± 47.8 1''' 184 ± 51.2 pg/mL; 
NS). Significant clearance of TNFa from blood occurred with filters used for'; 6 h 
(Fig Sa). Mass transfer of TNFa from blood with filter duration'; 6 h was greater 
than that appearing in the ultrafiltrate (Jb 2.7 ± 0.8 vs J" 0.03 ± 0.01 nglmin [1-2h]; 
Jb 0.5 ± 0.7 I'S J" 0.02 ± 0.01 ng/min [4-6h]; p < 0.001), suggesting that membrane 
adsorption occurs. However, with prolonged filter use, postfiiter values were 
significantly higher than prefilter values (prefilter TNFa 159 ± 22.1 vs postfilter 
TNFa 233 ± 58.6 pg/mL [20-24h]; 1'<0.05). Negative mass balance (-4.3 ± 1.6 
ng/min) and blood clearance of TNFa with filters used for <: 20 h (Fig Sa), suggest 
that either desorption of increased generation of TNFa. occurs. No differences in the 
mean sieving coefficient of IL-6 were found, when correlated to filter duration (S 
0.28 ± 0.06 [1-2h], 0.30 ± 0.08 [4-6h], 0.24 ± 0.02 [20-24h]; NS). Postfilter levels of 
IL-6, corrected for hemoconcentration, were lower with filters used for l-2h (prefilter 
IL-6 level 733 ± 160 vs 628 ± 100 pg/mL; p < 0.05). Pre- and postfilter levels of IL-
6 did not differ significantly with filters used for <: 4 h (699 ± 114 l'S 692 ± 153 
pg/mL [4-6h], and 665 ± 89 vs 735 ± 106 pg/mL [20-24h]; NS). Significant blood 
clearance of IL-6 occurred with filters used for ::; 6 h, but became negative with 
prolonged filter use (Fig 5b). Mass transfer of IL-6 from blood did not differ 
significantly from that appearing in the ultrafiltrate for any given filter duration. 
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Fig 5 a,b: Clearance of TNFa (a) and IL-6 (b) from blood (KJ and u//raji//ra/e (K"), correlated to 
jilter duration, during continuolls hemojiltration wilh the AN69 membrane. KI; of TNFa and IL-6 
declined following prolonged jilter use alld became negatil'e over time. No appreciable ultrafiltration 
ofTNFa (Kvj < 0.2 mUmin) occ/lrred. ',' fJ < 0.05 \IS 1-211. 
Discussion 
The present study demonstrates that circulating cytokines can be removed during 
continuous hemofiltration. During the first period of in vitro hemofiltration, 
significant amounts of TNFa disappeared from the blood compartment with only 
minimal amounts detectable in the uitrafiltrate. The only plausible explanation for the 
observed Illass balance error in the closed-loop recirculation model is that TNFa is 
bound to the membrane. Results also suggested that the sieving property of the 
monomeric form of TNFa was masked by the large capacity of the AN69 membrane 
to bind TNFa. When the membrane was saturated, mass transfer of TNFa into the 
ultrafiItrate was maximal (i.e., the se of TNFo: was 1.0). These findings are in 
accordance with those of Leypoldt el al., who found that initial sieving of model 
macromolecules (i.e., polydisperse DEAE dextran) during hemofiltration were 
masked by their rapid adsorption to the AN69 mcmbrane [i5]. We also noted 
significant adsorption of this cytokine to the AN69 membrane ill vivo. However, the 
sieving capacity of TNFa in vivo was low, irrespective of filter duration. Other 
investigators also detected no [10,16] or only small amounts of TNFa [17,18] in 
ultradiafiltrate samples during CHF. One explanation for the low sieving capacity of 
TNFa in vivo may be that it exists in its bioactive form as a trimer (52 kDa) [19]. 
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thereby exceeding the molecular cut~off point of the membrane. Another explanation 
may be that TNFa is rapidly bound to the soluble TNF receptor (sTNFR)[20]. When 
plasma levels of TNFa are less than 500 pg/ml, there is a positive correlation 
between sTNFR and TNFa levels. However, when plasma levels of TNFa exceed 
500 pg/ml, levels of sTNFR may not rise proportionally [20]. With very high TNFa 
levels, therefore, it may be that a greater proportion of TNFa circulates unbound, 
thus being potentionally removed via the ultrafiltrate. This might also explain the 
difference in sieving characteristics of TNFa between this and other studies (serum 
TNFa levels varying from 60-153 pg/ml), in which little or no sieving of TNFa was 
observed [10,16,18), and the study of Bellomo el al. (mean serum TNFa level 765 
pg/ml), in which significant amounts of TNFa were detected in 69.5% of 
ultradiafiltrate samples during continuous venovenous hemodiafiltration (CVVHD) in 
septic patients [11]. In the present study, significant removal of IL-6 via the 
ultrafiltrate was demonstrated in all patients. In addition, senun IL~6 levels decreased 
over time during CA VH~D. Gueugniaud el al. also detected significant amounts of 
IL~6 in ultradiafiltrate samples of 4 severely burned patients and decreasing serum 
levels of this cytokine during CVVHD [16]. Our in vitro data suggest that significant 
removal of IL-Ill via the ultrafiltrate can be expected. Although we could not 
confirm our in vitro data because of lack of elevated serum IL-Ill levels in our 
patientsJ others have noted significant amounts of this cytokille in the ultradiafiItrate 
of septic patients [11]. However, because of its transient appearance [7,8], significant 
IL-Ill clearance will probably occur only when hemofiltration is instituted during the 
early phase of (non-)septic shock. 
The binding capacity of the AN69 membrane for IL-Ill and IL-6 was significantly 
less compared to that for TNFa. In addition to these cytokine-dependent differences, 
our in vitro data suggest that synthetic membranes differ in adsorption capacity. This 
might explain why Byrick el al. did not find removal of TNFa from the circulation 
during CA VH~D without ultrafiltration with the polysulfone membrane, irrespective 
of filter duration, in a patient with rhabdomyolysis [10). The affinity of synthetic 
membranes for cytokines may reside in their hydrofobic surfaces [21]. One important 
factor explaining the comparatively high adsorption capacity of the AN69 membrane 
may be its electrical charge. For example, the anaphylatoxins C3a (9,0 kDa) and C5a 
(11,2 kDa) have shown to display high affinity for the AN69 membrane, presumably 
because of electrostatic interactions [21). 
Adsorption of cytokines as well as other proinflammatory peptides may be 
beneficial because of their removal from. the circulation. Conversely. however, a high 
concentration of these proteins locally on the membrane surface may elicit an 
inflammatory response by stimulating adherent neutrophils and monocytes. \Ve and 
others [18] observed higher post filter TNFa values, corrected for hemoconcentration, 
following prolonged filter use. An increase in IL-l J3 levels, although not corrected for 
hemoconcentration, was also observed after 4 h of CVVHD treatment in septic 
patients [II]. In addition, Kaplan el al. observed significantly higher post filter values 
of another important proinflanunatory peptideJ i.e. C5a, corrected for 
hemoconcentration, during CA VH in ARF patients [22). These results may be 
explained either by desorption of these peptides from the membrane [15] or by 
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increased generation. Recent data indicate that blood-membrane interaction in cluonic 
hemodialysis patients does not directly lead to increased cytokine production, but 
results in priming of mononuclear cells for enhanced release of cytokines following 
secondary stimulation, e.g. LPS-fragments from contaminated dialysate [23). 
Therefore, it is possible that the immunologic response to (prolonged) blood-
membrane interaction during continuous hemofiltration in critically ill patients 
suffering from sepsis or SIRS is significantly different compared to that resulting 
from shorHerm blood-membrane interaction in uremic but otherwise healthy patients. 
However, despite this potentially adverse effect of prolonged blood-membrane 
interaction in critically ill patients, it does not seem to have any clinical significance. 
On the contrary, (improved) hemodynamic stability (Table I) is uniformly found 
during continuous hemofiltration [1,2]. It may be that the positive effect of an 
unselective removal of both identified (e.g., cytokines, anaphylatoxins) and as-yet-to-
be-identified vasoactive mediators from the circulation outweighs the possible 
negative effect of prolonged blood-membrane interaction during continuous 
hemofiltration. This would also explain the correlation between the ultrafiltrate 
volume and hemodynamic changes, recovery time of diuresis and survival, which has 
been found by some investigators in animal and retrospective, clinical studies 
[1,2,24). 
In conclusion, the present study suggest that cytokines can be removed from the 
circulation with continuous hemofiltration, either by their adsorption to the membrane 
(i.e., TNFa) or by their convective removal (i.e., IL-lfi and IL-6, unbound TNFa ?) 
into the uitrafiltrate. In addition to these cytokine-dependent differences, synthetic 
membranes seem to differ in adsorption and sieving capacities, which may be of 
clinical relevance. However, prolonged blood-membrane interaction seemingly affects 
adversely cytokine clearances, possibly by desorption and/or increased generation. If 
removal of cytokines is of primary concern, high ultrafiltrate volumes and frequent 
change of filters are needed to extract sign.ificant amounts of cytokines from the 
circulation. However, further research is warranted to establish whether this will have 
an impact on the outcome of human septic and non-septic shock. Untill such studies 
are performed, the rational for the use of CRRT in critically ill patients in the 
absence of conventional indications for dialytic support remains unproven. 
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Summary and conclusions 
Over the last decade, significant advances have been made in the techniques 
available for the treatment of acute renal failure (ARF) in critically ill patients on the 
intensive care unit (ICU). First introduced by Kramer el al. [1] as continuous 
arteriovenous hemofiltration (CA VH), there are now various forms of continuous 
renal replacement therapy (CRRT) which are touted as having major advantages 
relative to conventional dialysis treatment (i.e., intermittent hemodialysis, peritoneal 
dialysis) [2]. However, while abundant (and often confusing) data is available upon 
the efficacy of CRRT, comparative data is scanty. This has led to considerable 
controversy as to which specific form of dialytic support should be preferred in this 
group of patients [3,4]. This thesis contains a series of studies examining the efficacy 
of CRRT as renal support for critically ill patients and its proposed superiority over 
intermittent hemodialysis (lHD). In addition, it was studied by which mechanisms 
CRRT, as opposed to IHD, could have an beneficial influence on the clinical course 
in these patients. 
Chapter I gives relevant background information on the incidence and outcome of 
ARF, different dialytic treatment modalities and on severity~of-illness scoring 
systems, which use is of great il1lp0l1ance in risk-stratification and in comparing 
outcome data. In addition, inflammatory mediators thought to play an important role 
in the development of the 'systemic inflammatory response syndrome' (SIRS) and 
ARF are discussed. 
In chapter II a comprehensive review is given of the various continuous renal 
replacement techniques and an attempt is made to clarify the possible beneficial role 
of CRRT in reducing patient morbidity and m011ality. Available data suggest distinct 
advantages of CRRT relative to conventional dialysis treatment but no clear survival 
advantage of patients treated with CRRT has yet been shown. In addition, no data 
clearly illustrate the superiority of one specific form. of CRRT over the other forms. 
All, except CA VH, are effective in controlling biochemistry and fluid balance in 
hemodynamically unstable patients. Pump~driven forms have the advantages of 
obviating the need for arterial cannulation and its inherent complications and by 
providing high ultrafiltrate volUlues (i.e., a high convective blood purification rate) 
which may be of particular value. However, no survival advantage of patients treated 
with pump~driven forms has yet been shown. 
Chapter III describes the use of the 'Acute Physiology And Chronic Health 
Evaluation' (APACHE) II scoring system on the day of ICU admission and on the 
day dialytic support was initiated. Using logistic regression analysis, use of the 
APACHE II system at the time of initiation of dialytic support (APACHE II,), as 
opposed to the use of APACHE" at the time of ICU admission (APACHE "\), 
proved to be a valid way to risk-stratify ARF patients by the severity of their illness 
and to compare outcome data. Estimating the risk of death with the APACHE II 
equation did not improve the use fullness of this system. However, reliability of this 
index of severity~of~disease was improved significantly by using the ratio between the 
APACHE II, and APACHE 11\ score. The higher the ratio, i.e., the greater the change 
in APACHE II score, the lower was the chance of survivaL This suggests that 
ultimate outcome is related to the degree of reversibility of physiologic derangements 
that led to the development of ARF. Using multivariate analysis, no impact of age, 
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diagnostic category, time from ICU admission to start of dialytic support, or specific 
form of dialytic support was observed. 
In chapter IV the efficacy of the continuous treatment modality as employed in 
our hospital, i.e., continuous arteriovenous hemodiafiltration (CA VHD), was 
examined. In addition, a detailed description of the patient population was provided, 
including APACHE II scoring and factors (other than uremia pel' se) influencing 
survival, to allow a meaningfull comparison with other reports. It was shown that the 
majority of patients required mechanical ventilation and/or inotropic support and 
suffered from multiple organ systems failure (MOSF). In this group of 
hemodynamically unstable patients, CA VHD proved efficient in controlling fluid 
balance and azotemia and in correcting acid~base and electrolyte disturbances. Despite 
the fact that most patients were severely ill (mean APACHE II score 26.5) and 
suffered from MOSF, 26 patients (43%) survived until discharge from the ICU, of 
whom 23 (38%) survived to leave hospital. These results compared favourably to 
other reports in the literature. The need for mechanical ventilation and the presence 
of sepsis were both associated with a poor prognosis. Another important finding was 
the inverse correlation of prognosis with the number of (additional) organ system 
failures. 
In chaptcl' V a direct comparison of CA VHD and IHD was made in ARF patients 
treated in the same ICU. A detailed description of the patient population, including 
the APACHE II score and relevant biochemical and hematological data, was 
provided. Although patients treated continuously were more severely ill as compared 
to patients treated with alternate-day IHD, CA VHD proved superior in controlling 
biochemistry and fluid balance. There was no difference in the incidence of 
hemorrhagic complications between groups} despite continuous anticoagulation in 
CA VHD treated patients. Severe hypotension and cardiac arytlunias were frequent 
complications during IHD, which was not observed in patients treated with CA VHD. 
In addition, CA VHD was associated with increased nutritional intake and a shorter 
duration of oliguria. This latter is possibly related to the observed differences in 
hemodynamic stability between groups in favor of CA VHD treated patients. Despite 
greater illness severity in those treated with CA VHD, no significant difference in 
ICU outcome was observed bet\veen groups. 
Chapter VI describes the results of a controlled animal study, in which 
ultrafiltrate, obtained (under sterile conditions) during hemofiItration of endotoxemic 
pigs, was infused into healthy pigs and their hemodynamics compared with those of 
pigs who were infused with ultrafiltrate from normal pigs. It was shown that infusion 
of ultrafiltrate from endotoxemic pigs, in contrast to ultrafiltl'ate from normal pigs, 
into healthy pigs induced pulmonary hypertension and decreased cardiac performance, 
suggesting that ultrafiltrate of endotoxemic pigs contains soluble, filtrable factors that 
are responsible for these deleterious effects. This study supports the hypothesis that 
convective blood purification pel' se is at least in part responsible for the observed 
beneficial hemodynamic effects of CRRT in some patients with MOSF. 
Chapter VII describes the results of a study in which the impact of hemofiltration 
membranes on the kinetics of some key mediators of SIRS (i.e., TNFu, IL-lll, IL-6) 
was investigated during both in vitro and ill vivo CRRT, with emphasis on the 
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possibJe mechanisms involved in mediator clearance and the effects hereon of 
prolonged filter use. Although significant sieving of the monomeric form of INFa 
(16,5 kDa) was observed in vitro with the AN69 membrane, no appreciable sieving 
occurred in vivo with this membrane. This may be explained either by the fact that 
TNFa circulates in its bio-active form as a trimer (52 kDa) or that circulating TNFa 
is rapidly bound to soluble TNF receptors, in both ways thereby exceeding the 
molecular cut-off point of the membrane. However, significant adsorption of TNFa 
onto the membrane surface was noted. In contrast to INFa and despite its higher 
molecular weight (22 kDa), appreciable ultrafiltrate clearance of IL-6 was observed 
during both in vitro and in vivo CRRT with the AN69 membrane. Significant 
ultraftltrate clearance of IL-lJ3 occurred with different synthetic membranes during in 
vitro CRRT. However, IL-lJ3 was not detectable in any patient, thereby precluding 
calculation of in vivo clearance rates of this cytokine. Of importance, prolonged 
blood-membrane interaction seemingly affected adversely cytokine clearances, 
possibly by desorption or increased generation. Results suggested that if removal of 
cytokines is of primary concern, high ultrafiltrate volumes and frequent change of 
filters are needed to extract significant amounts of cytokines from the circulation. In 
addition, synthetic membranes seem to differ in adsorption and sieving capacities, 
which may be of clinical relevance. 
From these studies it can be concluded that final proof that CRRT improves 
outcome in ARF on the ICU has still to be provided. It may be that renal failure as 
such does not contribute sufficiently important to death in MOSF for there to be a 
demonstrable difference in outcome between patients treated with CRRT and 
conventional dialysis treatment. However, ease of implementation, the facility of full 
nutritional support, superior metabolic control, improved hemodynamic stability and 
perhaps a shorter duration of oliguria afforded by CRRT, would appear to justify its 
use as the treatment of choice in the ICU setting. Although no particular form of 
CRRT has yet been shown to be superior in terms of survival, experimental and 
clinical data suggest that a high convective blood purification rate (i.e., a high 
ultrafiltrate volume) may be of value, not only by providing efficient renal suppol1, 
but also by counter-acting the exaggerated inflammatory response in patients with 
SIRS by the removal of mediators with vasoactive and cardiodepressant properties 
into the uitrafiltrate. If this were to be true, than the early initiation of pump-driven 
CRRT in critically ill patients with SIRS (i.e., before the occurence of ARF) might 
have a (more) beneficial effect on the clinical course, thereby perhaps preventing 
ARFIMOSF. However, one must recognize that CRRT is an invasive procedure with 
substantial risks (e.g., due to continuous anticoagulation, prolonged vascular access, 
errors in fluid balance), which requires continuous vigilence. In addition, recent data 
indicate that pump-driven CRRT may induce platelet dysfunction, thereby 
aggrevating coagulopathy [5]. Future research should focus on the impact of the early 
initiation of CRRT, independent of the presence of ARF, on the clinical course of 
patients with SIRS and on the importance of using high ultrafiltrate volumes. In 
addition, more research is warranted to identify the charactistics of mediators, and 
their clearance (either by convection or adsorption) in relation to observed clinical 
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effects of CRRT to substantiate a possible 'cause-and-effect' relationship. 
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SamenmUing en conclusies 
Gedurende de laatste 10 jaar zijn er belangrijke vorderingen gemaakt in de 
beschikbare nierfunctievervangende technieken voor de behandeling van acute 
nierinsufficientie op de intensive care. Sinds de introductie van de eerste continue 
techniek door Kramer en anderen [1] als continue al1erioveneuze hemofiltratie 
(CA VH), zijn hiervan verschillende modificaties ontwikkeld die belangrijke voordelen 
zouden bieden ten opzichte van conventionele dialyse (intermitterende hemodialyse, 
peritoneaal dialyse)[2]. Hoewel nu vele, soms verwarrende, gegevens voorhanden zijn 
over de efficientie van continue nierfunctievervangende technieken zijn er nauwelijks 
vergelijkende data beschikbaar, hetgeen heeft geleid tot een belangrijke controverse 
omtrent welke therapie de voorkeur zou moeten krijgen [3,4]. Dit proefschrift omvat 
verschillende studies waarin de efficientie van continue nierfullctievervangende 
technieken en de vermeende superioriteit ten opzichte van conventionele dialyse 
werden onderzocht. Daarnaast werd onderzocht door welke mechanismen deze 
continue nierfunctievervangende technieken, in tegenstelling tot intermitterende 
hemodialyse (IHD), een gunstige invloed zouden kUllnen hebben op het klinisch 
beloop bij kritisch zieke patienten. 
In hoofdstuh.: I werd relevante achtergrond informatie gegeven omtrent de 
ineidentie en uiteindelijke uitkomst van acute nierinsufficientie, de verschillende 
beschikbare nierfunctievervangende technieken en scoringssystemen om adeqaat de 
ernst van de ziekte uit te kunnen drukken. Dit laatste is van groot belang voor risico-
stratificatie en om het zinvol te kunnen vergelijken van mortaliteitscijfers. Tevens 
werd beschreven welke ontstekingsmediatoren een rol spelen bij de gegeneraliseerde 
onstekingsreactie en acute nierinsufficientie, welke gezien worden bij patienten met 
shock als gevolg van bijvoorbeeld trauma, pancreatitis en sepsis. 
In hoofdstuk II werd een uitgebreid overzicht gegeven van de literatuur over de 
verschillende continue nierfunctievervangende technieken en werd op grond van de 
beschikbare gegevens geanaJyseerd op welke manier deze technieken mogelijk een 
gunstige invloed zouden kUllllen hebben op de morbiditeit en mortaliteit van patienten 
met acute nierinsufficientie op de intensive care, Hoewel hieruit blijkt dat continue 
teclmieken belangrijke voordelen bieden ten opzichte van conventionele dialyse, is 
(nog) niet duidelijk aangetoond dat dit leidt tot een verbetering van de overleving. 
Ook is nog niet duidelijk welke specifieke continue teclllliek de voorkeur zou moeten 
verdienen. Allen, behalve CA VH, zijn effectief in termen van metabole controle en 
regulering van de vloeistofbalans in hemodynamisch instabiele patienten. 
Pompgedreven vormell hebhen het voordeel dat geen arterHHe canulatie nodig is en 
dat hoge ultrafiltraat volumina (= hoge convectieve bloedzuiveringssnelheid) bereikt 
kunnen worden. Dit laatste is mogelijk van specifiek belang. 
In hoofdstuk III werd het gebruik van het 'Acute Physiology And Chronic Health 
Evaluation' (APACHE) II scoringssysteem zowel op de dag van opname op de 
intensive care, als op de dag dat nierfunctievervangende therapie werd gestart, 
geanalyseerd. Logistische regressie analyse liet zien dat het gebmik van het APACHE 
II systeem op de dag dat nierfunetievervangende therapie werd gestart (APACHE II,), 
in tegenstelling tot het gebmik van dit systeem op de dag van opname op de 
intensive care (APACHE III)' valide was om patienten te stratificeren naar de ernst 
van hun ziekte en om overlevingscijfers te vergelijken. Gebruik van de 'APACHE II 
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vergelijking' om het risico (%) om te overlijden te voorspellen leidde niet tot een 
verbetering van het scoringssysteem. De betrouwbaarheid van het scoringssysteem 
nam echter significant toe wanneer gebruik gemaakt werd van de ratio tussen de 
APACHE H, en APACHE H,. Hoe hoger de ratio, of weI hoe groter de verandering 
in APACHE score, hoe kleiner de kans op overleving. Dit suggereert dat de 
uiteindelijke overleving bepaald wordt door de reversibiliteit van de fysiologische 
ontregeling welke heeft geleid tot het ontstaan van acute nierinsufficientie. 
Multivariaat analyse liet geen invloed zien van leeftijd, diagnostische categorie, tijdsR 
interval tussen opname op de intensive care en start van nierfunctievervangende 
therapie of specifieke nierfunctievervangende therapie op de overleving. 
In hoofdsfuk IV werd de efficientie van de continue nierfunctievervangende 
teclmiek zoals die wordt toegepast in het 'Dijkzigt' ziekenhuis, continue 
arterioveneuze hemodiafiltratie (CA VHD), onderzocht. Tevens werd de 
patientenpopuiatie nauwkeurig beschreven in tennen van de ernst van hun ziekte, 
waaronder de APACHE H score en factoren (anders dan het nierfalen per so) welke 
een invloed op de overleving hadden, om een zinvolle vergelijking met andere studies 
mogelijk te maken. Het bleek dat de meerderheid van patienten werd beademd en 
inotrope ondersteuning nodig hadden; de meesten hiervan leden aan het 'multipel 
orgaanfaien syndroom'(MOF). In deze greep van hemodynamisch instabiele patienten 
bleek CA VHD een effectieve methode voor het reguleren van de vloeistof balans en 
uremie en voor het corrigeren van electroliet alswel zuurRbase evenwichts 
verstoringen. Ondanks het feit dat de meeste patienten kritisch ziek waren 
(gemiddelde APACHE H score 26.5) en leden aan MOF, konden 26 patienten (43%) 
de intensive care verlaten, waarvan 23 patienten (38%) uiteindelijk uit het ziekenhuis 
konden worden ontslagen. Deze getallen zijn relatief gunstig in vergelijking met 
andere mortaliteitsstudies in de literatuur. Noodzaak tot mechanische beademing en 
de aanwezigheid van sepsis waren beiden geassocieerd met een slechte prognose. Een 
andere belangrijke bevinding was de correlatie tussen het aantal uitgevallen 
orgaansystemen en overleving. 
In hoofdsfuk V werd een vergelijkende studie beschreven tussen intensive care 
patienten met acute nierinsufficientie welke werden behandeld met CA VHD of IHD. 
Beide patientengroepen werden gedetaileerd beschreven, waaronder de APACHE H 
score en relevante biochemische en hematologische data) om een zinvolle vergelijking 
mogelijk te maken. Hoewel patienten welke continue behandeld werden veel zieker 
waren dan die welke werden behandeld met IHD bleek CA VHD superieur in het 
reguleren van het 'milieuRinterieur' en de vloeistofbalans. Ondanks continue 
antistolling in patienten welke werden behandeld met CA VHD was er geen verschil 
in de incidentie van ernstige bloedillgscomplicaties. Ernstige hypotensie en cardiale 
aritmieen waren frequent optredende complicaties tijdens IHD, hetgeen niet werd 
gezien tijdens behandeling met CA VHD. Patienten welke werden behandeld met 
CA VHD hadden bovendien een hogere voedingsintake en een kortere oligurische 
peri ode. Dit laatste lijkt samen te hangen met de verbeterde hemodynamische 
stabiliteit van patienten welke worden behandeld met CA VHD in vergelijking tot met 
IHD behandelde patienten. Ondanks het feit dat de met CA VHD behandelde patienten 
veel zieker waren was er geen significant verschil in overleving tussen be ide groepell. 
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In hooCdstuk VI werden de resuItaten beschreven van een gecontroleerde studie 
waarin uitrafiltraat, verkregen (onder steriele omstandigheden) tijdens hemofiltratie 
van endotoxemische varkens, werd geinfundeerd in gezonde varkens en hun 
hemodynamiek vergeleken met die van varkens welke waren geinfundeerd met 
uItrafiltraat van gezonde varkens. In tegensteUing tot uItrafiltraat van gezonde 
varkens, leidde infusie van ultrafiltraat van endotoxemische varkens tot pulmonale 
hypertensie en verminderde cardiale prestatie, hetgeen suggereert dat dit ultrafiltraat 
oplosbare, filtreerbare factoren bevat welke verantwoordelijk waren voor de 
waargenomen negatieve hemodynamische effecten. Deze studie steunt de hypothese 
dat convectieve bloedzuivering per se in ieder geval voor een deel verantwoordelijk 
is voor de soms waargenomen gunstige effecten van continue teclmieken op het 
klinisch beloop bij patienten met MOF. 
Hoofdstuk VII beschrijft de resultaten van een studie waarin de impact van 
hemofiIters op de kinetiek van eukele mediatoren welke een belangrijke rol spelen bij 
het ontstaan van de systemische ontstekingsreactie en MOF (TNFa, IL-lfi, IL-6) 
werd onderzocht tijdens zowel in vitro als in vivo hemofiltratie, met de nadruk op het 
klaringsmechanisme en op het effect van langdurig filtergebruik hierop. Hoewel 
tijdens in vitro hemofiltratie met de AN69 membraan een redelijke convectieve 
klaring van de monomere vonn van TNFa (16.5 kDa) werd gezien, werd tijdens in 
vivo hemofiltratie met ditzelfde membraan geen convectief transport van TNFa 
gevonden. Dit kan mogelijk worden verklaard door het feit dat de bio-actieve vorm 
van TNFa circuleert als een trimeer (52 kDa) of dat circulerend TNFa snel word 
gebonden aan oplosbare TNF receptoren, waardoor in beide gevallen het moleculaire 
cut-off punt van de membraan word overschreden. Er werd eclller wei significante 
adsorptie van TNFa aan het membraanoppervlak waargenomen. In tegenstelling tot 
TNFa en ondauks het hogere molecuulgewicht (22 kDa), werd een redelijke 
convectieve klaring van IL-6 waargenomen tijdens zowel in vitro als in vivo 
hemofiltratie met de AN69 membraan. Tijdens in vitro hemofiltratie met 
verschillende synthetische membranen werd significant convectief transport gevonden 
van IL-Ill. Bij geen eukele patient werd echter een detecteerbare IL-Il concentratie 
gevonden zodat geen in vivo klaringen konden worden berekend. Van belang was de 
observatie dat langere bloed-membraan interactie een schijnbaar negatief effect had 
op de klaringskarakteristieken, waarschijnlijk door desorptie en/of (grotere) generatie 
van deze cytokinen. Deze gegevens suggereren dat wanueer de verwijdering van 
circulerende cytokinen (en mogelijk ook andere mediatoren) van primair belang is, 
grote ultrafiltraat volumina en frequente filter wisseling noodzakelijk zijn om 
significante hoeveelheden circulerende cytokines te kunnen verwijderen. De 
verschillen in adsorptie en convectie eigenschappen van synthetische membranen zijn 
hierbij mogelijk van klinisch belang. 
Vanuit bovenstaande studies kan geconcludeerd worden dat het definitieve bewijs 
dat continue nierfunctievervangende technieken de overleving van patienten met acute 
nierinsufficientie op de intensive care verbetert nog steeds moet worden geleverd. Het 
is mogelijk dat acute nierinsufficientie op zich te weinig bijdraagt aan de uiteindelijkc 
prognose van patienten met MOF om een verschil in overleving tussen patienten 
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welke worden behandeld met continue technieken en IHD te kunnen aantonen. De 
duidelijke voordelen van continue nierfunctievervangende technieken ten opzichte van 
conventionele dialyse, zoals superieure metabole contrale, verbeterde 
hemodynamische stabiliteit, het mogelijk maken van adequate (par)enterale voeding, 
het relatieve gemak waarmee de techniek kan worden geimplementeerd en mogelijk 
de kortere oligurische peri ode rechtvaardigen het gebruik van deze technieken als de 
therapie van keuze voor acuut nierfalen op de intensive care. Hoewel nag niet is 
aangetoond dat een specifieke vorm van continue nierfunctievervangende teclmiek 
superieur is in tel"men van overleving, suggereren zowel experimentele als klinische 
gegevens dat een hoge convectieve bloedzuiveringssnelheid (of wei een groot 
ultrafiltraatvolume), naast het garanderen van efficiente nierfunctievervanging, ook 
van specifieke waarde is door het onderdmkken van de gegeneraliseerde 
onstekingsreactie in patienten met shock (t.g.v. trauma, sepsis, pancreatitis) door 
verwijdering van circulerende mediatoren met vasoactieve en cardiodepressieve 
eigenschappen. Indien dit het geval zou zijllt betekent dit dat het vroegtijdig, m.a.w. 
v66r het onstaan van acute nierinsufficientie, initieren van pompgedreven continue 
nierfunctievervangende therapie een (meer) gepranonceerde invloed op het klinische 
beloop kan hebben, waardoor het onstaan van acuut nierfalenIMOF mogelijk wordt 
voorkomen. Men moet zich echter realiseren dat deze teclmiek een invasieve 
procedure is met potentieel belangrijke complicaties (bijv. ais gevolg van continue 
antistolling, langdurige canulatie grote vaten, fouten in vloeistof balans), hetgeen 
continue surveillance vereist. Bovendien werd recentelijk aangetoond dat deze 
pompgedreven teclmiek plaatjes dysfunctie kan induceren waardoor bestaande 
coagulopathie kan worden verergerd [5]. Toekomstig onderzoek moet worden gericht 
op de impact van het vroegtijdig initieren van continue nierfunctievervangende 
therapie op het klinisch beloop van kritisch zieke patienten met cen gegeneraliseerde 
ontstekingsl"eactie (bijv. ten gevolge van trauma, sepsis) en op de rol van het 
ultrafiltraat volume hierbij. Bovendien is meer onderzoek nodig om de eigenschappen 
te identificeren van oplosbare mediatoren en hun klaring (door convectie en/of 
adsorptie aan het filtermembraan) in relatie tot waargenomen klinische cffecten van 
continue technieken om eell 'oorzaak en gevolg'- relatie te kunnen onderbouwen. 
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